UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the transition period from ______________ to _____________
Commission file number 001-12965
ZEVEX INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 87-0462807
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4314 ZEVEX Park Lane
Salt Lake City, Utah 84123
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (801) 264-1001
Securities Registered Pursuant to Section 12(b) of the Exchange Act: None
Securities Registered Pursuant to Section 12(g) of the Exchange Act:
Common Stock, par value $0.001 per share
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes: X No:____
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K:____
The aggregate market value of the registrant's voting stock held by
nonaffiliates computed with reference to the closing price as quoted on the
NASDAQ Stock Market on March 15, 2000, was approximately $27,441,518. For the
purposes of the foregoing, the registrant assumed that affiliates included only
the registrant's directors, executive officers and principal shareholders filing
Schedules 13D or 13G with respect to the registrant's common stock.
The number of shares outstanding of the Company's Common Stock as of
March 15, 2000 was 3,420,726
Documents incorporated by reference: none
<PAGE>
TABLE OF CONTENTS
Part I
Item 1 BUSINESS -- 3
Item 2 PROPERTIES -- 22
Item 3 LEGAL PROCEEDINGS -- 22
Item 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS -- 22
Part II
Item 5 MARKET FOR REGISTRANT'S COMMON EQUITY AND
RELATED STOCKHOLDER MATTERS -- 22
Item 6 SELECTED FINANCIAL DATA -- 23
Item 7 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS -- 24
Item7A QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT
MARKET RISK -- 30
Item 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA -- 30
Item 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE -- 30
Part III
Item 10 DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT -- 31
Item 11 EXECUTIVE COMPENSATION -- 33
Item 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT -- 36
Item 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS -- 38
Part IV
Item 14 EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS
ON FORM 8-K -- 38
Item 14(c) INDEX TO EXHIBITS -- 41
SIGNATURES -- 40
<PAGE>
PART I
ITEM 1. BUSINESS
GENERAL
Through its three wholly owned subsidiaries, ZEVEX(R) International, Inc.
("ZEVEX"), a Delaware corporation, is in the business of designing,
manufacturing and distributing medical devices. ZEVEX' product lines include
proprietary medical devices that it designs, manufactures, and distributes, and
contract-manufactured products that it designs and manufactures for original
equipment manufacturers (OEM's).
ZEVEX' subsidiary, ZEVEX Inc., a Delaware corporation ("ZEVEX Inc.") provides
products for enteral nutrition delivery. Enteral nutrition delivery involves the
infusion of feeding solutions directly into the stomach or intestines of
patients. These products include electromechanical pumps, disposable delivery
sets, feeding tubes and accessories. ZEVEX Inc.'s enteral nutrition delivery
products are sold to home health care providers, nursing homes, and hospitals.
ZEVEX Inc. is also a contract manufacturer of medical devices, which include
ultrasonic sensors, surgical handpieces, and electronic instruments. ZEVEX Inc.
customizes the design of each of these products to meet the specific
requirements of the OEM customer.
ZEVEX' subsidiary, Aborn Electronics, Inc., a California corporation ("Aborn"),
specializes in the design and manufacturing of optoelectronic components. At its
San Jose, California facility, Aborn produces optical emitters, detectors, and
transducer assemblies that include custom integrated circuits. Aborn products
are used in medical devices and instrumentation, as well as in industrial and
military applications.
ZEVEX' subsidiary, JTech Medical Industries, Inc., a Utah corporation ("JTech"),
provides musculoskeletal evaluation products to chiropractors, occupational
therapists, osteopaths, and physical therapists. The JTech product line consists
of hand-held devices used for evaluating isolated muscle strength, joint ranges
of motion, and functional capacity, coupled through a JTech interface module to
a standard personal computer. JTech also develops and sells unique,
user-friendly software that is employed by the customer for assessing and
documenting clinical outcomes.
ZEVEX' current strategy is to continue to aggressively grow proprietary product
revenues with the acquisition and internal development of products that
complement its existing two lines of proprietary products. This is intended to
augment ZEVEX' contract manufacturing business, which historically has been the
core competence of ZEVEX. ZEVEX, together with its subsidiaries, is hereafter
collectively referred to as the "Company".
DEVELOPMENTS DURING 1999
The Company substantially grew revenues and earnings during 1999, further
diversifying its offering of proprietary products and gaining market share in
both markets for its proprietary products, as well as growing its contract
manufacturing business. Key contributors to the year's growth were:
1. In July 1998, ZEVEX Inc. entered into an agreement with Nutrition Medical,
Inc., a Minnesota corporation, to acquire Nutrition Medical's product line of
stationary feeding pumps, disposable sets and feeding tubes for enteral
nutrition delivery. Company management believes that the Nutrition Medical
stationary pump and feeding tube product line complements the line of ambulatory
enteral feeding pumps and disposable sets that the Company has developed
internally. The Company completed the acquisition of the Nutrition Medical
product line on December 23, 1998, providing for a full year of revenue
generation in 1999.
2. On December 31, 1998, the Company acquired JTech through a stock purchase
transaction with the four shareholders of JTech. JTech was organized in 1988 to
manufacture and sell range of motion measurement devices. As mentioned above,
JTech currently manufactures and markets its own proprietary musculoskeletal
evaluation products for health care providers, a line of products not previously
manufactured or sold by the Company. JTech's revenues combined with revenues
from the Company's proprietary enteral nutrition delivery products, accounted
for more than 47% of total ZEVEX revenues in 1999.
3. On December 31, 1998, the Company acquired Aborn through a stock purchase
transaction with the sole shareholder of Aborn. Aborn contributed to the
Company's revenues and earnings throughout the entire 1999 year. As described
above, Aborn currently designs and manufactures a variety of sophisticated
optical sensors, custom computer chips, and semiconductor components for medical
technology and other companies, and has brought new design and manufacturing
expertise to the Company.
4. On May 6, 1999, ZEVEX Inc. entered into an agreement with Applied Medical
Technology, Inc. ("AMT"), to distribute AMT's MINI(TM) button low-profile
gastrostomy access devices and related accessories within the home care market.
Management believes that these important enteral nutrition delivery devices will
add significantly to the Company's growing product line.
SUBSEQUENT DEVELOPMENT
On March 29, 2000, ZEVEX Inc. entered into an agreement with Nestle USA, Inc.
("Nestle") to acquire a portion of its enteral nutrition delivery device
business in an asset purchase. The assets to be acquired include over 19,500
enteral feeding pumps owned by Nestle and placed with various health care
facilities under arrangements whereby the facilities agree to purchase
disposable accessories for use with Nestle pumps. The assets will also include
Nestle's line of pump administration sets, feeding tubes, irrigation kits
and ancillary devices for the pumps. The total purchase price for the assets
will range from $1.5 million to approximately $2.7 million depending on the
sales generated by the acquired assets during the first 12 months following
the purchase, plus the actual cost of the inventory acquired by the Company
which is estimated to be approximately $700,000. The company currently
anticipates that the acquisition will close by April 5, 2000.
For a period following the closing of the purchase, Nestle has agreed to assist
the Company with the transition of the Nestle business to the Company. Although
there is no assurance that the Company will be able to generate the same level
of revenue experienced by Nestle from the acquired assets, based on Nestle's
experience the Company currently anticipates that the acquisition of the Nestle
assets will generate approximately $3 million in additional revenue for the
Company during 2000.
ZEVEX' PROPRIETARY PRODUCTS
Enteral Nutrition Delivery Products
Through ZEVEX Inc., the Company sells two major lines of enteral feeding pumps
and a variety of related disposable feeding tubes and delivery sets. These
products are for patients who require direct gastrointestinal nutritional
therapy. Enteral feeding is a means of providing nutrition to patients who may
have experienced head or neck trauma, or have gastrointestinal disorders, such
as short bowel syndrome, Crohn's Disease, bowel pseudo-obstruction, and other
serious digestive disorders, that prevent them from digesting food normally.
Many enteral feeding patients require continuous administration of nutritional
solutions throughout the day, which requires the patient to carry an enteral
feeding pump.
The Company has successfully applied its engineering and regulatory expertise to
the development, commercialization, and marketing of the EnteraLite(R)
Ambulatory Enteral Feeding Pump for patients who require direct gastrointestinal
nutritional therapy. Management believes that the EnteraLite pump is the
lightest, most compact and most mobile enteral feeding pump on the market,
possessing unprecedented safety and accuracy in liquid nutrition delivery. The
EnteraLite's unique features include a 24-hour battery, which is one-third
longer than the battery life of its closest competitor. The EnteraLite pump
carries a two-year warranty, twice the industry average.
First introduced in 1996, the EnteraLite continues to gain acceptance in the
home health care market due to the product's superior mobility and
state-of-the-art features. By improving the convenience of nutrition delivery,
the EnteraLite can contribute to better clinical outcomes and improved quality
of life for enteral patients. The EnteraLite requires the use of disposable
feeding bags and tubing sets, which are also sold by the Company. ZEVEX Inc. has
been awarded seven U.S. patents for technology related to the EnteraLite and its
disposable sets.
The acquisition of Nutrition Medical's line of pumps, delivery sets and feeding
tubes significantly expanded the ZEVEX line of enteral delivery products. ZEVEX
now manufactures and distributes the Enteral EZ(TM) enteral feeding pump, which
is a cost-effective pump intended for applications where patients are not
mobile. Complementing this pump model is a broad line of disposable delivery
sets sold by ZEVEX for use with the Enteral EZ pump. These sets include bags and
bottles of various sizes, as well as spike sets for use with pre-filled
containers. Additionally, as a result of the Nutrition Medical acquisition,
ZEVEX now offers an array of Panda(R) feeding tubes, which include adult and
pediatric nasoenteric tubes, replacement gastrostomy tubes and a needle catheter
jejunostomy kit. These feeding tubes are expendable devices that allow access to
the gastrointestinal tract of the patient via commonly accepted procedures, and
are discarded after use by a single patient.
Building upon the success of its enteral nutrition delivery pumps, ZEVEX Inc.
has acquired distribution rights in the home care market for the AMT MINI button
product line of low-profile gastrostomy access devices. Many EnteraLite pump
customers utilize low-profile gastrostomy access devices in order to receive
nutrition directly into their stomachs. Management believes that the AMT MINI
button is a premium product with unique features that complements the premium
product marketing strategy for the EnteraLite Pump.
Musculoskeletal Evaluation Products
Through JTech, the Company is a manufacturer and marketer of both stand-alone
and computerized musculoskeletal evaluation products that measure isolated
muscle strength, joint ranges of motion, and sensation to document the
effectiveness of treatment or extent of injury. JTech is an internationally-
recognized leader in physical medicine measurement products, providing both
hardware and Windows(R)-compatible software. JTech's musculoskeletal evaluation,
functional capacity evaluation, upper extremity and hand testing, and pain
evaluation products are used, for example, by chiropractors, physical
therapists, osteopaths, and occupational therapists for outcome assessment
during rehabilitation, medical-legal evaluations for personal injury and workers
compensation claims, and clinical documentation.
CONTRACT DESIGN AND MANUFACTURING SERVICES
Through ZEVEX Inc. and Aborn, the Company provides design and manufacturing
services to medical and other technology companies who sell the Company's
systems and devices under private labels or incorporate them into their
products. The Company designs and manufactures over 120 different surgical
systems, device components, and sensors for more than 85 different established
and emerging technology companies, such as Alaris Medical Systems, Inc.,
Allergan, Inc., various divisions of Baxter Healthcare Corporation, Medtronic
Corporation, Mentor Corporation, SIMS Deltec, Inc., and Terumo. ZEVEX Inc. and
Aborn each offer their customers over 12 years of specialized engineering and
manufacturing expertise in their respective areas.
Industry sources indicate that there is a strong trend by medical device and
other companies to outsource their device manufacturing requirements. Many
emerging device companies do not have the engineering, manufacturing, or
regulatory expertise to quickly and efficiently bring a device from conception
to commercial use. Even larger, well-established companies, which may have the
capital to develop such expertise, may lack the required personnel and time to
accumulate such expertise or may want to focus their resources in areas other
than manufacturing. In the medical device industry in particular, there are
substantial regulatory compliance requirements, in both the United States and
overseas, that must be addressed in designing and manufacturing devices. By
focusing its resources and expertise in the design and manufacturing areas, the
Company believes it offers customers the ability to outsource engineering and
manufacturing needs on a cost-effective basis, often allowing the customer to
bring a product to market more quickly and efficiently, at a lower cost, and
with higher quality than a customer could achieve with its own resources.
The Company uses extensive engineering and regulatory expertise to deliver
integrated design and manufacturing solutions to its customers. For its medical
technology customers, ZEVEX Inc. has registered with the United States Food and
Drug Administration ("FDA") as a medical device manufacturer and has developed
internal systems intended to maintain compliance with the FDA's Good
Manufacturing Practices ("GMP"). ZEVEX Inc. also is certified by the
International Organization for Standardization ("ISO") to 9001 and EN46001
standards, which means that it has met internationally-recognized quality
standards for the design, manufacture, and testing of products. ZEVEX Inc.
devotes significant management time and financial resources to GMP compliance
and ISO certification.
PRINCIPAL CONTRACT MANUFACURING PRODUCTS
A majority of the Company's contract manufacturing business involves the
following five general product categories:
Ophthalmic Surgical Devices
ZEVEX Inc. designs and manufactures ultrasonic phacoemulsification handpieces
and handpiece drive circuits for the surgical removal of cataracts.
Phacoemulsification is a method of cataract extraction, which uses ultrasound
waves to break the cataract-obstructed lens of the eye into small fragments that
can be removed through a hollow needle. Phacoemulsification is currently used in
more than 90 percent of cataract procedures in the United States. ZEVEX Inc.
manufactures handpieces of several designs for Allergan, Inc., who is a major
customer and a market leader in ophthalmology. ZEVEX Inc. also provides
customized handpieces and handpiece drive circuits to many other customers
worldwide.
In addition ZEVEX Inc. manufactures the KeraVision(R) KV2000, which is a
precision vacuum instrument that facilitates the surgical insertion of
prescription Intacs(R) rings at a 2/3 depth in the cornea. These rings,
depending upon their thickness, will flatten the cornea, correcting an eye that
requires 1 to 5 diopters of correction. The KV2000 creates a vacuum that is
transmitted through tubing to a fixture called the vacuum centering guide
("VCG"), which is placed on top of the eye. When a vacuum is applied, the VCG
attaches itself to the eye, giving the surgeon both a means to hold the eye
still and a platform through which to perform the surgery.
Liposuction Handpieces
ZEVEX Inc. designs and manufactures handpieces for ultrasonically assisted
liposuction for Mentor Corporation. Liposuction, the removal of body fat, is one
of the most popular cosmetic procedures performed today. Current liposuction
procedures involve the use of a metal cannula to sheer fat from a patient while
a vacuum is applied, requiring the physician to exert a great amount of force.
In ultrasonically assisted liposuction, a generator sends ultrasonic waves
through a probe that is inserted under the skin. The ultrasonic energy
emulsifies the fat, which is then easily aspirated away, significantly reducing
patient trauma as well as the amount of force applied by the surgeon.
Ultrasonic Sensors
ZEVEX Inc. designs and manufactures a variety of non-invasive ultrasonic sensors
for the detection of air bubbles and the monitoring of liquid levels in medical
devices. ZEVEX Inc.'s air bubble detectors monitor intravenous fluid lines in a
variety of devices and systems, including drug infusion pumps, hemodialysis
machines, blood collection systems, and cardiopulmonary bypass systems. ZEVEX
Inc.'s liquid level detectors are used to monitor critical levels of liquids in
various reservoirs used in surgery, such as those employed in cardiopulmonary
bypass systems.
Optoelectronic Sensors and Custom Integrated Circuits
Aborn designs and manufactures a variety of optical emitters and detectors,
custom integrated circuit products, and semiconductor components used in
medical, industrial, and military applications. Aborn's products include fiber
optic links, integrated optoisolators, high-speed sensor integrated circuits,
application specific integrated circuit (ASIC) devices, and solid state relays.
Medical applications for these technology products include diagnostic and
therapeutic equipment, such as blood analyzers and dialysis machines.
Medical Systems
The ultimate level of product sophistication for ZEVEX Inc.'s manufacturing
services involves medical systems manufacturing. During 1999, ZEVEX Inc. began
manufacturing the Cardiac Science PowerHeart(R) AECD(R), which is a unique
external bedside defibrillator. Designed for the unattended monitoring of
patients at risk for heart attacks, the device detects certain abnormal heart
rates and responds automatically by delivering a charge to restore the heart to
its normal rhythm. According to Pacing And Clinical Electrophysiology, a peer
reviewed cardiology journal, by responding very quickly, the PowerHeart can save
lives and reduce trauma to the patient by delivering a lower level of energy
than would normally be required at traditional response times.
REVENUE SOURCES
The following table sets forth the source of the Company's total revenues during
the last 3 years, allocated between six product/service categories.
Revenue breakdown by product/service, by percentage
<TABLE>
<CAPTION>
<S> <C> <C> <C>
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Product 1999 1998 1997
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Enteral Nutrition Delivery 32.7% 29.9% 11.8%
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Ultrasonic and Optoelectronic 18.9% 24.5% 35.6%
Sensors, Custom IC's
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Ophthalmic Surgical Devices 18.0% 37.3% 34.8%
and Liposuction Handpieces
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Musculoskeletal Evaluation 14.2% 0.0% 0.0%
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Engineering/Tooling 8.5% 5.5% 8.9%
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
Medical Systems 7.7% 2.8% 8.9%
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
</TABLE>
CAPABILITIES
Design and Engineering
The Company has extensive design and engineering capabilities that it uses for
its own product development as well as for servicing its contract manufacturing
customers. ZEVEX Inc. engineers have broad experience in designing, engineering,
and testing an array of medical technology devices and systems, with particular
expertise in ultrasonic devices. Aborn has an engineering team experienced in
designing, engineering, manufacturing, and testing a broad range of
optical/electronic devices.
The Company's manufacturing service customers generally rely on the Company from
the outset of their projects for complete design, engineering, component
analysis, testing, and regulatory compliance for their devices or systems. In
some instances, customers have come to the Company with final drawings for
devices that they believe are ready for manufacturing. In such cases, the
Company tests the customer's existing design prior to manufacturing. Many times,
the Company's engineers identify and offer design alternatives, which may
improve performance or manufacturing efficiencies.
The Company's engineers assist sales and marketing personnel in evaluating
requests for proposals and in developing proposed solutions, cost estimates, and
bids for each product. The Company's project engineers act as customer contacts
throughout the design and engineering phase and have responsibility for all
aspects of a customer's project. A cooperative approach is used to ensure that
customers' expectations are met or exceeded in the final product. Both Aborn and
ZEVEX Inc.'s design and engineering services are generally provided on a
time-and-materials fee basis to a customer, and as part of a plan to eventually
manufacture the customer's product.
The Company has made significant investments in state-of-the-art equipment to
support its design and engineering staff, including product performance modeling
software, custom test stations, and three-dimensional computer aided design
("CAD") software. ZEVEX Inc. has independently developed what management
believes is the most sophisticated modeling software for ultrasonic surgical
device development. Management believes that ZEVEX Inc.'s unique modeling and
design capacities hasten product development for ultrasonic devices and improve
the quality of the final device.
Manufacturing
The Company's own products are generally assembled and tested at its
manufacturing facility in Salt Lake City, Utah. Design, engineering, and
manufacturing services for other companies are provided from the same facility.
ZEVEX Inc.'s enteral feeding disposable products are sub-contracted to specialty
manufacturers. Aborn provides its design, engineering, and manufacturing
services from its facility in San Jose, California.
In most cases, the manufacturing process begins with technical drawings and
specifications derived through the Company's engineering and design process.
Once the preliminary design has been completed, prototypes are manufactured and
further design refinements and adjustments are made based on the performance of
the prototypes. Following completion of final design specifications, the Company
orders the required electronic components, piezoelectric ceramic, molded
plastic, titanium and stainless steel components, and other materials from
qualified suppliers of such items.
Inventory management, work order, and MRP software programs are used to manage
inventory and control the ordering process for more than 20,000 parts used in
the Company's and its customer's products. As the evolution of a device or
system reaches production, team members with direct responsibility for
purchasing, manufacturing, and quality assurance assume a greater role in the
project. The project team develops an assembly process, product testing
protocol, and quality assurance procedures to produce high-quality products that
satisfy internal or customer specifications, as well as the FDA's GMP and ISO
9001/EN 46001 quality standards.
ZEVEX usually provides its services pursuant to negotiated manufacturing
agreements, which address quantity, pricing, warranty, indemnity, and other
terms of the relationship. Such contracts may or may not be exclusive
manufacturing arrangements, and may or may not include minimum volume
requirements. In some cases no minimum purchase is required. In other cases, a
customer commits to purchase a minimum quantity identified in a rolling forecast
of production. ZEVEX generally warrants its products to be free from defects in
materials and workmanship, and may indemnify the customer against losses arising
out of such breach of warranty.
SUPPLIERS
The Company purchases its component parts and raw materials from approved
suppliers. The Company is not dependent on a single supplier for any item, and
believes that it can acquire materials from various sources on a timely basis.
SALES AND MARKETING
Enteral Nutrition Delivery Products
ZEVEX Inc. has a network of over 40 independent manufacturer's representatives
who sell EnteraLite(R) Ambulatory Enteral Feeding Pumps and related disposable
delivery sets. These representatives have been selected for their experience
within the markets served by the Company's pumps, and they sell directly to home
health care service providers, hospitals, and nursing homes. The manufacturer's
representatives are regionally supported by specialists with clinical
credentials (registered dietitians or nurses), who are full-time employees of
the Company.
Customers generally purchase EnteraLite Ambulatory Enteral Feeding Pumps
directly from ZEVEX Inc. In cases where a lease or rental is preferred,
arrangements are made through a third party that specializes in medical
equipment financing. Disposable sets are then purchased as needed. Customers
typically purchase 30 disposable sets per month for each pump placed in service.
In the past, due to competition, lower-cost stationary pumps have been generally
placed at no up-front cost to the user, in return for set "usage" agreements
which typically guarantee minimum purchases of 15 disposable sets per pump per
month, once the pumps are placed in service. In order to increase accountability
and the efficiency of the health care delivery system in the United States,
there is a trend beginning which involves minimum lease charges for enteral
pumps placed with customers on such "usage" programs.
The distribution of the Enteral EZ stationary pump, delivery sets, and feeding
tubes are serviced by a national account manager. The AMT MINI Button product
will also be sold through both the Company's manufacturer reps as well as its
national account manager. During 1999, two versions of the stationary pump were
sold under private labels for distribution by two other companies, in the United
States and Europe.
For a period of ninety (90) days following the Closing of the Nestle asset
purchase, Nestle on behalf of and as an accommodation to ZEVEX Inc. will take
orders for disposables from the pump customers, place all such orders with ZEVEX
Inc. and invoice on behalf of ZEVEX Inc. ZEVEX Inc. will pay Nestle in
consideration for providing such services a fee of one percent (1%) of the total
"gross" sales amount of all orders for disposable products processed by Nestle.
Additionally, Nestle shall advise any party which is not a current pump customer
but is seeking to purchase or acquire products that ZEVEX Inc. is a supplier of
such products. After the 90 day transition period, ZEVEX Inc. will sell the
product line through both the Company's manufacturer reps as well as its
national account manager.
Musculoskeletal Evaluation Products
JTech markets its products worldwide through a network of over 70 independent
dealers and manufacturer's representatives. These dealers and representatives
were selected for their experience with marketing to chiropractors, osteopaths,
physical therapists and occupational therapists. Dealers and representatives are
supported by regional sales managers, who are full-time employees of JTech.
JTech also sells its products via seminars, directed mailings, catalogs, and
telemarketing through its customer service personnel.
Contract Design and Manufacturing Services
ZEVEX Inc. and Aborn generate new design and manufacturing projects from
customers using direct sales personnel who are trained in the Company's
engineering expertise and manufacturing capabilities. Project engineers also
participate extensively in sales and marketing activities. The Company promotes
its design and manufacturing capabilities at industry trade shows, by
advertising in leading industry publications, and by obtaining referrals from
customers and other persons who are familiar with the Company's services.
COMPETITION
Enteral Nutrition Delivery Products
Two major competitors exist in the U.S. market for ambulatory enteral feeding
pumps. Ross Laboratories, a division of Abbott Laboratories, offers the
Companion(R) pump, which was originally introduced to the market in the late
1980's. The Company estimates that Ross holds a market share of 45% for
ambulatory and non-ambulatory enteral feeding applications. Sherwood, Davis &
Geck, the second competitor offers the kangaroo(R) PET enteral feeding pump,
which has a limited market because it can be operated only in an upright
position. The Company estimates that Sherwood, Davis & Geck presently holds
greater than 21% of the total market for enteral pumps and disposable sets in
both ambulatory and non-ambulatory applications.
Well-established competitors such as Abbott and Sherwood, Davis & Geck typically
bundle products for the greatest advantage in group-purchasing situations. Each
of these competitors offers a breadth of product offerings that exceeds that of
the Company. Key to the Company's ability to compete effectively are the unique
features of its product offerings and the benefits to customers who utilize
them. The Company expects to build upon its reputation for innovation that was
earned by its EnteraLite(R) Ambulatory Enteral Feeding Pump for mobile enteral
patients. In order to continue to increase revenues, the Company plans to grow
its product line so that it too can bundle a family of products to meet the
enteral nutrition delivery needs of its customers. The Company expects to
develop and/or acquire products that are complementary to its enteral nutrition
delivery product line, particularly those having features that can significantly
improve the quality of life of patients, and the safety and ease of enteral
administration.
Musculoskeletal Evaluation Products
The Company's primary competitors in the musculoskeletal evaluation market are a
limited number of small privately held companies. Most notable are ARCON, The
Blankenship System, Key Methods, Isernhagen, Cedaron and Greenleaf Medical.
Generally, these companies concentrate on particular areas such as
musculoskeletal testing, functional capacity evaluation, or hand testing. JTech
management believes that few competitors can penetrate the broad spectrum of
medical professions possible with JTech products because their products lack the
full range of capabilities offered by JTech and none offer a completely modular
product line like JTech. Competitive factors in the musculoskeletal market
include perceived quality, price, name recognition, training capabilities,
support, operating system, and systems integration potential.
Contract Design and Manufacturing Services
The Company's primary competitors for design and manufacturing services include
Plexus, Inc., Colorado MedTech Inc., United Medical Manufacturing, Inc. and
Sparton Electronics Corporation. These contract manufacturers operate in the
medical technology industry, and some have substantially greater financial and
marketing resources than the Company. Competitive factors in medical device
design and manufacturing include quality, regulatory compliance, engineering
competence, cost of non-recurring engineering, price of the manufactured
product, experience, customer service, and ability to meet design and production
schedules. The Company believes that its unique expertise in ultrasound and
optoelectronics will allow it to compete effectively for contracts involving
these technologies.
Competition for design and manufacturing of medical devices is primarily limited
to those companies that meet the minimum applicable regulatory requirements of
the FDA and international standards for manufacturing and design. In the future,
the Company is likely to compete against new entrants as outsourcing expands in
the medical industry. For example, medical technology companies with design and
manufacturing capabilities (especially those with excess capacity), large
electronic contract manufacturers and defense contractors with extensive
engineering expertise may undertake the design and/or manufacture of medical
devices for third parties.
PATENTS AND TRADEMARKS
The Company's subsidiaries own and have applied for numerous trademarks in the
United States and abroad. The Company believes that its trademarks are well
recognized in the various markets for its products. With exception for the
EnteraLite trademark, which is registered for its ambulatory enteral feeding
pump, the Company believes that the loss of any trademark would not have a
material adverse effect on its overall business operations.
In addition, the Company's subsidiaries own twelve patents with respect to
proprietary medical products. Except for the patents relating to its EnteraLite
feeding pump, the Company believes that the loss of any of its patents would not
have a materially adverse effect on its overall business operations. The Company
also relies on trade secrets and confidentiality agreements to protect the
proprietary nature of its technologies.
RESEARCH AND DEVELOPMENT FOR THE COMPANY'S PROPRIETARY PRODUCTS
ZEVEX' research and development projects are primarily focused on new
proprietary products. As of December 31, 1999, ZEVEX had three full-time
engineers in research and development, and had several other designers and
engineers contributing to research and development projects. During the last
three fiscal years, ZEVEX continued independent research and development
activities with respect to the design of new and improved devices, spending
$670,886 in 1999, $290,699 in 1998, and $702,563 in 1997. In 1999, 1998 and
1997, research and development costs represented approximately 3%, 3%, and 8% of
the Company's revenues in each of those years. Significant fluctuations
experienced in research and development are due to timing of the Company's
research projects.
MAJOR CUSTOMERS
The Company's revenues have historically been derived from the sale of its
design and manufacturing services to a small number of major customers. During
the 1999 fiscal year, however, the Company grew its proprietary product
business, and the percentage of total revenue represented by a few major
customers decreased. As a result, the number of customers comprising more than
10% of the Company's revenues declined when compared to prior years. During the
1999 fiscal year, 13% of revenues were from Allergan, Inc. This was the only
customer that contributed more than 10% of revenue for 1999. During the 1998
fiscal year, 15% of revenues were from Allergan, 16% were from Mentor H/S, Inc.,
and 13% were from Alaris Medical Systems (formerly IVAC Corporation). During the
1997 fiscal year, 15% of revenues were from Allergan, 15% were from Paradigm
Medical, Inc., 18% were from Alaris, and 17% were from Mentor H/S. No assurances
can be given that the Company's major customers will continue to do business
with the Company or that the volume of their orders for the Company's OEM
devices and proprietary products will increase or remain constant. The loss of a
major customer, or a significant reduction in the volume of its orders from the
Company, would have a material adverse impact on the Company's operations. In
addition, if one or more of these customers were to seek and obtain price
discounts from the Company for the Company's OEM devices or proprietary
products, the resulting lower gross margins on those devices and products would
have a materially adverse effect on the Company's overall results of operations.
If any customer with which the Company does a substantial amount of business
were to encounter financial distress, the customer's lateness, unwillingness, or
inability to pay its obligations to the Company could result in a materially
adverse effect on the Company's results of operations and financial condition.
Company management expects, however, that with its continued focus toward
proprietary products, the percentage of total revenues represented by a few
major customers will continue to decline, so that the loss of such a customer
would have less potential to have a materially adverse effect on the financial
condition or results of operations of the Company in the future.
BACKLOG
At December 31, 1999, the Company had a backlog of approximately $5,640,478 on
orders for medical devices to be manufactured by ZEVEX Inc. for other medical
technology companies, as compared to backlogs at December 31, 1998 and 1997, of
$6,092,926 and $6,265,007, respectively. The Company estimates that
approximately 90% of the backlog will be shipped before December 31, 2000. As of
March 15, 2000, the Company had a backlog of $7,716,900. For purposes of the
above figures, backlog includes all orders received by the Company pursuant to
purchase orders that have not been completed and shipped by the Company. This
does not include any backlog for the Company's proprietary products, because the
Company manufactures these devices and holds appropriate levels in inventory for
sale to customers. Some of the orders included in the backlog may be canceled or
modified by customers without significant penalty. In addition, because
customers may place orders for delivery at various times throughout the year,
and because of the possibility of customer changes in delivery schedules or
cancellation of orders, the Company's backlog as of any particular date may not
necessarily be a reliable indicator of future revenue.
GOVERNMENTAL REGULATION
ZEVEX Inc.'s manufacturing facilities, its customer's medical devices, and its
own medical devices are subject to extensive regulation by the FDA under the
Food Drug and Cosmetics Act ("FDC Act"). Manufacturers of medical devices must
comply with applicable provisions of the FDC Act and associated regulations
governing the development, testing, manufacturing, labeling, marketing, and
distribution of medical devices, record-keeping requirements, and the reporting
of certain information regarding device safety. In addition, ZEVEX Inc.'s
facilities are subject to periodic inspection by the FDA (and certain state
agencies) for compliance with the FDA's GMP requirements. To ensure compliance
with GMP requirements, the Company expends significant time, resources, and
effort in the areas of training, production, and quality assurance.
For certain medical devices manufactured by the Company, the customer may need
to obtain FDA clearance of a premarket approval ("PMA") application. Such
applications require substantial preclinical and clinical testing to obtain FDA
clearance. Currently, at least two of the Company's customers are seeking or
plan to seek a PMA for devices to be manufactured by the Company. Other medical
devices can be marketed without a PMA, but only by establishing in a 510(k)
premarket notification "substantial equivalence" to a predicate device.
Besides the FDA regulations described above, the Company is also subject to
various state and federal regulations with respect to such matters as safe
working conditions, manufacturing practices, fire hazard control, environmental
protection, and the disposal of hazardous or potentially hazardous materials.
The Company's operations involve the use and disposal of relatively small
amounts of hazardous materials.
Beginning in 1998, all medical device manufacturers were required to obtain the
"CE Mark" to sell their products in the European Common Market. The CE Mark is a
quality designation given to products that meet certain policy directives of the
European Economic Area. The Company has received and maintained ISO 9001 and
EN46001 certification, which allows the Company to CE Mark its own products and
assist its customers with obtaining the CE Mark for their products.
EMPLOYEES
As of March 1, 2000, the Company employed a total of 179 people in the following
areas: in Design and Engineering, 37; in Manufacturing and Testing, 78; in
Quality Assurance and Customer Relations, 10; and in Marketing and
Administration, 54. The Company has 163 people located at its corporate
headquarters and manufacturing facility in Salt Lake City, Utah, 8 people
located at its San Jose, California, facility, and 8 people at various locations
throughout the United States.
The Company also retains 4 consulting and contract personnel in the areas of
finance, engineering, and regulatory compliance. The Company considers its labor
relations to be good, and none of its employees are covered by a collective
bargaining agreement. Currently, the local economy is growing and the
unemployment rate is low in the Salt Lake City metropolitan area, which means
that the Company faces competition to attract and retain qualified personnel. At
the same time, however, the Salt Lake City metropolitan area has a well-educated
work force and is considered an attractive place to live. Accordingly, the
Company does not anticipate having difficulty in attracting and retaining
qualified personnel to meet its projected growth, although the Company is likely
to experience continued moderate growth in labor costs.
ENVIRONMENTAL COMPLIANCE COSTS
Compliance with federal, state, and local provisions regarding the production
and discharge of material into the environment or the protection of the
environment is not expected to have a material adverse effect on capital
expenditures, earnings and the competitive position of the Company
FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC OPERATIONS AND SALES
The Company's revenues have historically been largely derived from the sale of
its design and manufacturing services to a small number of major customers
located in the United States. During the 1999 fiscal year the revenue mix
changed as a larger percent of the Company's revenues were derived from
proprietary products in domestic and foreign markets. During the 1999 fiscal
year, the Company had total revenues of $23,026,208, of which $1,567,825 was
considered foreign source revenues. During the 1998 fiscal year, the Company had
total revenues of $11,084,413, of which $623,572 was considered foreign source
revenues. During the 1997 fiscal year, the Company had total revenues of
$8,968,425, of which $457,390 was considered foreign source revenues.
During the last three fiscal years, the Company has had no long-lived assets,
long term customer relationships with a financial institution, mortgage or other
servicing rights, deferred policy acquisition costs, or deferred assets, in any
foreign country
FACTORS THAT MAY AFFECT FUTURE RESULTS
(Cautionary Statements Under the Private Securities Litigation Reform Act of
1995)
The disclosure and analysis set forth in this 1999 Form 10-K contain certain
forward-looking statements, particularly statements relating to future actions,
performance or results of current and anticipated products, sales efforts,
expenditures, and financial results. From time to time, the Company also
provides forward-looking statements in other publicly-released materials, both
written and oral. These statements are statements that do not relate strictly to
historical or current facts. They use words such as "plans," "expects," "will"
"believes" and other words and phrases of similar meaning. In all cases, a broad
variety of risks and uncertainties, both known and unknown, as well as
inaccurate assumptions can affect the realization of the expectations or
forecasts in those statements. Consequently, while such statements represent
Company management's current views, no forward-looking statement can be
guaranteed. Actual future results may vary materially.
The Company undertakes no obligation to update any forward-looking statements,
but investors are advised to consult any further disclosures by the Company on
this subject in its subsequent filings pursuant to the Securities Exchange Act
of 1934. Furthermore, in accordance with the Private Securities Litigation
Reform Act of 1995, the Company provides the following cautionary statements
identifying factors that could cause the Company's actual results to differ
materially from expected and historical results. It is not possible to foresee
or identify all such factors. Consequently, this list should not be considered
an exhaustive statement of all potential risks, uncertainties, and inaccurate
assumptions.
Additionally, the following factors should be reviewed for a full understanding
of the business of the Company and considered in evaluating the Company's
prospects for future growth. The occurrence of one or more of the following
risks or uncertainties could have a material adverse effect on the Company's
business, results of operations, and financial condition.
Risk Factors Relating to the Company's Customers
The Company's success in contract manufacturing depends largely on the success
of the customers for its manufacturing services and on the medical and
optical/electronic devices designed and manufactured by the Company for those
customers. Any unfavorable developments or adverse effects on the sales of those
devices or such customers' businesses, results of operations, or financial
position could have a corresponding adverse effect on the Company. In addition,
the Company sells certain types of medical devices to multiple customers and to
the extent there is an unfavorable development affecting the sales of any such
type of device generally, the adverse effect of such development on the Company
would be more substantial than that presented by the decline in sales to a
single customer for such type of device. Additionally, the Company believes that
its design and manufacturing customers and their devices (and the Company
indirectly) are generally subject to the following risks:
Competitive Environment. The medical and optical/electronic product industries
as well as the enteral nutrition delivery business are highly competitive and
subject to significant technological change. Participation in such industries
requires ongoing investment to keep pace with technological developments and
quality and regulatory requirements. These industries consist of numerous
companies, ranging from start-up to well-established companies. Many of the
Company's customers have a limited number of products, and some market only a
single product. As a result, any adverse development with respect to these
customers' products may have a material adverse effect on the business and
financial condition of such customer, which may adversely affect that customer's
ability to purchase and pay for its products manufactured by the Company. The
competitors and potential competitors of the Company's customers may succeed in
developing or marketing technologies and products that will be preferred in the
marketplace over the devices manufactured by the Company for its customers or
that would render its customers' technology and products obsolete or
noncompetitive.
Emerging Technology Companies. A significant number of the Company's customers
are emerging medical technology companies that have competitors and potential
competitors with substantially greater capital resources, research and
development staffs, and facilities, and substantially greater experience in
developing new products, obtaining regulatory approvals, and manufacturing and
marketing medical products. Approximately nine customers, representing 13% of
the Company's revenues in fiscal year 1999, were, in management's opinion,
emerging medical technology companies. These customers may not be successful in
launching and marketing their products, or may not respond to pricing,
marketing, or other competitive pressures or the rapid technological innovation
demanded by the marketplace and, as a result, may experience a significant drop
in product revenues.
Customer Regulatory Compliance. The FDA regulates many of the devices
manufactured by the Company under the FDC Act, which requires certain clearances
from the FDA before new medical products can be marketed. There can be no
assurance that the Company's customers will obtain such clearances on a timely
basis, if at all. The process of obtaining a PMA or a 510(k) clearance from the
FDA could delay the introduction of a product to market. A customer's failure to
comply with the FDA's requirements can result in the delay or denial of its PMA.
Delays in obtaining a PMA are frequent and could result in delaying or canceling
orders to the Company. Many products never receive a PMA. Similarly, 510(k)
clearance may be delayed, and in some instances, 510(k) clearance is never
obtained.
Once a product is in commercial distribution, discovery of product problems or
failure to comply with regulatory standards may result in restrictions on the
product's future use or withdrawal of the product from the market despite prior
governmental clearance. There can be no assurance that product recalls, product
defects, or modification or loss of necessary regulatory clearance will not
occur in the future.
Sales of the Company's medical products outside the United States are subject to
regulatory requirements that vary widely from country to country. The time
required to obtain clearance for sale in foreign countries may be longer or
shorter than that required for FDA clearance, and the requirements may differ.
The FDA also regulates the sale of exported medical devices, although to a
lesser extent than devices sold in the United States. In addition, the Company's
customers must comply with other laws generally applicable to foreign trade,
including technology export restrictions, tariffs, and other regulatory
barriers. There can be no assurance that the Company's customers will obtain all
required clearances or approvals for exported products on a timely basis, if at
all.
Medical devices manufactured by the Company and marketed by its customers
pursuant to FDA or foreign clearances or approvals are subject to pervasive and
continuing regulation by the FDA and certain state and foreign regulatory
agencies. FDA enforcement policy prohibits the marketing of approved medical
products for unapproved uses. The Company's customers control the marketing of
their products, including representing to the market the approved uses of their
products. If a customer engages in prohibited marketing practices, the FDA or
another regulatory agency with applicable jurisdiction could intervene, possibly
resulting in marketing restrictions, including prohibitions on further product
sales, or civil or criminal penalties.
Changes in existing laws and regulations or policies could adversely affect the
ability of the Company's customers to comply with regulatory requirements. There
can be no assurance that a customer of the Company, or the Company, will not be
required to incur significant costs to comply with laws and regulations in the
future, or that such customer or the Company will be able to comply with such
laws and regulations.
Uncertain Market Acceptance of Products. There can be no assurance that the
products created for the Company's customers will gain any significant market
acceptance even if required regulatory approvals are obtained. Some of the
Company's customers, especially emerging technology companies, have limited or
no experience in marketing their products and have not made marketing or
distribution arrangements for their products. The Company's customers may be
unable to establish effective sales, marketing, and distribution channels to
successfully commercialize their products.
Product and Inventory Obsolescence. Rapid change and technological innovation
characterize the marketplace for medical and opto/electronic products. As a
result, the Company and its customers are subject to the risk of product and
inventory obsolescence, whether from prolonged development or government
approval cycles or the development of improved products or processes by
competitors. In addition, the marketplace could conclude that the task for which
a customer's medical product was designed is no longer an element of a generally
accepted diagnostic or treatment regimen.
Customers' Future Capital Requirements. Many of the Company's customers,
especially the emerging medical technology companies, are not profitable and may
have little or no revenues, but they have significant working capital
requirements. Such customers may be required to raise additional funds through
public or private financings, including equity financings. Adequate funds for
their operations may not be available when needed, if at all. Insufficient funds
may require a customer to delay development of a product, clinical trials (if
required), or the commercial introduction of the product or prevent such
commercial introduction altogether.
Uncertainty of Third-Party Reimbursement. Sales of many of the medical devices
manufactured by the Company will be dependent in part on availability of
adequate reimbursement for those instruments from third-party health care
payers, such as government and private insurance plans, health maintenance
organizations, and preferred provider organizations. Third-party payers are
increasingly challenging the pricing of medical products and services. There can
be no assurance that adequate levels of reimbursement will be available to
enable the Company's customers to achieve market acceptance of their products.
Without adequate support from third-party payers, the market for the products of
the Company's customers may be limited.
Uncertainty of Market Acceptance of Out-Sourcing Manufacturing of
Medical Instruments
The Company believes that the market for out-sourcing the design and manufacture
of advanced medical products for medical technology companies is in its early
stages. Many of the Company's potential customers have internal design and
manufacturing facilities. The Company's engineering and manufacturing activities
require that customers provide the Company with access to their proprietary
technology and relinquish the control associated with internal engineering and
manufacturing. As a result, potential customers may decide that the risks of
out-sourcing engineering or manufacturing are too great or exceed the
anticipated benefits of out-sourcing. In addition, medical technology companies
that have previously made substantial investments to establish design and
manufacturing capabilities may be reluctant to out-source those functions. If
the medical technology industry generally, or any significant existing or
potential customer, concludes that the disadvantages of out-sourcing
manufacturing outweigh the advantages, the Company could suffer a substantial
reduction in the size of one or more of its current target markets, which could
have a material adverse effect on its business, results of operations, and
financial condition.
Competition in Out-Sourcing Manufacturing
The Company faces competition from design firms and other manufacturers that
operate in the medical and opto/electronic technology industries. Many
competitors have substantially greater financial and other resources than the
Company. Also, manufacturers focusing in other industries may decide to enter
into the industries served by the Company. Competition from any of the foregoing
sources could place pressure on the Company to accept lower margins on its
contracts or lose existing or potential business. To remain competitive, the
Company must continue to provide and develop technologically advanced
manufacturing services, maintain quality, offer flexible delivery schedules,
deliver finished products on a reliable basis, and compete favorably on the
basis of price. There can be no assurance that the Company will be able to
compete favorably with respect to these factors.
Early Termination of Agreements
The Company's agreements with major manufacturing customers generally permit the
termination of the agreements before expiration thereof if certain events occur
that are materially adverse to the design, development, manufacture, or sale of
the product. Examples of such events include the failure to obtain or the
withdrawal of regulatory clearance, or an alteration of regulatory clearance
that is materially adverse to the customer or which prohibits or interferes with
the manufacture or sale of the products. The performance of agreements with
major customers may be suspended or excused, if certain conditions, generally
beyond the control of the customer or the Company (so-called force majeure
events), cause the failure or delay of performance.
The Company's pump usage agreements, under which pumps are placed with users in
exchange for a commitment by the user to buy disposable products from the
Company, generally require only monthly commitments, and users can terminate any
purchase obligation by returning the pump. Thus, there is no assurance of
continued revenue from pumps placed with such users.
Risk Factors in Marketing the Company's Proprietary Products
In producing and marketing its own proprietary devices, the Company faces many
of the same risks that its design/manufacturing customers face. As discussed
above with respect to its customers, such risks include:
The medical products industry is highly competitive. A significant number of the
Company's competitors have substantially greater capital resources, research and
development staffs, and facilities, and substantially greater experience in
developing new products, obtaining regulatory approvals, and manufacturing and
marketing medical products. Competitors may succeed in marketing products
preferable to the Company's products or rendering the Company's products
obsolete.
The medical products industry is subject to significant technological change and
requires ongoing investment to keep pace with technological development,
quality, and regulatory requirements. In order to compete in this marketplace,
the Company will be required to make ongoing investment in research and
development with respect to its existing and future products.
The Company is subject to substantial risks involved in developing and marketing
medical products regulated by the FDA and comparable foreign agencies. There can
be no assurance that the Company will obtain the necessary FDA or foreign
clearances on a timely basis, if at all. As discussed above, commercialized
medical products are subject to further regulatory restrictions, which may
adversely affect the Company. Changes in existing laws and regulations or
policies could adversely affect the ability of the Company to comply with
regulatory requirements.
There can be no assurance that the Company's products will gain any significant
market acceptance in their intended target markets, even if required regulatory
approvals are obtained.
Revenues for many of the medical devices manufactured by the Company may be
dependent in part on availability of adequate reimbursement for those devices
from third-party health care payers, such as government and private insurance
plans. There is no assurance that the levels of reimbursements offered by
third-party payers will be sufficient to achieve market acceptance of the
Company's products.
Regulatory Compliance for Manufacturing Facilities
The Company expends significant time, resources, and effort in the areas of
training, production, and quality assurance to maintain compliance with
applicable regulatory requirements. There can be no assurance, however, that the
Company's manufacturing operations will be found to comply with GMP regulations,
ISO standards, or other applicable legal requirements or that the Company will
not be required to incur substantial costs to maintain its compliance with
existing or future manufacturing regulations, standards, or other requirements.
The Company's failure to comply with GMP regulations or other applicable legal
requirements can lead to warning letters, seizure of non-compliant products,
injunctive actions brought by the U.S. government, and potential civil or
criminal liability on the part of the Company and officers and employees who are
responsible for the activities that lead to any violation. In addition, the
continued sale of any instruments manufactured by the Company may be halted or
otherwise restricted.
Product Development
The success of the Company will depend to a significant extent upon its ability
to enhance and expand on its current offering of proprietary products and to
develop and introduce additional innovative products that gain market
acceptance. While the Company maintains research and development programs and
has established a Technical Advisory Board to assist it, there is no assurance
that the Company will be successful in selecting, developing, manufacturing, and
marketing new products or enhancing its existing products on a timely or
cost-effective basis. Moreover, the Company may encounter technical problems in
connection with its efforts to develop or introduce new products or product
enhancements. Some of the devices currently under consideration by the Company
(as well as devices of some of its customers) will require significant
additional development, pre-clinical testing and clinical trials, and related
investment prior to their commercialization. There can be no assurance that such
devices will be successfully developed, prove to be safe or efficacious in
clinical trials, meet applicable regulatory standards, be capable of being
produced in commercial quantities at reasonable costs, or be successfully
marketed.
Design and Manufacturing Process Risks
While the Company has substantial experience in designing and manufacturing
devices, the Company may still experience technical difficulties and delays with
the design and manufacturing of its or its customer's products. Such
difficulties could cause significant delays in the Company's production of
products. In some instances, payment by a manufacturing customer is dependent on
the Company's ability to meet certain design and production milestones in a
timely manner. Also, some major contracts can be canceled if purchase orders
thereunder are not completed when due. Potential difficulties in the design and
manufacturing process that could be experienced by the Company include
difficulty in meeting required specifications, difficulty in achieving necessary
manufacturing efficiencies, and difficulty in obtaining materials on a timely
basis.
Expansion of Marketing; Limited Distribution
The Company currently has a limited domestic direct sales force consisting of
eight individuals, complemented by a network of independent manufacturing
representatives. The Company anticipates that it will need to increase its
marketing and sales capability significantly to more fully cover its target
markets, particularly as additional proprietary devices become commercially
available. There can be no assurance that the Company will be able to compete
effectively in attracting and retaining qualified sales personnel or independent
manufacturing representatives as needed or such persons will be successful in
marketing or selling the Company's services and products.
Product Recalls
If a device that is designed or manufactured by the Company is found to be
defective, whether due to design or manufacturing defects, to improper use of
the product, or to other reasons, the device may need to be recalled, possibly
at the Company's expense. Furthermore, the adverse effect of a product recall on
the Company might not be limited to the cost of a recall. For example, a product
recall could cause a general investigation of the Company by applicable
regulatory authorities as well as cause other customers to review and
potentially terminate their relationships with the Company. Recalls, especially
if accompanied by unfavorable publicity or termination of customer contracts,
could result in substantial costs, loss of revenues, and a diminution of the
Company's reputation.
Risk of Product Liability
The manufacture and sale of products, especially medical products, entails an
inherent risk of product liability. The Company does maintain product liability
insurance with limits of $1 million per occurrence and $2 million in the
aggregate. There can be no assurance that such insurance is adequate to cover
potential claims or that the Company will be able to obtain product liability
insurance on acceptable terms in the future or that any product liability
insurance subsequently obtained will provide adequate coverage against all
potential claims. Such claims may be large in the medical products area where
product failure may result in loss of life or injury to persons. Additionally,
the Company generally provides a design defect warranty and in some instances
indemnifies its customers for failure to conform to design specifications and
against defects in materials and workmanship, which could subject the Company to
a claim under such warranties or indemnification.
Potential Inability to Sustain and Manage Growth
The Company's need to manage its growth effectively will require it to continue
to implement and improve its operational, financial, and management information
systems, to develop its managers' and project engineers' management skills, and
to train, motivate, and manage its employees. The Company must also be able to
attract and retain a sufficient number of suitable employees to sustain its
growth. If the Company cannot keep pace with the growth of its customers, it may
lose customers and its growth may be limited.
Dependence Upon Management
The Company is substantially dependent upon its key managerial, technical, and
engineering personnel, particularly ZEVEX' three executive officers, Dean G.
Constantine, Chief Executive Officer and President, David J. McNally, Executive
Vice President, Phillip L. McStotts, Chief Financial Officer and
Secretary/Treasurer, and key managerial personnel Leonard Smith, Vice President
of Sales and Marketing of ZEVEX Inc. and President of JTech, and Vijay Lumba,
President of Aborn. The Company must also attract and retain highly qualified
engineering, technical, and managerial personnel. Competition for such personnel
is intense, the available pool of qualified candidates is limited, and there can
be no assurance that the Company can attract and retain such personnel. The loss
of its key personnel could have a material adverse effect on the Company's
business, results of operations, and financial condition. Only Mr. Smith and Mr.
Lumba have employment agreements with their respective subsidiary companies.
None of the Company's other key personnel have employment agreements with the
Company.
The Company carries key-man life insurance on the lives of its Chief Executive
Officer, Chief Financial Officer, and Executive Vice President in the amount of
$500,000 each. No assurances can be given that such insurance would provide
adequate compensation to the Company in the event of the death of such key
employee.
Patent Protection
As of December 31, 1999, the Company held twelve U.S. patents on devices
developed by the Company. Such patents disclose certain aspects of the Company's
technologies and there can be no assurance that others will not design around
the patent and develop similar technology. The Company believes that its devices
and other proprietary rights do not infringe any proprietary rights of third
parties. There can be no assurance, however, that third parties will not assert
infringement claims in the future.
Control by Management and Certain Major Shareholders
As of March 15, 2000, the current executive officers and directors of ZEVEX,
together with those persons who are the beneficial owners of more than 5% of
ZEVEX' Common Stock, will beneficially own or have voting control over
approximately 34% of the outstanding Common Stock. Accordingly, these
individuals have the ability to influence the election of ZEVEX' directors and
most corporate actions. This concentration of ownership, together with other
provisions in ZEVEX' charter and applicable corporate law, may also have the
effect of delaying, deterring, or preventing a change in control of ZEVEX.
Suppliers and Shortages of Component Parts
The Company relies on third-party suppliers for each of the component parts used
in manufacturing its customers' devices. Although component parts are generally
available from multiple suppliers, certain component parts may require long lead
times, and the Company may have to delay the manufacture of customer devices
from time to time due to the unavailability of certain component parts. In
addition, even if component parts are available from an alternative supplier,
the Company could experience additional delays in obtaining component parts if
the supplier has not met the Company's vendor qualifications. Component
shortages for a particular device may adversely affect the Company's ability to
satisfy customer orders for that device. Such shortages and extensions of
production schedules may delay the recognition of revenue by the Company and may
in some cases constitute a breach of a customer contract. If shortages of
component parts continue or if additional shortages should occur, the Company
may be forced to pay higher prices for affected components or delay
manufacturing and shipping particular devices, either of which could adversely
affect subsequent customer demand for such devices.
Customer Conflicts
The medical technology industry reflects vigorous competition among its
participants. As a result, its customers sometimes require the Company to enter
into noncompetition agreements that prevent the Company from manufacturing
instruments for its customers' competitors. For example, the Company has agreed
with one customer not to manufacture certain devices for laser cataract surgery
for any other customer or potential customer. Such restrictions generally apply
during the term of the customer's manufacturing contract and, in some instances,
for a period following termination of the contract. If the Company enters into a
noncompetition agreement, the Company may be adversely affected if its
customer's product is not successful and the Company must forgo an opportunity
to manufacture a successful instrument for such customer's competitor. Any
conflicts among its customers could prevent or deter the Company from obtaining
contracts to manufacture successful instruments.
Future Capital Requirements
The Company believes that its existing capital resources and amounts available
under the Company's existing bank line of credit, will satisfy the Company's
anticipated capital needs for the next two years (depending primarily on the
Company's growth rate and its results of operations). The commercialization of
proprietary products, which is an element of the Company's growth strategy,
would require increased investment in working capital and could therefore
shorten this period. Thereafter, the Company may be required to raise additional
capital or increase its borrowing capacity, or both. There can be no assurance
that alternative sources of equity or debt will be available in the future or,
if available, will be on terms acceptable to the Company. Any additional equity
financing would result in additional dilution to the Company's shareholders.
Reliance on Efficiency of Distribution and Third Parties
The Company believes its financial performance is dependent in part on its
ability to provide prompt, accurate, and complete services to its customers on a
timely and competitive basis. Accordingly, delays in distribution in its
day-to-day operations or material increases in its costs of procuring and
delivering products could have an adverse effect on the Company's results of
operations. Any failure of either its computer operating system or its telephone
system could adversely affect its ability to receive and process customer's
orders and ship products on a timely basis. Strikes or other service
interruptions affecting Federal Express Corporation, United Parcel Service of
America, Inc., or other common carriers used by the Company to receive necessary
components or other materials or to ship its products also could impair the
Company's ability to deliver products on a timely and cost-effective basis.
Volatility of Revenues and Product Mix
The Company's annual and quarterly operating results are affected by volume and
timing of customer orders, which vary due to (i) variation in demand for the
customer's products as a result of, among other things, product life cycles,
competitive conditions, and general economic conditions, (ii) the customer's
attempt to balance its inventory, (iii) the customer's need to adapt to changing
regulatory conditions and requirements, and (iv) changes in the customer's
manufacturing strategy. Technical difficulties and delays in the design and
manufacturing processes may also affect such results. The foregoing factors may
cause fluctuations in revenues and variations in product mix, which could in
turn cause fluctuations in the Company's gross margin. Under the terms of the
Company's contracts with many of its customers, the customers have broad
discretion to control the volume and timing of product deliveries. Further, the
Company's contracts with its customers typically have no minimum purchase
requirements. As a result, production may be reduced or discontinued at any
time. Therefore, it is difficult for the Company to forecast the level of
customer orders with certainty, making it difficult to schedule production and
maximize manufacturing capacity. Other factors that may adversely affect the
Company's annual and quarterly results of operations include inexperience in
manufacturing a particular instrument, inventory shortages or obsolescence,
labor costs or shortages, low gross margins on design projects, an increase in
design revenues as a percentage of total revenues, price competition, and
regulatory requirements. Because the Company's business organization and its
related cost structure anticipate supporting a certain minimum level of
revenues, the Company's limited ability to adjust its short term cost structure
would compound the adverse effect of any significant revenue reduction.
Uncertain Protection of Intellectual Property
To maintain the secrecy of its proprietary information, the Company relies on a
combination of trade secret laws and internal security procedures. The Company
typically requires its employees, consultants, and advisors to execute
confidentiality and assignment of inventions agreements. There can be no
assurance, however, that the common law, statutory, and contractual rights on
which the Company relies to protect its intellectual property and confidential
and proprietary information will provide it with adequate or meaningful
protection. Third parties may independently develop products, techniques, or
information that are substantially equivalent to the products, techniques, or
information that the Company considers proprietary. In addition, proprietary
information regarding the Company could be disclosed in a manner against which
the Company has no meaningful remedy. Disputes regarding the Company's
intellectual property could force the Company into expensive and protracted
litigation or costly agreements with third parties. An adverse determination in
a judicial or administrative proceeding or failure to reach an agreement with a
third party regarding intellectual property rights could prevent the Company
from manufacturing and selling certain of its products.
Limited Market for Common Stock
Historically, the market for ZEVEX' Common Stock has been limited due to the
relatively low trading volume and the small number of brokerage firms acting as
market makers. In May 1997, ZEVEX' Common Stock was listed for trading on the
American Stock Exchange. In November 1998, ZEVEX' Common Stock was changed to a
listing on the NASDAQ Stock Market, which has increased the market for the
Common Stock. No assurance can be given, however, that the market for the Common
Stock will continue or increase or that the prices in such market will be
maintained at their present levels.
Possible Volatility of Stock Price
Announcements of technological innovations for new commercial devices by the
Company or its competitors, developments concerning the Company's proprietary
rights, or the public concern as to safety of its devices may have a material
adverse impact on ZEVEX' business and on the market price of its Common Stock,
particularly as the Company expands its efforts to become a medical technology
company that manufactures and markets its own proprietary devices. The market
price of ZEVEX' Common Stock may be volatile and may fluctuate based on a number
of factors, including significant announcements by the Company and its
competitors, quarterly fluctuations in the Company's operating results, and
general economic conditions and conditions in the medical technology industry.
In addition, in recent years the stock market has experienced extreme price and
volume fluctuations, which have had a substantial effect on the market prices
for many medical-technology companies and are often unrelated to the operating
performance of such companies.
Issuance of Additional Shares for Acquisition or Expansion
Any future major acquisition or expansion of the Company may result in the
issuance of additional common shares or other stocks or instruments that may be
authorized without shareholder approval. The issuance of subsequent securities
may also result in substantial dilution in the percentage of the Common Stock
held by existing shareholders at the time of any such transaction. Moreover, the
shares or warrants issued in connection with any such transaction may be valued
by the Company's management based on factors other than the trading price on the
NASDAQ Stock Market.
Impact of Anti-Takeover Measures; Possible Issuance of Preferred Stock;
Classified Board
Certain Provisions of the Company's Certificate of Incorporation and Bylaws and
the Delaware General Corporation Law may have the effect of preventing,
discouraging, or delaying a change in the control of the Company and may
maintain the incumbency of the Board of Directors and management. Such
provisions could also limit the price that certain investors might be willing to
pay in the future for shares of the Company's Common Stock. Pursuant to the
Company's Certificate of Incorporation, the Board of Directors is authorized to
fix the rights, preferences, privileges, and restrictions, including voting
rights, of unissued shares of the Company's Preferred Stock and to issue such
stock without any further vote or action by the Company's stockholders. The
rights of the holders of Common Stock will be subject to and may be adversely
affected by the rights of the holders of any Preferred Stock that may be created
and issued in the future. In addition, stockholders do not have the right to
cumulative voting for the election of directors. Furthermore, the Company's
Certificate and Bylaws provide for a staggered board whereby only one-third of
the total number of directors are replaced or re-elected each year. The
Certificate also provides that the provisions of the Certificate relating to
number, vacancies, and classification of the Board of Directors may only be
amended by a vote of at least 66 2/3% of the shareholders. Finally, the Bylaws
provide that special meetings of the stockholders may only be called by the
President of the Company or pursuant to a resolution adopted by a majority of
the Board of Directors.
The Company is subject to Section 203 of the Delaware General Corporation Law
("Section 203"), which restricts certain transactions and business combinations
between a corporation and an "Interested Stockholder" owning 15% or more of the
corporation's outstanding voting stock for a period of three years from the date
the stockholder becomes an Interested Stockholder. Subject to certain
exceptions, unless the transaction is approved in a prescribed manner, Section
203 prohibits significant business transactions such as a merger with,
disposition of assets to, or receipt of disproportionate financial benefits by
the Interested Stockholder, or any other transactions that would increase the
Interested Stockholder's proportionate ownership of any class or series of the
corporation's stock.
Foreign Exchange, Currency, and Political Risk
The Company's international business is subject to risks customarily encountered
in foreign operations, including changes in a specific country's or region's
political or economic conditions, nationalization, trade protection measures,
import or export licensing requirements, the overlap of different tax
structures, unexpected changes in regulatory requirements, other restrictive
government actions such as capital regulations, and natural disasters. The
Company is also exposed to foreign currency exchange rate risk inherent in its
foreign sales commitments and anticipated foreign sales because the prices
charged for its products are denominated in U.S. dollars. Consequently, the
Company's foreign sales commitments and anticipated sales could be adversely
affected by an appreciation of the U.S. dollar relative to other currencies.
ITEM 2. PROPERTIES
ZEVEX' executive offices, and the administrative offices and manufacturing
facilities of ZEVEX Inc. and JTech, are located in ZEVEX' 51,000 square foot,
mixed-use building in Salt Lake City, Utah. This building was constructed in
1997 to the Company's specifications and is subject to an Industrial Revenue
Bond, (see "Management's Discussion and Analysis of Financial Condition and
Results of Operations Liquidity and Capital Resources"). The building is
situated on nearly four acres of land a few miles from the downtown area. It
allows quick access to two major interstate freeways and to the Salt Lake
International Airport. The Company currently utilizes approximately 90% of the
building's available space and believes that the building will be adequate to
serve the Company's needs through the end of the year 2000.
To allow the Company to build additional facilities as growth may require, the
Company has acquired approximately 3.47 vacant acres adjacent to its facility.
The Company also leases on a month to month basis approximately 5,000 square
foot, adjacent to its facility for storage of its disposable sets for enteral
delivery.
Aborn's administrative and manufacturing operations are located in a leased
3,300 square foot building in San Jose, California. The building was constructed
in 1979 and is adequate for Aborn's needs.
ITEM 3. LEGAL PROCEEDINGS
The Company is not engaged in any legal proceedings.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to ZEVEX' shareholders for vote in the fourth quarter
of 1999.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
ZEVEX' Common Stock has been trading on the National Market system of The NASDAQ
Stock Market since November 2, 1998, under the symbol ZVXI. Prior to that date
the stock traded on the American Stock Exchange beginning May 19, 1997, under
the symbol ZVX. Prior to May 1997, the stock traded on the OTC Bulletin Boards
under the symbols ZVXI and ZVXIU. As of March 15, 2000, there were 177 holders
of record of ZEVEX' Common Stock (calculated without reference to individual
participants in securities position listings). Based on the number of proxy
materials requested by brokers and other record holders for distribution to
beneficial owners for the Company's 1999 Annual Meeting, ZEVEX estimates there
are roughly 1,250 beneficial owners of ZEVEX Common Stock. ZEVEX has never
declared or paid any cash dividends on its Common Stock. ZEVEX currently intends
to retain all future earnings to finance future growth and does not anticipate
paying any cash dividends in the foreseeable future. ZEVEX has a negative
covenant in its bank line of credit agreement that prevents the payment of any
cash dividend without prior approval of the bank.
The following table lists the high and low sales prices for ZEVEX Common Stock
for each full quarterly period since January 1, 1998.
<TABLE>
<CAPTION>
<S> <C> <C> <C>
------------------------------------- -------------------------------------
1999 1998
High Low High Low
------------------ ------------------ ------------------- ------------------
1st Quarter $7.25 $4.75 $12.63 $7.88
2nd Quarter $6.63 $4.13 $11.25 $6.75
3rd Quarter $6.50 $4.13 $7.63 $4.50
4th Quarter $5.50 $4.00 $7.88 $4.00
</TABLE>
During 1999, ZEVEX issued 1,850 shares of Common Stock which were not registered
under the Securities Act of 1933 (the "Securities Act"). The shares were issued
pursuant to the exercise of stock options by employees of the Company and as
such are exempt from registration under SEC Rule 505. The exercise price on such
shares ranged from $2.50 to $5.00 per share. The aggregate exercise price of the
securities issued was $6,175.
ITEM 6. SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA - FIVE-YEAR REVIEW
The following selected statement of operations data for the years ended December
31, 1999, 1998 and 1997, and the balance sheet data as of December 31, 1999 and
1998 are derived from the audited consolidated financial statements included in
this report and should be read in conjunction with those consolidated financial
statements and notes thereto. The selected statement of operations data for the
years ended December 31, 1996 and 1995 and the balance sheet data as of December
31, 1997, 1996 and 1995 are derived from the audited consolidated financial
statements of the Company, which are not included herein, and are qualified by
reference to such financial statements and the notes thereto.
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C>
Fiscal Year Ended December 31
1999 1998 1997 1996 1995
---------------------------------------------------------------------
Statement of Operations Data
Revenues $23,026,208 $11,084,413 $8,968,425 $5,663,733 $5,295,762
Gross profit 10,551,998 4,237,970 4,211,368 2,727,678 2,230,209
Selling, general and administrative expenses 6,988,044 3,879,408 2,481,090 1,892,317 1,324,928
Research and development expenses 670,886 290,669 702,563 527,562 502,255
Other (income)/expenses 78,706 (407,469) (47,136) (243,947) (40,829)
Provisions for taxes 1,187,989 113,169 356,609 206,169 127,055
Net income 1,626,373 362,193 718,242 345,577 316,800
Net income per share basic .48 .11 .34 .25 .24
Weighted average shares outstanding 3,413,023 3,298,150 2,097,831 1,388,511 1,305,812
Net Income per share diluted .47 .10 .29 .24 24
Weighted average shares outstanding` assuming
dilution
3,431,566 3,636,434 2,443,482 1,411,687 1,333,768
- -----------------------------------------------------------------------------------------------------------------------
1999 1998 1997 1996 1995
- -----------------------------------------------------------------------------------------------------------------------
Balance Sheet Data
Total assets $34,049,689 $33,760,979 $22,582,543 $6,368,670 $3,247,375
Total current liabilities 5,782,319 7,395,946 1,290,466 588,009 346,504
Long-term debt (less current portion) 7,170,000 6,150,000 1,900,000 2,000,000 --
Stockholders' equity 21,090,722 20,114,535 19,265,697 3,701,449 2,900,871
</TABLE>
Please refer to Item 7 for a discussion of the main factors causing the
substantial changes in certain of the items set forth above, particularly when
comparing 1999 to earlier periods. Also as discussed in Item 7, the Company's
management anticipates that the financial performance during 2000 and future
periods will be materially affected by the acquisition from Nestle USA of its
enteral feeding pump and related disposable product business.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
General
Through its subsidiaries, ZEVEX is in the business of designing, manufacturing
and distributing medical devices. The Company's product lines include
proprietary medical devices which it designs, manufactures, and distributes, and
contract-manufactured products which it designs and manufactures for original
equipment manufacturers (OEM's).
ZEVEX' current strategy is to continue to aggressively grow proprietary product
revenues with the acquisition and internal development of products that
complement its existing two lines of proprietary products. This is intended to
augment ZEVEX' contract manufacturing business, which historically has been the
core competence of ZEVEX.
Developments During 1999
The Company substantially grew revenues and earnings during 1999, diversifying
its offering of proprietary products further and gaining market share in both
proprietary markets, as well as growing its contract manufacturing business. Key
contributors to the year's growth were:
1. The acquisition in July 1998, of Nutrition Medical Inc.'s product line of
stationary feeding pumps, disposable sets and feeding tubes for enteral
nutrition delivery.
2. The acquisition on December 31, 1998, of JTech Medical Industries, Inc. JTech
manufactures and markets its own proprietary musculoskeletal evaluation products
for health care providers, a line of products not previously manufactured or
sold by ZEVEX.
3. The acquisition on December 31, 1998, of Aborn Electronics, Inc. Aborn
designs and manufactures a variety of sophisticated optical sensors, custom
computer chips and semiconductor components for medical technology and other
companies, and has brought new design and manufacturing expertise to the
Company.
4. The agreement with Applied Medical Technology, Inc. on May 6, 1999 to
distribute AMT's MINI(TM) button low-profile gastrostomy access devices within
the home care market. Management believes that this important component used in
enteral nutrition delivery will be a significant addition to the Company's
growing product line.
Results of Operations
The Company's sales results for 1999 were the strongest in the Company's
history. Revenues were $23,026,208, a 108% increase over revenues of $11,084,413
in 1998, which were a 23% increase over revenues of $8,968,425 in 1997. Revenues
for 1999 increased primarily due to demand for the Company's proprietary
products, the award of significant engineering and manufacturing service
contracts, and the contribution of the acquisitions of the Nutrition Medical
product line, Aborn, and JTech. Also contributing to the year's performance
was a strong shift of contract manufacturing revenue from the first quarter of
2000 into the fourth quarter of 1999 due to the accelerated shipment of products
in late 1999 at the request of ZEVEX Inc.'s customers. The Company estimates
that this shift involves $500,000 to $1 million. Accordingly, Company
management expects the revenues for the first quarter of 2000 to be lower than
expected. This is due not only to the shift in revenues described above, but
also due to reduced sales of enteral feeding pumps to Nestle in the first
quarter of 2000. This reduction in sales to Nestle, estimated to be as much as
$750,000, was due to the anticipated acquisition of Nestle assets described
previously.
The Company's current strategy as stated above is to continue to aggressively
grow proprietary product revenues with the acquisition and internal development
of proprietary products that complement its existing two lines of proprietary
products. This strategy is intended to augment continuing growth in ZEVEX Inc.'s
contract manufacturing business, which historically has been the core competence
of ZEVEX. As a result of the growth of the Company's proprietary product
business, the portion of the Company's revenues represented by that business has
risen significantly over prior years. In 1999, 47% of the Company's revenue was
derived from proprietary products sold by the Company, in comparison to 30% in
1998 and 12% in 1997. This shift in revenue sources has the benefit of
decreasing the percentage of the Company's revenues generated by a small number
of major customers. During 1999, only one customer accounted for over 10% of the
Company's revenues, generating 13% of total revenues. During 1998 and 1997,
three customers each accounted for over 10% of the Company's revenues, together
generating 44% and 65% of total revenues in each year respectively.
Future revenue growth for many of the medical devices manufactured by the
Company may be dependent in part on availability of adequate reimbursement for
those devices from third-party health care payers, such as government and
private insurance plans. The medical products industry is also subject to
significant technological change and requires ongoing investment to keep pace
with technological development, quality, and regulatory requirements. In order
to compete in this marketplace, the Company will be required to make ongoing
investments in research and development with respect to its existing and future
products.
Manufacturing revenue growth depends upon growth in demand for systems, devices,
and instruments manufactured by the Company, as well as on the Company's ability
to acquire additional manufacturing service contracts from medical technology
companies. The Company's contract manufacturing customers have complete control
over the marketing and sales of products that the Company manufactures for them.
The Company has no ability to increase demand for instruments that it
manufactures for its contract-manufacturing customers. No assurances can be
given that orders from any customer will increase or remain at current levels or
that they will not decline.
The Company markets its manufacturing capabilities and rarely undertakes design
work without securing manufacturing rights (See "Manufacturing Capabilities").
The volume and timing of future manufacturing revenues related to any specific
engineering project are highly variable. Certain engineering projects may not
lead to future manufacturing revenues. The manufacturing gross margin percentage
from year to year depends primarily on the product mix, as gross margins vary by
instrument and as a result of negotiated volume discounts. Management may
negotiate volume discounts if the larger volume results in smaller per unit
overhead, improving operating margin. The gross margin percentage for
manufacturing revenues from instruments not yet approved for commercial use is
generally lower because a smaller number of units produced limits opportunities
to achieve economies of scale. Additionally, the instrument and its
manufacturing process are being refined, resulting in larger per unit costs
during the initial manufacturing phase.
The Company's annual and quarterly operating results are affected by acceptance
of the markets for the Company's proprietary and contract manufactured products,
including the volume and timing of customer orders, which vary due to (i)
variation in demand for the customer's products as a result of, among other
things, product life cycles, competitive conditions, and general economic
conditions, (ii) the customer's attempt to balance its inventory, (iii) the
customer's need to adapt to changing regulatory conditions and requirements, and
(iv) changes in the customer's manufacturing strategy. Technical difficulties
and delays in the design and manufacturing processes may also affect such
results. The foregoing factors may cause fluctuations in revenues and variations
in product mix, which could in turn cause fluctuations in the Company's gross
margin. During the first quarter of 1999, the Company had continued to work with
a certain customer on a fixed price contract, which had an adverse impact on the
Company's gross margin. Also during 1999, the Company completed a reengineering
project with a customer on a cost sharing basis which adversely affected gross
margin.
The following table sets forth, for the periods indicated, the relative
percentages that certain items in the income statement bear to revenues.
Year Ended December 31, Income Statement Data -- Percentage of Gross Sales
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C>
1999 1998 1997 1996 1995
------------- ------------- -------------- ------------- -------------
Revenues 100% 100% 100% 100% 100%
Gross profit 46% 38% 47% 48% 42%
Selling, general and 30% 34% 27% 33% 25%
administrative expenses
Research and development expenses 3% 3% 8% 10% 9%
Operating income 13% 1% 12% 5% 8%
Other income/(expense) (1)% 3% --% 4% 1%
Income before taxes 12% 4% 12% 9% 9%
Provisions for taxes 5% 1% 4% 3% 3%
Net income 7% 3% 8% 6% 6%
</TABLE>
Sales of the Company's proprietary enteral feeding products line accounted for
approximately 33% of the total revenues for the year ended December 31, 1999,
compared to 30% and 12% for the years ended December 31, 1998 and 1997,
respectively. Sales of the Company's proprietary JTech product line, accounted
for approximately 14% of the total revenues for the 1999 year. Fifty-three
percent of the Company's revenues during the 1999 year were products that are
manufactured for and sold to OEM customers, who market the final product. The
Company's gross profit as a percentage of sales was 46% in 1999, as compared to
38% in 1998 and 47% in 1997. Management attributes the increase in gross profit
percentage from 1998 to 1999 to a number of matters, including (1) a shift in
the revenue mix of its products to higher margin items that were sold during
1999, (2) consistent delivery schedules dictated by the Company's larger
customers, and (3) the Company not having similar costs to those incurred in
1998 related to the Nutrition Medical acquisition as well as non-recurring
engineering (NRE) tooling expenses.
Selling, general and administrative expenses increased during 1999 to
$6,988,044, 30% of gross sales, as compared to $3,879,408, 34% of gross sales in
1998, and $2,481,090, 27% of gross sales in 1997. During 1999, increased
expenses resulted from the Company's continuing growth, which has resulted
primarily from the acquisitions of JTech and Aborn. An expanded sales and
marketing effort increased staffing, travel, advertising, and administrative
expenses related to the Company's proprietary clinical nutrition delivery
product line and JTech product lines. The Company also had an increase in
expenses related to employees, such as insurance, taxes, and pension benefits.
After consideration for the one-time expenditures related to the Nutrition
Medical product line acquisition, the Company believes that general and
administrative expenses in 2000 as related to sales will continue at
approximately the same percentage as in the previous two years.
As of December 31, 1999, the Company had three full-time engineers in research
and development, and had several other designers and engineers contributing to
research and development projects. The Company's research and development
projects are primarily focused on new proprietary products. During the last
three fiscal years, the Company continued independent research and development
activities with respect to the design of new and improved devices, spending
$670,886 in 1999, $290,699 in 1998, and $702,563 in 1997. In 1999 and 1998,
research and development costs represented approximately 3% of revenues in each
of those years and 8% in 1997. Significant fluctuations experienced in research
and development are due to timing of the Company's research projects. The
Company expects research and developments costs in 2000 to be approximately 3%
of revenues.
Depreciation and amortization expenses increased to $1,557,221 in 1999 from
$471,752 in 1998, and $284,174 in 1997. This increase reflects increased
depreciation due to capital expenditures for property and equipment purchased to
increase engineering, design, and manufacturing capabilities to support
anticipated growth, as well as increased amortization of goodwill related to
1998 acquisitions.
Goodwill represents the excess of the purchase price of companies and products
the Company purchased over the fair value of the tangible and other specifically
identified intangible assets of those companies and products. Goodwill
amortization lives were determined by comparing recent acquisitions of similar
companies and industries. Goodwill is amortized over a periods ranging from 15
to 23 years. The current value of goodwill included in the financial statements
is $10,642,304, and represents approximately 31% of total assets.
Income tax expenses increased to $1,187,989 in 1999 from $113,169 in 1998, and
$356,609 in 1997. The increase is primarily due to the increased income before
taxes and non-deductible goodwill amortization.
At December 31, 1999, the Company had deferred tax assets of approximately
$200,000. Realization of the deferred tax assets is dependent on the Company's
ability to generate approximately $600,000 in taxable income in the year the
assets are realized. Management believes that sufficient income will be earned
in the future to realize these assets. Management will evaluate the
realizability of the deferred tax assets annually and assess the need for
valuation allowances.
Operating income increased to $2,893,068, 13% of gross revenue in 1999 compared
to $67,893, 1% of gross revenue in 1998, and $1,027,715, 11% of gross revenue in
1997. Similarly, the Company had a net income of $1,626,373, 7% of gross revenue
in 1999, compared to $362,193, 3% of gross revenue in 1998, and $718,242, 6% of
gross revenue in 1997. The changes during 1999 as compared to 1998 and 1997 are
principally due to the increase in revenues from proprietary products, the costs
addressed above in relation to cost of sales and selling, general and
administrative costs, and changes in the Company's product mix of higher margin
items delivered during the 1999 year.
Liquidity and Capital Resources
The Company increased its working capital requirements during 1999, mostly as a
result of increasing accounts receivable associated with growth in revenues and
the Company's efforts to expand its operations by acquisitions of products and
technologies. Prior to 1997, working capital had been funded primarily by a
combination of increased accounts payable and borrowings under the Company's
revolving line of credit. Beginning in 1997, working capital was also provided
by a $1.25 million private placement of ZEVEX' Common Stock and warrants in
February, 1997 and a secondary public offering of ZEVEX' Common Stock in
November 1997, from which ZEVEX received approximately $13 million in net
proceeds.
During 1999, the Company produced $1,626,373 in net income. Cash and cash
equivalents increased by $1,803,429 for 1999 from operating activities, as the
Company had an increase in payables and decreased its inventories which was
offset by increased accounts receivable which increased as the Company continued
to expand its proprietary businesses and meet customer requirements. During
1998, the Company had net income of $362,193, and cash and cash equivalents
decreased from operating activities by $1,837,748, as the Company funded
increases in accounts receivable and inventories. During 1997, the Company had
net income of $718,242, and cash and cash equivalents decreased by $1,362,938
from operating activities, while the Company funded an increase in accounts
receivable.
In 1997, the Company completed construction of its new 51,000 square foot
headquarters and manufacturing facility. The cost of this undertaking was
approximately $2,591,177. In 1996, the company negotiated a $2.0 million
Industrial Development Bond to finance this construction. The Company's
purchases of land, leasehold improvements to its facilities, and new research,
production, testing equipment, and tooling totaled $566,958 in 1999, as compared
to $1,185,805 in 1998, and $3,004,926 in 1997. The amount spent during 1998 is
primarily attributed to the Company's purchase of approximately 3.5 acres of
land adjacent to the Company's current facility in Salt Lake City in March 1998,
as well as to continued upgrading of the Company's production fixturing,
tooling, and research and engineering capabilities. The difference in purchases
between 1998 and 1997 is primarily due to the construction of the Company's
headquarters and manufacturing facility and upgrading the Company's production
fixturing, tooling and research and engineering capabilities during 1997.
The Company's working capital at December 31, 1999, was $11,935,524, compared to
$11,669,033 at December 31, 1998, and $17,235,516 at December 31, 1997. The
portion of working capital represented by cash and short-term investments at
such dates was $6,608,361, $9,558,543 and $12,663,535 respectively. In 1999, the
Company's increase in working capital of $266,491 was primarily due to operating
activities. The decrease in working capital during 1998 compared to 1997 is
primarily attributed to (i) cash outlays and current payables related to the
acquisitions of the product line from Nutrition Medical and the stock purchases
of JTech and Aborn, (ii) increases in accounts and accrued payables, and (iii)
an increase of the Company's line of credit. In 1997, the increase in working
capital was primarily attributed to (i) completion of a secondary offering of
the Company's common stock in November, 1997, of approximately $13 million, (ii)
increased income from operations during the year, and (iii) a private placement
that was completed in February, 1997.
On December 23, 1998, ZEVEX issued 115,000 shares of Common Stock and paid
$500,000 to Nutrition Medical, Inc. as consideration for the acquisition of
Nutrition Medical's assets relating to its enteral feeding pump and related
disposable feeding product business.
On December 31, 1998, ZEVEX committed to pay up to $1,875,000 in cash and a
convertible debentures in the aggregate amount of $1,350,000 to Vijay Lumba and
Harry Parmar as partial consideration for the acquisition of all issued and
outstanding stock of Aborn. All or part of the outstanding principal of each
debenture is convertible by the holder into ZEVEX Common Stock at a rate of
$11.00 per share at any time between one and three years from the date of
issuance. In 1999, the Company paid cash of $1,850,000 related to the
acquisition. On December 31, 1999, ZEVEX committed to pay $950,000 in cash and a
convertible debentures in the aggregate amount of $950,000 to Vijay Lumba and
Harry Parmar as payment of the earn-out portion of the acquisition of all issued
and outstanding stock of Aborn.
On December 31, 1998, ZEVEX committed to pay up to of $3,100,000 in cash and a
convertible debentures in the aggregate amount of $3,000,000 to Leonard Smith,
Tracy Livingston, and David Bernardi as partial consideration for the
acquisition of all issued and outstanding stock of JTech. All or part of the
outstanding principal of each debenture is convertible by the holder into ZEVEX
Common Stock at a rate of $11.00 per share at any time between one and three
years from the date of issuance. In 1999, the Company paid cash of $3,100,000
related to the acquisition. On December 31, 1999, ZEVEX committed to pay up to
of $175,000 in cash and a convertible debentures in the aggregate amount of
$175,000 to Leonard Smith, Tracy Livingston, and David Bernardi as payment of
the earn-out portion of the acquisition of all issued and outstanding stock of
JTech.
On February 12, 1997, the Company completed a private placement of $1,250,000 of
its securities, which consisted of 500,000 units at a price of $2.50 per unit.
Each unit consisted of one share of Common Stock and a warrant to purchase one
share of Common Stock at a price of $3.50 per share. As of December 31, 1998,
30,000 of the warrants included in the above units were exercised. In June 1999
the Company repurchased for $1,175,000 the remaining 470,000 common stock
warrants related to the above units.
On December 11, 1996, the Company entered into a $500,000 open line of credit
arrangement with a financial institution. The line of credit was increased to
$1,000,000 on September 10, 1997, and increased again to $5,000,000 on December
31, 1997. The line matures on May 31, 2000. The line of credit is collateralized
by accounts receivable and inventories, and bears interest at the financial
institutions prime rate. The Company owed $1,613,453 on the line of credit at
December 31, 1999, $541,993 at December 31, 1998, and zero at December 31, 1997.
Inflation and Changing Prices
The Company has not been, and in the near term is not expected to be, materially
affected by inflation or changing prices.
New Accounting Pronouncements
In December 1999, the Securities and Exchange Commission issued Staff Accounting
Bulletin (SAB) 101, Revenue Recognition in Financial Statements. The effective
date of SAB 101 is the second quarter of the fiscal year ending after December
15, 1999. The SAB clarifies proper methods of revenue recognition given certain
circumstances surrounding sales transactions. The Company continues to evaluate
the impact of SAB 101, but believes it is in compliance with the provisions of
the SAB and accordingly, does not expect SAB 101 to have a material effect on
its financial statements.
Subsequent Acquisition
In line with the Company's strategy of acquiring additional proprietary product
lines, on March 29, 2000, the Company entered into an agreement to acquire
from Nestle USA, Inc. ("Nestle") a portion of Nestle's enteral nutrition
delivery device business. In the asset purchase, the Company will acquire over
19,500 enteral feeding pumps which have been placed with various health care
facilities under arrangements whereby the users commit to purchase disposable
accessories for use with the feeding pumps or return the pumps. The
assets will also include Nestle's line of pump administration sets, feeding
tubes, irrigation kits and ancillary devices. Based on Nestle's historical
experience generating revenues from the acquired assets, the Company currently
estimates that the Nestle assets will generate approximately $3 million
in additional revenue to the Company during 2000 through the sale of
disposable accessories for the feeding pumps currently in use. The Company
currently anticipates that the acquisition will close by April 5, 2000.
Under the purchase agreement with Nestle, Nestle will provide certain transition
services to assist the Company in acquiring the business with a minimum of
disruption for the customers using the acquired pumps. There is no assurance,
however, that during the transition of the business from Nestle, the Company
will not encounter difficulties which reduce the revenues generated by the pumps
following the acquisition. In particular, there is no assurance that the users
of the pumps acquired from Nestle will continue to purchase disposable
accessories from the Company at the rate historically experienced by Nestle, in
which case the anticipated revenue estimated by the Company might not be
realized.
Year 2000 Compliance
State of Readiness
With regard to its information systems (financial, supply, inventory, order,
office support, etc.) the Company timely converted all necessary systems and was
ready for the year 2000. 100% of the necessary systems have been determined to
be Y2K compliant by the Company, or have been upgraded to new systems which are
certified by the manufacturer as Year 2000 compliant.
With regard to its
non-information system
operations, the Company has
reviewed and corrected Y2K
problems in the following areas: products currently manufactured by the Company;
manufacturing and engineering systems; and building systems. This review is 100%
complete and the Company has been able to correct each material Y2K issue
identified in the review.
With regard to potential Y2K issues for the Company's major material suppliers,
the Company has not yet identified any major supplier that believes it will be
unable to operate due to Y2K problems in 2000. Generally, the Company has
alternative sources for supplies in the event a supplier experiences such
difficulties and the Company does not presently anticipate material difficulties
in obtaining materials due to suppliers' Y2K problems.
With regard to major customers, the Company has had communications with such
parties and has reviewed responses regarding Y2K compliance. To date, the
Company has not experienced any problems regarding Y2K difficulties with such
customers.
With regard to third-party utilities and services (for example, telephone
electrical, bankcard processing and shipping services), the Company has not
experienced any problems regarding Y2K readiness of such providers.
Cost to Address Y2K
Issues
As of March 1, 2000, the Company has spent approximately $200,000 in hardware
and software expenses to upgrade or correct Y2K problems with the Company's
internal systems. These costs were paid out of operating cash flows. The Company
does not expect to incur any additional costs for further upgrades and
corrections relating to the Y2K issue. The costs stated above do include,
however, costs to upgrade and replace systems that the Company otherwise would
have incurred in the normal course of business. The Company has not yet been
able to estimate the costs it may incur as a result of its suppliers and
customers experiencing Y2K difficulties.
Risk of the Company's
Y2K Issues
The Company anticipates that the material risks related to its information and
non-information systems has been timely mitigated by the efforts made by the
Company to identify and correct internal Y2K problems. However, there is no
guarantee that the Company has successfully identified or corrected all Y2K
problems in a timely manner. For example, due to the inherent limitations of
real-time clock devices and system BIOS in the Company's manufacturing equipment
or building systems, continued review and testing could uncover additional
problems. In some cases, problems may be unforeseen, and occur regardless of the
testing and review that has been done.
Other major Y2K risks for the Company arise from the potential for major
customers to experience financial or operational difficulties resulting from Y2K
problems. If such customers reduce their orders for the Company's products or
services, the Company's operations could be adversely affected.
Additionally, although the Company has not experienced any disruption in service
from third-party providers that supply telephone, electrical, banking and
shipping services, any disruption of these critical services would hinder the
Company's ability to receive, process and ship orders.
Other Matters
Summary of Quarterly Data
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C> <C> <C>
12/99 9/99 6/99 3/99 12/98 9/98 6/98 3/98
------------- ------------- ------------- ------------- ------------- ----------- ----------- -----------
Revenue $7,195,220 $5,688,131 $5,481,404 $4,661,453 $3,451,206 $2,346,143 $3,099,353 $2,187,711
Gross profit 3,266,877 2,520,801 2,489,974 2,274,346 1,502,990 307,943 1,516,749 910,288
Net income 700,869 331,741 305,995 287,768 319,748 (419,844) 347,281 115,008
EPS basic .21 .10 .09 .08 .09 (.13) .11 .04
EPS diluted .20 .10 .09 .08 .09 (.13) .10 .03
</TABLE>
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to market risk in the form of fluctuations in
interest rates and their potential impact upon its industrial development bond
of $1,800,000. The variable rate on the industrial development bond is based on
a weekly tax-exempt floater rate. Principle payments of $100,000 are made
annually with the balance due October 1, 2016.
Additionally, the Company holds marketable securities with a fair value
of $254,817, at December 31, 1999 with fixed interest rates of 5.40% and 6.375%
and maturities in 2000. The Company's marketable equity securities with a fair
value of $2,970,000, at December 31, 1999, consist of public companies in the
small-cap market. At December 31, 1998, the Company held marketable securities
with a fair value of $1,209,235, with fixed interest rates of 5.40% and 6.375%
and maturities ranging from 1999 to 2000. The Company's marketable equity
securities held at December 31, 1998 had a fair value of $388,797, and consisted
of public companies in the small-cap market.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Company's financial statements for the fiscal years ended December
31, 1999 and 1998, are included beginning at page 42, immediately following Item
14.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
The Company has no changes in or disagreements with its independent
auditors with regard to financial disclosures.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The following table sets forth the name, age, and principal position of each
ZEVEX director and executive officer, as well as the expiration of each
director's term of office.
<TABLE>
<CAPTION>
<S> <C> <C> <C>
Expiration
Name Age Position of Term
Dean G. Constantine 47 President, Chief Executive Officer and Director 2001
David J. McNally 38 Executive Vice President and Director 2000
Phillip L. McStotts 42 Chief Financial Officer, Secretary/Treasurer and Director 2002
Leonard C. Smith 51 Vice President Sales and Marketing and Director 2001
Bradly A. Oldroyd 42 Director 2000
Darla R. Gill 48 Director 2002
Kirk Blosch 44 Director 2002
</TABLE>
ZEVEX' executive officers serve at the discretion of the Board of Directors.
None of the executive officers have employment agreements with ZEVEX with the
exception of Mr. Smith. Certain biographical information with respect to each of
the officers and directors is set forth below.
Dean G. Constantine is a founder of ZEVEX and has served as ZEVEX' CEO,
President, and Chairman of the Board since its inception in 1986. He also serves
as a director of ZEVEX Inc., JTech, and Aborn, and as President and CEO of ZEVEX
Inc. Prior to joining ZEVEX, he was employed by EDO Corporation, Western
Division, in Salt Lake City, Utah, from October 1985 to September 1987, and from
January 1971 to June 1983. During his nearly fifteen years of employment with
EDO Corporation, Mr. Constantine had various responsibilities including project
supervision, management of engineering for commercial and industrial
transducers, and research and development. From July 1983 through October 1985,
Mr. Constantine was employed as an engineering specialist at Northrop
Corporation Electro-Mechanical Division, Anaheim, California, where his
responsibilities included engineering project management and applications
engineering.
David J. McNally is a founder of ZEVEX and has served as ZEVEX' Executive Vice
President and as a director since its inception in 1986. He also serves as a
director of ZEVEX Inc., JTech, and Aborn, and as a Vice President of ZEVEX Inc.
Prior to joining ZEVEX, he was employed by EDO Corporation in Salt Lake City,
Utah as a marketing manager of transducers from October 1985 to September 1987.
From June 1984 to October 1985, Mr. McNally was employed by Physical Acoustics
Corporation, a Princeton, New Jersey based manufacturer of acoustic testing
systems, as its regional sales manager for the Southeastern United States. From
June 1983 to June 1984, he was employed by Hercules, Inc., in Magna, Utah, as an
advanced methods development engineer. Mr. McNally received a Bachelor of
Science Degree in Mechanical Engineering from LaFayette College in May 1983 and
a Master of Business Administration Degree from the University of Utah in June
1992.
Phillip L. McStotts is a founder of ZEVEX and has served as ZEVEX' CFO,
Secretary, and Treasurer, and as a director since its inception. He also serves
as a director of ZEVEX Inc., JTech, and Aborn, as CFO, Secretary and Treasurer
of ZEVEX Inc., as Vice President and Secretary of Aborn, and as CFO and
Secretary of JTech. In addition to running his own professional corporation ,
Phillip L. McStotts, CPA P.C. since October 1986, Mr. McStotts was employed from
May 1985 to September 1986, as an accountant with the Salt Lake City firm of
Chachas & Associates, where he was tax manager. He has also worked in the tax
departments of the regional accounting firms of Pearson, Del Prete & Company,
and Petersen, Sorensen & Brough. Mr. McStotts received a Bachelor of Science
Degree in Accounting from Westminster College in May 1980, and received a Master
of Business Administration Degree in Taxation from Golden Gate University in May
1982.
Leonard C. Smith has been a director of ZEVEX since April 1999 and has served as
its Vice President of Sales and Marketing since October 1999. He is a founder of
JTech and has served as its President since 1995. Prior to joining JTech, in
1994 he established "The Charles Group," a medical marketing company
specializing in diagnostic and rehabilitation products. From 1993 to 1994, Mr.
Smith was Vice President of Four Corners, a large chain of health clubs, based
in the southwest United States. From 1979 to 1993, Mr. Smith was a partner and
Vice President of Sales and Marketing at Hoggan Health Industries, a
manufacturer of commercial fitness equipment. Mr. Smith received a Bachelor of
Science Degree in Business Management from the University of Utah in June 1977.
Bradly A. Oldroyd has been a director of ZEVEX since October 1991. He is the
founder and principal shareholder of Pinnacle Management Group, a Salt Lake
City-based personnel services firm, serving as its president since 1986. Mr.
Oldroyd is also the founder and CEO of TeamONE Ford and Fuel Centers, a Salt
Lake City-based petroleum and convenience goods retailer. He is also a member of
the faculty of the University of Phoenix campus in Salt Lake City, where he
teaches management and marketing courses in undergraduate and graduate programs.
Mr. Oldroyd received a Bachelor of Science degree in Marketing from Utah State
University in 1981 and a Master of Business Administration Degree from the
University of Utah in 1982.
Darla R. Gill has been a director of ZEVEX since May 1993. She is a founder of
Merit Medical Systems, Inc., in Salt Lake City, and served until 1992 as
Executive Vice President and Director. In 1999 she became Vice President of
International Sales and Marketing for Merit Medical Systems. Ms. Gill is also
the owner of DRG Enterprises, a consulting company specializing in marketing,
sales, and new product development. Ms.Gill was also the founder, President
and Chairman of Momentum Medical Corp., a Salt Lake City-based manufacturer and
distributor of home health care products from 1993 to 1998. She continues to
serve as a Director for Momentum Medical. She was also previously employed by
Utah Medical Products, Inc., a company where she served as Vice President of
Marketing and Sales. Ms. Gill also currently serves as a Director of the Board
of NYB Corporation a company located in Salt Lake City. Ms.Gill graduated from
the University of Phoenix with a Bachelors Degree in Business
Administration in 1988.
Kirk Blosch has been a general partner in the partnership of Blosch and Holmes ,
a business consulting and private venture funding general partnership since
1984. For the past fifteen years Mr. Blosch has been an advisor for various
public and private companies. During 1995 and 1996 Mr. Blosch provided bridge
financing for private companies prior to their initial offerings. Mr. Blosch
graduated from the University of Utah with a Bachelors Degree in Speech
Communications in 1977.
OTHER KEY EMPLOYEES
Vijay Lumba, 50, is the founder Aborn and has served as the President,
CEO and Director since 1983. He was previously employed by Fairchild
Semicondutor Optoelectronics Division, where he served as a Product Manager
with responsibilities of design and development of new products and the transfer
of manufacturing technologies to the Far East for high volume production. Mr.
Lumba graduated from Delhi University, India with a Bachelors Degree in Physics,
Chemistry and Mathematics in 1969. Mr. Lumba also graduated from Heald
Engineering College, in San Francisco, California with a Bachelors Degree in
Electrical Engineering in 1972.
COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors has two committees, the Audit Committee and the
Compensation Committee. The Audit Committee is composed of Ms. Darla R.Gill and
Mr. Bradly A. Oldroyd. The Compensation Committee is also composed of Ms. Gill
and Mr. Oldroyd. The Audit Committee is authorized to review proposals of ZEVEX'
independent auditors regarding annual audits, recommend the engagement or
discharge of ZEVEX' independent auditors, review recommendations of such
auditors concerning accounting principles and the adequacy of internal controls
and accounting procedures and practices, review the scope of the annual audit,
approve or reject each professional service or type of service other than
standard auditing services to be provided by the auditors, and review and
discuss the audited financial statements with the auditors. The Compensation
Committee makes recommendations to the Board of Directors regarding remuneration
of the executive officers and directors of ZEVEX and oversees the administration
of the Company's stock option plans.
MEETINGS OF THE BOARD OF DIRECTORS
The Board of Directors held six meetings during the last fiscal year. The Audit
Committee held one meeting during the last fiscal year. The Compensation
Committee held two meetings during the last fiscal year.
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth the compensation paid by ZEVEX to each of ZEVEX'
executive officers during the three-year period ended December 31, 1999.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION> <S> <C> <C> <C> <C> <C>
Annual Compensation Long Term Compensation
Awards Payouts
(a) (b) (c) (d) (e) (f) (g) (h) (i)
Other Restricted All
Name and Annual Stock LTIP Other
Principal Position Year Salary Bonus Comp. Awards Options Payouts Comp.
Dean G. Constantine 1999 $114,070 $0 0 0 0 0 $4,605(1)
CEO and President 1998 $107,755 $50,000 0 0 0 0 $5,000(1)
1997 $105,000 $11,125 0 0 0 0 $4,207(1)
David J. McNally 1999 $114,070 $0 0 0 0 0 $4,605(1)
Executive Vice President 1998 $107,755 $50,000 0 0 0 0 $5,000(1)
1997 $105,000 $11,125 0 0 0 0 $4,207(1)
Phillip L. McStotts 1999 $114,070 $0 0 0 0 0 $4,605(1)
Secretary/Treasurer 1998 $107,755 $50,000 0 0 0 0 $5,000(1)
1997 $105,000 $11,125 0 0 0 0 $4,207(1)
Leonard C. Smith 1999 $100,000 $0 0 0 0 0 $4,000(1)
V. Pres. Sales and Marketing 1998 N/A N/A N/A N/A N/A N/A N/A
1997 N/A N/A N/A N/A N/A N/A N/A
</TABLE>
(1) Represents the amount paid by ZEVEX as a contribution to ZEVEX' 401(k)
Pension and Profit Sharing Plan on the officer's behalf.
OPTIONS GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C> <C>
Individual Grants
Percent Of
Number of Total
Securities Options/ Potential Realizable Value At
Underlying SAR's Assumed Annual Rates Of Stock
Options/ SARs Granted To Exercise Of Price Appreciation For Option
Granted Employees In Base Price Expiration Term
Fiscal
Name (#) Year ($/Sh) Date 5% ($) 10% ($)
(a) (b) (c) (d) (e) (f) (g)
Dean G. Constantine 30,000 6.8% $5.00 1/7/08 $94,334 $239,061
David J. McNally 30,000 6.8% $5.00 1/7/08 $94,334 $239,061
Phillip L. McStotts 30,000 6.8% $5.00 1/7/08 $94,334 $239,061
Leonard C. Smith 40,000 9.1% $4.88 1/4/04 $53,875 $119,049
</TABLE>
Effective January 1, 1999, the Compensation Committee approved the grant of
Common Stock purchase options for 30,000 shares each to Messrs. Constantine,
McNally, and McStotts. The options vest over a period from one years to six
years, with accelerated vesting based upon the Company meeting certain financial
goals, but with full vesting after six years. The options are exercisable at
$5.00 per share. Effective January 1, 1999, the Compensation Committee approved
the grant of Common Stock purchase options for 40,000 shares to Mr. Smith as
part of the acquisition of JTech. The options vest over a period from one to
four years and are exercisable at $4.875 per share.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND YEAR-END OPTION VALUES
The following table sets forth the options exercised during the year ended
December 31, 1999, by each executive officer of ZEVEX and the value of options
held by such persons at such year-end.
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
Value of
Number of Unexercised
Unexercised In-the-Money
Options at Options at
FY-End FY-End
Shares
Name and Acquired Value Exercisable/ Exercisable/
Principal Position or Exercised Realized Unexercisable Unexercisable
Dean G. Constantine
CEO, President 0 0 51,150/61,250 $14,444/7,656
David J. McNally
Executive Vice President 0 0 51,150/61,250 $14,444/7,656
Phillip L. McStotts
Secretary/Treasurer 0 0 51,150/61,250 $14,444/7,656
Leonard C. Smith
V. Pres. Sales and Marketing 0 0 0/40,000 $0/10,000
</TABLE>
Of the unexercised options listed above for each of Messrs. Constantine,
McNally, and McStotts, 5,400 were granted on December 17, 1992, and expire on
December 16, 2001. The exercise price on such options is $5.00. Of the
unexercised options listed above for each of Messrs. Constantine, McNally, and
McStotts, 7,000 were granted on February 13, 1997, and expire on February 12,
2002. The exercise price on such options is $3.85. Of the unexercised options
listed above for each of Messrs. Constantine, McNally, and McStotts, 70,000 were
granted on September 30, 1997 and expire on September 29, 2002. The exercise
price on such options is $5.00. Of the unexercised options listed above for each
of Messrs. Constantine, McNally, and McStotts, 30,000 were granted on January 8,
1999 and expire on January 7, 2005. The exercise price on such options is $5.00.
Of the unexercised options listed above for Mr. Smith, 40,000 were granted on
January 5, 1999 and expire on January 4, 2004. The exercise price on such
options is $4.875. The value of the unexercised options was determined by
reference to the closing sales price for ZEVEX' Common Stock on the NASDAQ Stock
Market as of the end of 1999, which was $5.13 .
COMPENSATION OF DIRECTORS
The Company pays each director who is not an employee of the Company a
director's fee of $625 per Board of Directors meeting attended, $250 for any
annual meeting attended, and $125 per hour for any special meeting attended.
Additionally, the Company has issued stock options to the non-employee directors
in the past and may do so in the future. Although the Company may also issue
stock options to directors who are employees for their service as directors,
these employee directors currently receive no additional compensation for
serving as directors or attending meetings of directors or shareholders.
EMPLOYMENT AGREEMENTS
Except for Leonard Smith, the Company has no employment agreements with its
executive officers. Mr. Smith's employment agreement is for a term of three
years beginning December 31, 1998. Under the agreement Mr. Smith is paid a base
salary of $100,000 and cash bonuses at the end of each year as determined by
the Company's Compensation Committee. Termination without "cause" or
termination for "good reason" by Mr. Smith will result in certain severance
payments to Mr. Smith. Termination for "cause" by the Company or termination
without good reason by Mr. Smith will reduce certain of the Company's further
payment obligations to Mr. Smith under the JTech Purchase Agreement between
the Company and Mr. Smith.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding beneficial
ownership of ZEVEX' Common Stock (par value $0.001) as of March 15, 2000, by (i)
each person (or group of affiliated persons) who is known by ZEVEX to
beneficially own more than 5% of the outstanding shares of ZEVEX' Common Stock,
(ii) each director and executive officer of ZEVEX, and (iii) all executive
officers and directors of ZEVEX as a group. As of such date, ZEVEX had a total
of 3,420,726 shares of Common Stock outstanding. Unless indicated otherwise, the
address for each officer, director and 5% shareholder is c/o ZEVEX
International, Inc., 4314 ZEVEX Park Lane, Salt Lake City, Utah 84123.
Number of Percent
Name and address of beneficial owner Shares Owned(1) Of Class(1)
Kirk Blosch(2) 377,500 11.0%
Jeff Holmes(3) 375,000 11.0%
Blosch & Holmes, L.L.C.(4) 250,000 7.3%
Dean G. Constantine(5) 309,380 8.9%
David J. McNally(6) 291,348 8.4%
Phillip L. McStotts(7) 200,550 5.8%
Leonard C. Smith(8) 19,200 *
Bradly A. Oldroyd(9) 15,000 *
Darla R. Gill(10) 12,480 *
All Officers and Directors
as a Group (7 persons) 1,225,458 33.9%
*Less than 1%
(1) For each shareholder, the number of shares owned includes shares of Common
Stock subject to options held by the shareholder that are currently exercisable
or exercisable within 60 days. For each shareholder the calculation of the
percent of class is based on 3,420,726 shares outstanding and assumes that the
shareholder has exercised all options to obtain additional shares of common
stock and that no other shareholder has exercised such rights. Except as
indicated otherwise below, the persons and entity named in the table have sole
voting and investment power with respect to all shares of Common Stock shown as
beneficially owned by them, subject to applicable community property laws.
(2) Director. Includes 125,000 shares of Common Stock held directly by Mr.
Blosch, 250,000 shares of Common Stock held by Blosch & Holmes, L.L.C. of which
Mr. Blosch is a principal (and which 250,000 shares are also reported as
beneficially owned by Mr. Holmes and Blosch & Holmes, L.L.C.), 2,500 shares of
Common Stock issuable upon exercise of options held by Mr. Blosch that are
currently exercisable or will become exercisable within 60 days. Excludes 7,500
shares of Common Stock issuable upon exercise of options held by Mr. Blosch that
are not currently exercisable and will not become exercisable within 60 days.
Mr. Blosch's address is 2081 S.Lakeline Drive, Salt Lake City, UT 84109.
(3) Includes 125,000 shares of Common Stock held directly by Mr. Holmes and
250,000 shares of Common Stock held by Blosch & Holmes, L.L.C. of which Mr.
Holmes is a principal (and which 250,000 shares are also reported as
beneficially owned by Mr. Blosch and Blosch & Holmes, L.L.C.). Mr. Holmes'
address is 8555 E. Voltaire Ave., Scottsdale, AZ 85260.
(4) Includes 250,000 shares of Common Stock held by Blosch & Holmes, L.L.C. of
which Messrs. Blosch and Holmes are principals (and which 250,000 shares are
also separately reported as beneficially owned by Mr. Holmes and Mr. Blosch).
The address for Blosch & Holmes, L.L.C. is 2081 S. Lakeline Drive, Salt Lake
City, UT 84109.
(5) Chief Executive Officer, President and Chairman of ZEVEX. Includes 258,000
shares of Common Stock held directly, 51,150 shares of Common Stock issuable
upon exercise of options held by Mr. Constantine that are currently exercisable
or will become exercisable within 60 days, and 230 shares of Common Stock owned
by his dependent child. Excludes 61,250 shares of Common Stock issuable upon
exercise of options held by Mr. Constantine that are not currently exercisable
and will not become exercisable within 60 days.
(6) Executive Vice President and director of ZEVEX. Includes 240,198 shares of
Common Stock held directly and 51,150 shares of Common Stock issuable upon
exercise of options held by Mr. McNally that are currently exercisable or will
become exercisable within 60 days. Excludes 61,250 shares of Common Stock
issuable upon exercise of options held by Mr. McNally that are not currently
exercisable and will not become exercisable within 60 days.
(7) Chief Financial Officer, Secretary, Treasurer, and director of ZEVEX.
Includes 149,400 shares of Common Stock held directly and 51,150 shares of
Common Stock issuable upon exercise of options held by Mr. McStotts that are
currently exercisable or will become exercisable within 60 days. Excludes 61,250
shares of Common Stock issuable upon exercise of options held by Mr. McStotts
that are not currently exercisable and will not become exercisable within 60
days.
(8) Vice President Sales and Marketing, and director of ZEVEX. Includes 9,200
shares of Common Stock held directly and 10,000 shares of Common Stock issuable
upon exercise of options held by Mr. Smith that are currently exercisable or
will become exercisable within 60 days. Excludes 30,000 shares of Common Stock
issuable upon exercise of options held by Mr. Smith that are not currently
exercisable and will not become exercisable within 60 days.
(9) Director. Includes 15,000 shares of Common Stock issuable upon exercise of
options that are currently exercisable or will become exercisable within 60
days. Excludes 7,000 shares of Common Stock issuable upon exercise of options
held by Mr. Oldroyd that are not currently exercisable and will not become
exercisable within 60 days.
(10) Director. Includes 480 shares of Common Stock held directly and 12,000
shares of Common Stock issuable upon exercise of options that are currently
exercisable or will become exercisable within 60 days. Excludes 6,000 shares of
Common Stock issuable upon exercise of options held by Ms. Gill that are not
currently exercisable and will not become exercisable within 60 days.
SECTION 16(a) BENEFICIAL REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), requires ZEVEX' directors, executive officers, and 10% shareholders to
file with the Securities and Exchange Commission initial reports of ownership
and reports of changes in ownership of Common Stock. Based solely on a review of
the copies of such reports furnished to ZEVEX and written representations that
no other reports were required, ZEVEX believes that during 1999 all directors,
executive officers, and 10% shareholders complied on a timely basis with all
applicable filing requirements under Section 16(a) of the Exchange Act, except
as follows: Leonard Smith filed one late report on Form 4, due in October 1999,
for one transaction regarding the purchase of common shares of the Company in
September 1999. Messrs. Constantine, McNally and McStotts each filed one late
report on Form 4, for the grant of Company options to purchase common stock.
CONTROL ARRANGEMENTS
Pursuant to a Stock Purchase Agreement, dated December 31, 1996 between ZEVEX
and Blosch & Holmes, L.L.C., a Utah limited liability company ("Blosch &
Holmes"), as amended on September 30, 1997, Blosch & Holmes has the right to
appoint one member of ZEVEX' board of directors, provided that such nominee must
be acceptable to ZEVEX. Kirk Blosch and Jeff W. Holmes, principal shareholders
of ZEVEX, are the two member/managers of Blosch & Holmes. The right to appoint a
member of ZEVEX' board of directors expires when Blosch & Holmes, together with
Kirk Blosch and Jeff W. Holmes, no longer holds at least 6.5% of the voting
stock of ZEVEX. Blosch & Holmes have exercised this right with the appointment
of Mr. Blosch to the board in June 1998.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
On May 31, 1999, ZEVEX repurchased 470,000 outstanding Common Stock Warrants for
$1,175,000, of which 350,000 of the Common Stock Warrants were held by Kirk
Blosch and Jeff W. Holmes, two of ZEVEX' principal shareholders.
On April 15, 1997, ZEVEX International entered into a consulting contract with
DMG Advisors, L.L.C., a Nevada limited liability company ("DMG"). Kirk Blosch
and Jeff W. Holmes, two of ZEVEX' principal shareholders, are members and
managers of DMG. Under the consulting contract, ZEVEX International paid an
initial fee of $50,000 and is paying $10,000 per month for a two year period, in
exchange for the consulting services of DMG in the nature of strategic planning,
public relations, advice regarding financings, and the identification and
evaluation of potential acquisitions of new products or companies.
This agreement expired in April 1999.
Please also refer to the description of Mr. Leonard Smith's employment agreement
in Item 11 and his involvement with the Company's acquisition of JTech described
in Item 7.
PART IV
ITEM 14 EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) Documents Filed as a Part of this Report.
(1) - Financial Statements.
The following Consolidated Financial Statements of ZEVEX' for the years ended
December 31, 1999 and 1998, and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the three years in
the period ended December 31, 1999, are filed as part of this report:
Report of Ernst & Young LLP, Independent Auditors
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Cash Flows
Consolidated Statements of Stockholders' Equity
Notes to Consolidated Financial Statements
(2) - Financial Statement Schedules.
Not required in accordance with the applicable rules and regulations.
(3) - Exhibits
A list of exhibits required to be filed as part of this report is set forth in
the Index to Exhibits, which immediately precedes such exhibits, and is
incorporated herein by reference.
(b) No reports on Form 8-K were filed during the quarter ended December 31,
1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
ZEVEX INTERNATIONAL, INC.
Dated: March 29, 2000 By: /s/ DEAN G. CONSTANTINE
Dean G. Constantine
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicates.
POWER OF ATTORNEY
Know all men by these presents, that each person whose signature
appears below constitutes and appoints each of Dean G. Constantine and Phillip
L. McStotts, jointly and severally, his true and lawful attorney in fact and
agent, with full power of substitution for him and in his name, place and stead,
in any and all capacities to sign any or all amendments to this report on Form
10-K and to file the same, with all exhibits thereto and other documents in
connection therewith with the Securities and Exchange Commission, hereby
ratifying and confirming all that each said attorney in fact or his substitute
or substitutes may do or cause to be done by virtue hereof.
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
Signature Title Date
/s/ DEAN G. CONSTANTINE Chairman of the Board of Directors, March 29, 2000
Dean G. Constantine Chief Executive Officer, and President
(Principal Executive Officer)
/s/ DAVID J. MCNALLY Director, Executive Vice President, March 29, 2000
David J. McNally
/s/ PHILLIP L. McSTOTTS Director, Chief Financial Officer, March 29, 2000
Phillip L. McStotts Secretary, and Treasurer (Principal
Financial and Accounting Officer)
/s/ LEONARD C. SMITH Director, V. Pres. Sales and Marketing, March 29, 2000
Leonard C. Smith
/s/ BRADLY A. OLDROYD Director March 29, 2000
Bradly A. Oldroyd
/s/ DARLA R. GILL Director March 29, 2000
Darla R. Gill
/s/ KIRK BLOSCH Director March 29, 2000
Kirk Blosch
</TABLE>
<PAGE>
INDEX TO EXHIBITS
(Item 14(c))
Number Exhibits
3.1 Articles of Incorporation of ZEVEX International, Inc., a
Delaware corporation (1).
3.2 Bylaws of ZEVEX International, Inc., a Delaware corporation
(1).
10.1 Revolving Line of Credit Agreement between Bank One and ZEVEX
International, Inc.,dated September 29, 1997 (1).
10.2 Amendment to Revolving Line of Credit Agreement between Bank
One and ZEVEX International, Inc., dated December 31,1997 (2).
10.3 Stock Purchase Agreement between Blosch & Holmes, LLC and
ZEVEX International, Inc., dated December 1, 1996, including
one amendment dated September 30, 1997 (1).
10.4 Registration Rights Agreement among Kirk Blosch, Jeff W.
Holmes and ZEVEX International, Inc., dated February 1,
1998 (2).
10.5# ZEVEX International, Inc., Amended 1993 Stock Option Plan (3).
10.6 Industrial Development Bond Offering Memorandum, dated October
30, 1996 (4).
10.7 Industrial Development Bond Reimbursement Agreement, dated
October 30, 1996 (4).
10.8 Warrant to Purchase 50,000 shares of Common Stock issued to
Wedbush Morgan Securities, Inc., dated November 20, 1997(2).
10.9 Warrant to Purchase 50,000 shares of Common Stock issued to
Everen Securities, Inc., dated November 20, 1997 (2).
10.10 Warrant to Purchase 500,000 shares of Common Stock originally
issued to Blosch & Holmes, LLC, dated February 12, 1997 (2).
10.11 Description of Property Acquisition, dated March 4, 1998 (2).
10.12 Quit-Claim Deed for purchase of 3.47 acres of land, dated
March 4, 1998 (2).
10.13 Stock Purchase Agreement, dated December 31, 1998, between
ZEVEX International, Inc., and Vijay Lumba (5).
10.14 Stock Purchase Agreement, dated December 31, 1998, among ZEVEX
International, Inc., Leonard Smith, Tracy Livingston,
David Bernardi, and Corporation of the President of the Church
of Jesus Christ of Latter Day Saints (5).
10.15 Convertible Debenture, dated January 6, 1999, issued to Vijay
Lumba (6).
10.16 Convertible Debenture, dated January 6, 1999, issued to
Leonard Smith (6).
10.17 Convertible Debenture, dated January 6, 1999, issued to Tracy
Livingston (6).
10.18 Convertible Debenture, dated January 6, 1999, issued to David
Bernardi (6).
10.19# ZEVEX International, Inc., 1999 Stock Option Plan and Form of
Stock Option Grant (6).
10.20 Form of January 1, 1999, Stock Option Grant to Messrs.
Constantine, McNally, McStotts.
10.21 Asset Purchase Agreement, dated March 29, 2000, between ZEVEX,
Inc. and Nestle USA, Inc.
21 List of Subsidiaries.
27 Financial Data Schedule.
(1) Incorporated by reference to Amendment No. 1 on Registration Statement
on Form S-1 filed October 24, 1997 (File No. 333-37189).
(2) Incorporated by reference to the Company's Annual Report on Form 10-K
for the year ended December 31, 1997 (File No. 001-12965).
(3) Incorporated by reference to Registration Statement on Form S-1 filed
October 3, 1997 (File No. 001-12965).
(4) Incorporated by reference to the Company's amended Quarterly Report on
Form 10-Q for the quarter ended September 30, 1996 (File No. 033-19583).
(5) Incorporated by reference to the Company's Current Report on Form 8-K
filed January 14, 1999 (File No. 001-12965).
(6) Incorporated by reference to the Company's Annual Report on Form 10-K
for the year ended December 31, 1998 (File No. 001-12965).
# Identifies a "management contract or compensatory plan or arrangement".
<PAGE>
Consolidated Financial Statements
ZEVEX International, Inc.
Years ended December 31, 1999, 1998 and 1997
with Independent Auditors' Reports
<PAGE>
Independent Auditors' Report
Board of Directors and Stockholders
ZEVEX International, Inc.
We have audited the accompanying consolidated balance sheets of ZEVEX
International, Inc. and its subsidiaries as of December 31, 1999 and 1998 and
the related consolidated statements of operations, stockholders' equity, and
cash flows for each of the three years in the period ended December 31, 1999.
These consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the consolidated
financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of ZEVEX
International, Inc. and its subsidiaries as of December 31, 1999 and 1998, and
the results of their operations and their cash flows for each of the three years
in the period ended December 31, 1999 in conformity with accounting principles
generally accepted in the United States.
February 25, 2000, except for Note 15, as to
which the date is March 29, 2000
<PAGE>
ZEVEX International, Inc.
Consolidated Balance Sheets
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
December 31
1999 1998
------------------------------------
Assets
Current assets:
Cash and cash equivalents $ 3,383,544 $ 7,960,511
Cash restricted for sinking fund payment on industrial
development bond 86,549 182,049
Accounts receivable, net of allowance for doubtful
accounts of $175,000 in 1999 and $138,000 in 1998 5,843,229 3,435,181
Inventories 5,119,291 5,574,394
Marketable securities 3,224,817 1,598,032
Deferred income taxes - 198,993
Prepaid expenses 33,554 65,561
Other current assets 26,859 -
------------------------------------
------------------------------------
Total current assets 17,717,843 19,014,721
Property and equipment, net 5,333,577 5,505,643
Patents, trademarks, and acquisition costs, net 349,354 371,038
Goodwill, net 10,642,304 8,780,621
Other assets 6,611 38,698
------------------------------------
$ 34,049,689 $ 33,710,721
====================================
Liabilities and stockholders' equity Current liabilities:
Accounts payable $ 1,134,946 $ 1,076,110
Accrued liabilities 731,852 469,079
Income taxes payable 957,309 50,891
Bank line of credit 1,613,453 541,993
Current portion of long-term debt 1,234,483 5,042,000
Deferred income taxes 110,276 -
Other - 215,873
------------------------------------
Total current liabilities 5,782,319 7,395,946
Deferred income taxes 6,648 46,970
Industrial development bond 1,700,000 1,800,000
Convertible debt, long-term portion 5,470,000 4,350,000
Other long-term liabilities - 3,270
Stockholders' equity:
Common stock, $.001 par value: 10,000,000 shares
authorized; 3,420,726 and 3,418,876 shares issued
and outstanding in 1999 and 1998, respectively 3,421 3,419
Additional paid in capital 16,212,966 17,381,793
Retained earnings 4,542,851 2,927,422
Treasury stock, at cost - (50,790)
Unrealized gain (loss) on available-for-sale
securities, net of tax (expense) benefit of
$(197,199) and $87,633 in 1999 and 1998, respectively 331,484 (147,309)
------------------------------------
Total stockholders' equity 21,090,722 20,114,535
------------------------------------
$ 34,049,689 $ 33,710,721
====================================
</TABLE>
See accompanying notes.
<PAGE>
ZEVEX International, Inc.
Consolidated Statements of Operations
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
Year ended December 31
-----------------------------------------------------
1999 1998 1997
-----------------------------------------------------
Revenues:
Product sales $21,070,153 $10,475,256 $ 8,176,155
Engineering services 1,956,055 609,157 792,270
-----------------------------------------------------
23,026,208 11,084,413 8,968,425
Cost of sales 12,474,210 6,846,443 4,757,057
-----------------------------------------------------
Gross profit 10,551,998 4,237,970 4,211,368
Operating expenses:
General and administrative 4,357,273 2,609,763 1,738,375
Selling and marketing 2,238,629 1,269,645 742,715
Research and development 670,886 290,669 702,563
Goodwill amortization 392,142 - -
-----------------------------------------------------
7,658,930 4,170,077 3,183,653
-----------------------------------------------------
Operating income 2,893,068 67,893 1,027,715
Other income (expense):
Interest income 235,148 567,991 125,315
Interest expense (481,615) (92,152) (78,179)
Unrealized gain (loss) on marketable securities 167,761 (68,370) -
-----------------------------------------------------
Income before provision for income taxes 2,814,362 475,362 1,074,851
Provision for income taxes 1,187,989 (113,169) (356,609)
-----------------------------------------------------
Net income $ 1,626,373 $ 362,193 $ 718,242
=====================================================
Basic net income per common share $ .48 $ .11 $ .34
=====================================================
Diluted net income per common share $ .47 $ .10 $ .29
=====================================================
</TABLE>
See accompanying notes.
<PAGE>
ZEVEX International, Inc.
Consolidated Statements of Stockholders' Equity
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C>
Unrealized
Gain (Loss)
Additional on Available-
for-Sale
Common Stock Paid-in Retained Treasury
-------------------------
Shares Amount Capital Earnings Stock Securities Total
-----------------------------------------------------------------------------------------
Balances at December 31, 1996 1,495,716 $1,496 $ 1,852,966 $1,846,987 - $ 3,701,449
Issuance of common stock for 1,700,000 1,700 14,592,681 - - - 14,594,381
cash
Exercise of stock options for 44,610 45 70,580 - - - 70,625
cash
Exercise of warrants for cash 24,000 24 179,976 - - - 180,000
Issuance of warrants to
purchase 100,000 shares of
common stock for cash - - 1,000 - - - 1,000
Net income - - - 718,242 - - 718,242
-----------------------------------------------------------------------------------------
Balances at December 31, 1997 3,264,326 3,265 16,697,203 2,565,229 - - 19,265,697
Comprehensive income:
Net income - - - 362,193 - - 362,193
Other comprehensive income,
net of tax:
Unrealized loss on
available-for-sale
securities - - - - - (147,309) (147,309)
-------------
Total comprehensive income 214,884
Exercise of stock options for 9,550 9 33,485 - - - 33,494
cash
Exercise of warrants for cash 30,000 30 104,970 - - - 105,000
Issuance of common stock for
product line acquisition 115,000 115 546,135 - - - 546,250
Purchase of 6,700 shares of
treasury stock - - - - (50,790) - (50,790)
-----------------------------------------------------------------------------------------
Balances at December 31, 1998 3,418,876 3,419 17,381,793 2,927,422 (50,790) (147,309) 20,114,535
Comprehensive income:
Net income - - - 1,626,373 - - 1,626,373
Other comprehensive income,
net of tax:
Unrealized gain on
available-for-sale
securities - - - - - 478,793 478,793
-------------
Total comprehensive income 2,105,166
Exercise of stock options for 1,850 2 6,173 - - - 6,175
cash
Purchase of warrants for cash - - (1,175,000) - - - (1,175,000)
Purchase of 10,000 shares of
treasury stock - - - - (45,731) - (45,731)
Transfer of 16,700 shares of
treasury stock to ESOP - - - (10,944) 96,521 - 85,577
-----------------------------------------------------------------------------------------
Balances at December 31, 1999 3,420,726 $3,421 $16,212,966 $4,542,851 $ $331,484 $21,090,722
-
=========================================================================================
</TABLE>
See accompanying notes.
<PAGE>
ZEVEX International, Inc.
Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
Year ended December 31,
-----------------------------------------------
1999 1998 1997
-----------------------------------------------
Cash flows from operating activities
Net income $ 1,626,373 $ 362,193 $ 718,242
Adjustments to reconcile net income to net cash provided
by (used in) operating activities:
Depreciation and amortization expense 1,157,221 471,752 284,174
Provision (benefit) for deferred income taxes (15,885) (136,473) (35,762)
Realized gain on marketable securities (65,816) - -
Unrealized (gain) loss on trading marketable -
securities (167,761) 68,370
Changes in operating assets and liabilities, net of
acquisitions:
Increase (decrease) in restricted cash for
sinking fund payment on industrial development 95,500 (105,885) (76,164)
bond
Increase in accounts receivable (2,408,048) (989,046) (665,934)
Decrease in trading securities 80,623 - -
Decrease (increase) in inventories 455,103 (1,612,638) (2,196,294)
Decrease (increase) in prepaid expenses 32,007 12,411 (20,499)
Decrease (increase) in other assets 5,228 (46,539) 2,734
Increase in accounts payable 58,836 260,235 301,556
Increase in accrued liabilities and other 43,630 112,384 75,606
Increase (decrease) in income taxes payable 906,418 (234,512) 285,403
-----------------------------------------------
Net cash flows provided by (used in) operating activities 1,803,429 (1,837,748) (1,326,938)
Cash flows from investing activities
Purchase of property and equipment (566,958) (1,185,805) (3,004,926)
Purchase of businesses, net of cash acquired - (9,480,313) -
Purchases of available-for-sale marketable securities (1,827,150) (1,698,235) (10,200,000)
Redemption of available-for-sale marketable securities 1,116,944 10,200,000 -
Addition of patents and trademarks (4,370) (27,511) (78,663)
-----------------------------------------------
Net cash flows used in investing activities (1,281,534) (2,191,864) (13,283,589)
Cash flows from financing activities
Proceeds from issuance of common stock - - 14,594,381
Proceeds from exercise of warrants - 105,000 180,000
Repurchase of common stock warrants (1,175,000) - -
Proceeds from exercise of stock options 6,175 33,494 70,625
Proceeds from sale of 100,000 warrants - - 1,000
Issuance of debt related to business acquisitions - 9,300,000 -
Net proceeds from (repayments of) bank line of credit 1,071,460 441,993 (60,108)
Stock contribution to Employee Stock Ownership Plan 85,577 - -
Purchase of treasury stock (45,731) (50,790) -
Payment on debt from business acquisition (4,941,343) - -
Payments on industrial development bond (100,000) (100,000) -
-----------------------------------------------
Net cash flows (used in) provided by financing activities (5,098,862) 9,729,697 14,785,898
-----------------------------------------------
Net (decrease) increase in cash and cash equivalents (4,576,967) 5,700,085 175,371
Cash and cash equivalents at beginning of year 7,960,511 2,260,426 2,085,055
-----------------------------------------------
Cash and cash equivalents at end of year $3,383,544 $ 7,960,511 $ 2,260,426
===============================================
</TABLE>
See accompanying notes
<PAGE>
1. Summary of Significant Accounting Policies
Description of Organization and Business
The Company was incorporated under the laws of the State of Nevada on December
30, 1987. The Company was originally incorporated as Downey Industries, Inc. and
changed its name to ZEVEX International, Inc. on August 15, 1988. In November
1997 the Company reincorporated into Delaware. In December 1998, the Company
acquired an additional product line and completed the acquisition of two
additional subsidiaries (See Note 2). The Company and its subsidiaries design
and manufacture advanced medical devices, including surgical systems, device
components, and sensors for medical and industrial technology companies. The
Company and its subsidiaries also design, manufacture, and market their own
medical devices using its proprietary technologies. The Company's design and
manufacturing service customers are primarily medical technology companies,
which sell the Company's systems and devices under private labels or incorporate
the Company's devices into their products.
Principles of Consolidation
The consolidated financial statements at December 31, 1999 include the accounts
of ZEVEX International, Inc. (Company) and its wholly-owned operating
subsidiaries ZEVEX, Inc., Aborn Electronics, Inc., and JTech Medical Industries,
Inc. The consolidated statement of operations for 1998 excludes the results of
Aborn and JTech, because these two acquisitions were consummated as of December
31, 1998. All significant intercompany balances and transactions have been
eliminated in consolidation.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year
presentation.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all certificates of deposit and highly liquid debt
instruments with a maturity of three months or less when purchased to be cash
equivalents.
Concentration of Credit Risk
The Company's financial instruments consist primarily of cash, cash equivalents,
marketable securities, trade accounts receivable and certain debt issuances (see
Note 8). Cash and cash equivalents are held in federally insured financial
institutions or invested in high grade short-term commercial paper issued by
major United States corporations. Marketable securities consist principally of
corporate stocks and high grade corporate and municipal bonds. The Company sells
its products primarily to, and has trade receivables with, independent durable
medical equipment manufacturers and dealers in the United States and abroad. The
Company's customers accounting for more than 10% of net product sales were one,
three, and four for the years ended December 31, 1999, 1998, and 1997,
respectively. Less than 10% of product sales are to foreign customers.
1. Summary of Significant Accounting Policies (continued)
Concentration of Credit Risk (continued)
As a general policy, collateral is not required for accounts receivable;
however, the Company periodically monitors the need for an allowance for
doubtful accounts based upon expected collections of accounts receivable and
specific identification of uncollectible accounts. Additionally, customers'
financial condition and credit worthiness are regularly evaluated. Historical
losses have not been material.
Inventories
Inventories are stated at the lower of cost or market; cost is determined using
the first-in, first-out method.
Marketable Securities
The Company's short-term investments are comprised of debt and equity
securities, all classified as either trading or available-for-sale securities,
which are carried at their fair value based upon quoted market prices of those
investments at December 31, 1999 and 1998. Unrealized gains or losses for
trading securities are included in income. Unrealized gains and losses on
available-for-sale securities are reported, net of tax, in a separate component
of stockholders' equity. The amortized cost of debt securities in this category
is adjusted for amortization of premiums and accretion of discounts to maturity.
Such amortization is included in investment income. Realized gains and losses
and declines in value judged to be other-than-temporary on available-for-sale
securities are included in investment income. The cost of securities sold is
based on the specific identification method. Interest and dividends on
securities classified as available-for-sale are included in investment income.
Net unrealized holding gains (losses) on trading securities for the periods
ending December 31, 1999 and 1998 of $167,761 and ($68,370), respectively, are
included in net income; and, net unrealized holding gains on available-for-sale
securities for the period ending December 31, 1999 of $528,683 ($331,484 net of
taxes) and net unrealized holding losses for the period ending December 31, 1998
of $234,942 ($147,309 net of taxes), are included in stockholders' equity.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation.
Depreciation is provided over expected useful lives of three to twenty-five
years using the straight-line method. Leasehold improvements are amortized on a
straight-line basis over the lesser of the remaining lease term or their
estimated useful lives.
Major replacements, which extend the useful lives of equipment, are capitalized
and depreciated over the remaining useful life. Normal maintenance and repair
items are charged to costs and expenses as incurred.
Patents, Trademarks, and Acquisition Costs
Acquisition costs and the costs of acquired and internally developed patents and
trademarks are amortized over the lesser of fifteen years or the estimated
useful life of the intangible asset on a straight-line basis. For the years
ended December 31, 1999 and 1998, accumulated amortization related to patents,
trademarks, and acquisition costs of $43,493 and $17,439, respectively, has been
recorded by the Company. The Company periodically reviews the recoverability of
its intangible assets as well as other long-term assets and, where impairment in
value has occurred, such intangibles are written down to net realizable value.
1. Summary of Significant Accounting Policies (continued)
Goodwill
Goodwill is recorded at the lower of cost or its net realizable value and is
being amortized on a straight-line basis over 15 to 23 years. At December 31,
1998, no accumulated amortization for goodwill was recorded, since the
acquisitions giving rise to the goodwill were consummated December 31, 1998 (see
Note 2). For the year ended December 31, 1999, the Company recorded $392,142 of
goodwill amortization. The Company periodically reviews the recoverability of
these intangible assets in order to record them at their net realizable value.
Impairment of Long-Lived Assets
In accordance with Statement of Financial Accounting Standards (SFAS) No. 121,
"Accounting for the Impairment of Long-Lived Assets to be Disposed Of," the
Company assesses on an ongoing basis the recoverability of long-lived assets,
comparing estimates of future undiscounted cash flows to net book value. If
future undiscounted cash flow estimates were less than net book value, net book
value would be reduced to fair value based on estimates of discounted cash
flows. The Company also evaluates amortization periods of assets, including
goodwill and other intangible costs, to determine if events or circumstances
warrant revised estimates of useful lives.
Income Taxes
The Company provides for income taxes based on the liability method, which
requires recognition of deferred tax assets and liabilities based on differences
between financial reporting and tax bases of assets and liabilities measured
using enacted tax rates and laws that are expected to be in effect when the
differences are expected to reverse.
Stock Options
The Company has elected to follow Accounting Principles Board Opinion No. 25,
Accounting for Stock Issued to Employees (APB 25) and related Interpretations in
accounting for its employee stock options rather than adopting the alternative
fair value accounting provided for under Statement of Financial Accounting
Standards (SFAS) No. 123, Accounting for Stock-based Compensation. Under APB 25,
because the exercise price of the Company's stock options equals the market
price of the underlying stock on the date of grant, no compensation expense is
recognized.
Revenue Recognition
The Company records revenue from the sale of manufactured products upon
shipment. Revenue from contracts to perform engineering design and product
development services are generally recognized as milestones are achieved; costs
are expensed as incurred.
New Accounting Pronouncements
In December 1999, the Securities and Exchange Commission issued Staff Accounting
Bulletin (SAB) 101, Revenue Recognition in Financial Statements. The effective
date of SAB 101 is the second quarter of the fiscal year ending after December
15, 1999. The SAB clarifies proper methods of revenue recognition given certain
circumstances surrounding sales transactions. The Company continues to evaluate
the impact of SAB 101, but believes it is in compliance with the provisions of
the SAB and accordingly, does not expect SAB 101 to have a material effect on
its financial statements.
1. Summary of Significant Accounting Policies (continued)
Advertising Costs
Advertising costs are expensed during the year in which they are incurred.
Advertising expenses were $284,452, $137,627, and $82,530, respectively for the
years ended December 31, 1999, 1998 and 1997.
Net Income Per Common Share
Basic net income per common share is calculated by dividing net income for the
period by the weighted-average number of the Company's common shares
outstanding.
Diluted net income per common share includes the dilutive effect of options,
convertible debentures and warrants in the weighted-average number of the
Company's common shares outstanding as calculated using the treasury stock
method.
Net income as presented on the statements of operations represents the numerator
used in calculating basic and diluted net income per common share. The following
table sets forth the computation of the shares used in determining basic and
diluted net income per common share:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
(in thousands) 1999 1998 1997
----------- ----------- ------------
Denominator for basic net income per common share -
weighted average shares 3,413 3,298 2,098
Dilutive securities: warrants and stock options 25 428 345
----------- ----------- ------------
Denominator for diluted net income per common share -
adjusted weighted average shares 3,438 3,726 2,443
=========== =========== ============
</TABLE>
Options, convertible debentures and warrants to purchase approximately 597,000,
495,000, and 312,000 shares of common stock were outstanding at December 31,
1999, 1998, and 1997, respectively, but were not included in the computation of
diluted earnings per share because they were anti-dilutive.
All shares held in the Company's Employee Stock Ownership Plan (ESOP) are
considered outstanding for both basic and diluted earnings per share
calculations.
Supplemental Cash Flow Information
Supplemental disclosures of cash flow information were as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
1999 1998 1997
-----------------------------------------------
Cash paid during the year for:
Interest $ 402,191 $ 92,887 $ 77,641
Income taxes 263,279 481,589 71,206
Schedule of non cash financing activities:
Issuance of common stock for acquisition
of Nutrition Medical product line - 546,250 -
Issuance of convertible debentures for earn-out
provisions relating to prior year acquisitions 2,253,826
</TABLE>
2. Acquisitions
On December 23, 1998, the Company acquired a product line of enteral feeding
pumps from Nutrition Medical, Inc. to complement its own existing product line.
The aggregate purchase price of $1,072,469 was paid in cash of $500,000 and
115,000 shares of the Company's common stock. In addition, Nutrition Medical,
Inc. entered into a noncompete agreement. The acquisition has been accounted for
as a purchase.
On December 31, 1998, the Company acquired all of the issued and outstanding
capital stock of Aborn Electronics, Inc. (Aborn), a California corporation
engaged in designing, developing and manufacturing optical sensor components for
medical and industrial applications. These components are incorporated into the
end products of Aborn's design and manufacturing service customers, which are
primarily medical products and electronic products companies. The aggregate
purchase price of $5,100,000 was paid in cash of $1,850,000 and a 7% interest
bearing convertible debenture of $1,350,000. The purchase price also included an
earn-out provision that provides additional consideration, not to exceed cash of
$950,000 and a convertible debenture of $950,000, which is triggered based on
Aborn achieving certain levels of revenue and pretax income for the year ending
December 31, 1999. Based on the earn-out formula, additional consideration equal
to the full $1,900,000 has been earned and was recorded as an adjustment to
goodwill at December 31, 1999. The convertible debentures are convertible into
ZEVEX common stock at $11 per share between one to three years from the issuance
dates. The acquisition has been accounted for as a purchase.
On December 31, 1998, the Company acquired all of the issued and outstanding
capital stock of JTech Medical Industries, Inc. (JTech), a Utah corporation
engaged in designing, developing and manufacturing advanced medical devices for
use in several medical specialties, including occupational medicine,
orthopedics, physical medicine and rehabilitation, chiropractic, physical
therapy, neurology, podiatry and athletic training. JTech also provides
educational products and services, such as in-office training, seminars, and
multimedia disks. The aggregate purchase price of $7,250,000 was paid in cash of
$3,100,000 and a 8% interest bearing convertible debenture of $3,000,000. The
purchase price also included earn-out provisions over the following two years
that provide additional consideration, not to exceed, in total, cash of $575,000
and a convertible debenture of $575,000, which are triggered based on JTech
achieving certain levels of revenue and pretax income. Based on the earn-out
formula, additional consideration equal to approximately $350,000 has been
earned for the year ended December 31, 1999 and was recorded as an adjustment to
goodwill at that date.
The convertible debentures are convertible into common stock at $11 per share
between one to three years from the issuance dates. The acquisition has been
accounted for as a purchase.
The unaudited pro forma results of operations assuming consummation of these
acquisitions as of January 1, 1997 are as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
1998 1997
----------------------------------------
Revenues $ 15,131,000 $ 13,049,000
Net income 461,000 894,000
Basic net income per common share $ .14 $ .43
Diluted net income per common share $ .12 $ .37
========================================
</TABLE>
3. Inventories
Inventories consist of the following at December 31, 1999 and 1998:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
1999 1998
---------------------------------------
Materials $ 2,228,174 $ 3,156,276
Work in Progress 1,867,894 1,831,112
Finished goods, including completed subassemblies
1,023,223 587,006
---------------------------------------
$ 5,119,291 $ 5,574,394
=======================================
</TABLE>
4. Marketable Securities
The following is a summary of marketable securities at December 31, 1999:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
Gross Gross Unrealized Estimated Fair
Unrealized
Cost Gains Losses Value
----------------- ---------------- ----------------- ----------------
Available for Sale
U.S. corporate securities $ 254,817 $ - $ - $ 254,817
Equity securities 2,138,817 528,683 - 2,667,500
----------------- ---------------- ----------------- ----------------
2,393,634 528,683 - 2,922,317
Trading
Equity Securities - 302,500 - 302,500
----------------- ---------------- ----------------- ----------------
Total Marketable Securities $2,393,634 $831,183 $ - $3,224,817
================= ================ ================= ================
The following is a summary of marketable securities at December 31, 1998:
Gross Gross Unrealized Estimated Fair
Unrealized
Cost Gains Losses Value
----------------- ---------------- ----------------- ----------------
Available for Sale
U.S. corporate securities $ 1,209,235 $ - $ - $ 1,209,235
Equity securities 489,000 234,942 254,058
-
----------------- ---------------- ----------------- ----------------
1,698,235 234,942 1,463,293
-
Trading
Equity Securities - 134,739 - 134,739
----------------- ---------------- ----------------- ----------------
Total Marketable Securities $ 1,698,235 $ 134,739 $ 234,942 $ 1,598,032
================= ================ ================= ================
</TABLE>
The amortized cost and estimated fair value of debt and marketable equity
securities, by contractual maturity, are shown below. Expected maturities will
differ from contractual maturities because the issuers of the securities may
have the right to prepay obligations without prepayment penalties.
4. Marketable Securities (continued)
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
December 31, 1999 December 31, 1998
Estimated Estimated
Cost Fair Value Cost Fair Value
------------------ ---------------- ----------------- -----------------
U.S. corporate securities:
Due within 1 year $ 254,817 $ 254,817 $ 1,209,235 $ 1,209,235
Equity securities 2,138,817 2,970,000 489,000 388,797
------------------ ---------------- ---------------- -----------------
Total $2,393,634 $3,224,817 $ 1,698,235 $ 1,598,032
================== ================ ================= ==================
</TABLE>
5. Property and Equipment
Property and equipment consist of the following at December 31:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
1999 1998
------------------ -------------------
Machinery and equipment $1,440,031 $ 1,351,078
Furniture and fixtures 1,290,979 1,017,847
Vehicles 8,500 13,000
Tooling costs 914,610 753,786
Building 2,841,005 2,755,644
Land 1,084,415 1,084,415
------------------ -------------------
7,579,540 6,975,770
Less accumulated depreciation and amortization
2,245,963 1,470,127
------------------ -------------------
$ 5,333,577 $ 5,505,643
================== ===================
</TABLE>
Depreciation expense for the years ended December 31, 1999, 1998 and 1997
amounted to $739,024, $462,031, and $278,156, respectively.
6. Accrued Liabilities
Accrued liabilities consist of the following:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
1999 1998
------------------ -------------------
Accrued payroll and related taxes and benefits
$478,639 $311,558
Accrued vacation 102,535 86,267
Warranty reserve 65,000 65,000
Accrued interest 85,678 6,254
------------------ -------------------
$731,852 $469,079
================== ===================
</TABLE>
7. Income Taxes
The provision for income taxes is made, at Federal and State statutory rates,
based on pre-tax income reported in the financial statements.
Deferred taxes are classified as current or non-current, depending on the
classification of the assets and liabilities to which they relate. Deferred
taxes arising from temporary differences that are not related to an asset or
liability are classified as current or non-current depending on the periods in
which the temporary differences are expected to reverse.
Significant components of the Company's net deferred income taxes as of December
31 are as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
1999 1998
------------------- --------------------
Deferred tax assets:
Non-deductible accruals and expenses $199,755 $ 161,618
Unrealized loss on available-for-sale securities - 87,633
------------------- --------------------
Total deferred tax assets 199,755 249,251
Deferred tax liabilities:
Accelerated depreciation (6,648) (46,970)
Unrealized gains on trading securities (112,833) (50,258)
Unrealized gains on available-for-sale securities (197,198) -
------------------- --------------------
Total deferred tax liabilities (316,679) (97,228)
------------------- --------------------
$(116,924) $ 152,023
=================== ====================
</TABLE>
The provision for income taxes consists of the following:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
1999 1998 1997
------------------- ---------------- ----------------
Current taxes:
Federal $(1,063,807) $ (165,840) $(333,620)
State (199,595) (24,244) (56,793)
R&D credit 59,528 28,075 69,565
Deferred taxes:
Federal 14,480 44,519 (31,176)
State 1,405 4,321 (4,585)
------------------- ---------------- ----------------
Provision for income taxes $(1,187,989) $ (113,169) $(356,609)
=================== ================ ================
</TABLE>
<PAGE>
7. Income Taxes (continued)
The actual tax expense differs from the 34% Federal statutory rate as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
1999 1998 1997
------------------- ---------------- ----------------
Expected tax (expense) at federal rate $ (956,883) $(161,623) $(365,449)
State income tax expense, net of federal benefit
(130,805) (15,687) (35,470)
Research and development credit 59,528 28,075 69,565
Non-deductible goodwill amortization (135,142)
Other non-deductible expenses (28,750) (11,985) (8,782)
Tax-exempt interest - 57,549 7,381
Other 4,063 (9,498) (23,854)
------------------- ---------------- ----------------
Total provision for income taxes $(1,187,989) $(113,169) $(356,609)
=================== ================ ================
</TABLE>
8. Debt
Bank Lines of Credit
The Company renewed its line of credit arrangement with a financial institution
for $5 million. The line matures on May 31, 2000. The line of credit is
collateralized by accounts receivable and inventory and bears interest at the
prime rate, which is 8.5% at December 31, 1999 and 7.75% at December 31, 1998.
The Company's balance on its line of credit was $1,613,453 at December 31, 1999
and $441,993 at December 31, 1998. Under the line of credit agreement, the
Company is restricted from declaring cash dividends and must maintain certain
levels of working capital and meet certain other financial covenants.
Industrial Development Bond
On October 30, 1996, the Company completed a transaction defined as "Murray
City, Utah, Adjustable Rate Industrial Development Revenue Bonds, Series 1997
(ZEVEX, Inc. Project)" in the amount of $2,000,000. The bonds are secured by an
irrevocable Letter of Credit issued by a bank, which is subject to expiration no
later than April 15, 2002. The bonds bear interest at an adjustable rate based
on the weekly tax-exempt floater rate as determined by the remarketing agent.
The bonds mature on October 1, 2016. Principal reductions occur in the amount of
$100,000 per year at a rate of $8,333 per month starting April 1, 1997. The
outstanding balance was $1,800,000 at December 31, 1999, of which $100,000 is
classified as current.
Convertible Debt
In connection with the acquisitions of Aborn and JTech, the Company issued
$1,350,000 in 7% interest bearing convertible debentures and $3,000,000 in 8%
interest bearing convertible debentures, respectively (See Note 2). Accrued
interest is due and payable quarterly beginning on April 1, 1999. All accrued
interest and principal is due and payable January 6, 2002. The debentures are
convertible to common stock between January 6, 2000 and January 6, 2002 at $11
per share. The convertible debt increased to $5,470,000 at the end of 1999 due
to the earn-out provisions (See Note 2).
9. Employee Benefit Plans
401(k) Profit Sharing Plan
During 1991, the Company established a qualified 401(k) profit sharing plan
covering substantially all employees. Eligible employees may defer a portion of
their salary. At the discretion of the Board of Directors, the Company may make
a contribution of an additional amount of up to four percent (4%) of the
eligible employees' salary and a discretionary amount to be determined each year
by the Board of Directors. Employees are fully vested after seven years.
Contributions to the plan for the year ended December 31, 1999, 1998, and 1997
were $143,645, $98,865, and $60,274, respectively. The Company has recorded a
payable to the plan of $1,630 and $18,844 at December 31, 1999 and 1998,
respectively, which is included in accrued liabilities.
Employees' Stock Ownership Plan
Effective October 14, 1993, the Company adopted an Employee Stock Ownership Plan
that covers all employees who are over the age of 21, have been employed for at
least 90 days and who provide at least 1,000 hours of service.
Full vesting will occur after seven years of service or upon normal retirement
at 65 years of age. Contributions to the plan are at the discretion of the Board
of Directors with no minimum annual funding requirements. Contributions to the
plan will be primarily made with common stock of the Company.
A contribution of 16,700 shares with a value of $85,577 was made to the Employee
Stock Ownership Plan in December of 1999. No contribution was made for the years
ended December 31, 1998 and 1997.
10. Stockholders' Equity
Change in Authorized Shares and Par Value
In connection with the 1997 reincorporation into Delaware, the Company adopted
an Amended and Restated Certificate of Incorporation which provides that the
Company is authorized to issue 2,000,000 shares of $.001 par value preferred
stock and 10,000,000 shares of $.001 par value common stock.
Issuance of Common Stock
On February 12, 1997, the Company completed a private placement offering for
$1,250,000 of its securities, which consist of 500,000 units at a price of $2.50
per unit. Each unit consists of one share of common stock and a warrant to
purchase one share of common stock at a price of $3.50 per share. The issued
shares and shares underlying the warrants are entitled to registration rights
for a period of five years from completion of the offering.
In November 1997 the Company completed a secondary public offering of 1,200,000
shares of its common stock. Total net proceeds from the offering were
$13,344,381.
10. Stockholders' Equity (continued)
Warrants
In February 1997, the Company issued 500,000 warrants in connection with a
$1,250,000 private placement offering, as discussed above. During 1998, 30,000
warrants were exercised for a total consideration of $105,000 and in 1999, the
remaining 470,000 warrants were purchased by the Company for $1,175,000.
In connection with the secondary public offering in November 1997, the Company
issued the underwriters warrants to purchase 100,000 shares of common stock at
$15 per share. The underwriters paid a price of $.01 per warrant. These warrants
expire 5 years from the date of the offering. The underwriters' warrants are
restricted from exercise, sale, transfer, assignment or hypothecation for a
period of one year commencing from the offering date. These warrants are
entitled to certain registration rights.
Common Stock Reserved for Future Issuance
At December 31, 1999, the Company had reserved 1,243,990 shares of common stock
for future issuance, including 100,000 shares reserved for exercise of warrants
and 1,143,990 shares reserved under the Company's stock option plan.
Stock Option Plans
In September 1997, the Board of Directors consolidated its previous three stock
option plans into one plan and established the Amended 1993 Stock Option Plan
(the "1993 Plan"). Under the 1993 Plan, 600,000 shares of common stock were
authorized for issuance, subject to adjustment for such matters as stock splits
and stock dividends.
The 1993 Plan provides for the grant of incentive stock options, stock
appreciation rights and stock awards to eligible participants and may be
administered by the Board of Directors or by the Compensation Committee.
On September 30, 1997, the Company granted a total of 210,000 options under the
1993 Plan with an exercise price of $16.44 to three officers/directors. In 1998,
the options were subsequently repriced with an exercise price of $5.00. The
options vest ratably over a four-year period from the grant date.
All options granted under the 1993 Plan expire after five to seven years from
the grant date and become exercisable no later than four years from the grant
date.
During 1999 the Board of Directors established the 1999 Stock Option Plan (the
"1999 Plan"), which was ratified by shareholders in June 1999. The 1999 Plan
authorized 600,000 shares of common stock for issuance, subject to adjustment
for such matters as stock splits and stock dividends.
The 1999 Plan provides for the grant of incentive stock options, stock
appreciation rights and stock awards to eligible participants and may be
administered by the Board of Directors or by the Compensation Committee.
In January 1999, 331,000 options were granted under the 1999 Plan with an
exercise price equal to the corresponding stock price on the grant date.
10. Stockholders' Equity (continued)
Stock Option Plans (continued)
All options granted under the 1999 Plan expire after five to ten years from the
grant date and become exercisable between one and six years from the grant date.
A summary of stock option activity for both plans, and related information for
the years ended December 31, 1997, 1998 and 1999 follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
Shares Outstanding Stock Options Weighted-
------------------------------------
Available Number of Price Average
for Grant shares Per Share Exercise Price
------------------------------------ ----------------- ------------------
Balance at December 31, 1996 313,900 86,100 $ .79-5.00 $ 2.93
Additional authorization 200,000 - - -
Options granted (275,050) 275,050 3.50-17.50 13.51
Options exercised - (44,610) .79-$5.00 1.58
Options canceled 2,850 (2,850) 3.50-$5.00 3.97
------------------------------------ ----------------- ------------------
Balance at December 31, 1997 241,700 313,690 2.50-17.50 12.39
Options granted (390,000) 390,000 5.00-7.64 6.48
Options exercised - (9,550) 2.50-5.00 3.51
Options canceled 299,500 (299,500) 3.50-17.50 15.77
------------------------------------ ----------------- ------------------
Balance at December 31, 1998 151,200 394,640 2.50-5.00 4.76
Additional authorization 600,000 - - -
Options granted (331,000) 331,000 4.88-5.00 4.98
Options exercised - (1,850) 2.50-5.00 3.34
Options canceled 19,750 (19,750) 2.50-5.00 4.71
------------------------------------ ----------------- ------------------
Balance at December 31, 1999 439,950 704,040 $ 2.50-5.00 $ 4.80
==================================== ================= ==================
</TABLE>
During 1998, the Company canceled options to purchase up to 298,000 shares with
exercise prices ranging from $7.63 to $17.50 and regranted options to purchase
the same number shares at an exercise price of $5.00 per share. Of these 298,000
options, 212,000 were outstanding at the beginning of the year, with the
remaining 86,000 shares granted in early 1998.
Pro forma information regarding net income and earnings per share is required by
SFAS 123, and has been determined as if the Company had accounted for its
employee stock options under the fair value method. The fair value of these
options was estimated at the date of grant using a Black-Scholes option pricing
model with the following weighted average assumptions for 1999, 1998, and 1997,
respectively: risk-free interest rate of 4.7%, 5.3%, and 5.9%; dividend yield of
0%; volatility factors of the expected market price of the Company's common
stock of .68, .88, and .90; and a weighted-average expected life of the option
of 3.6, 4, and 4 years. The estimated weighted average fair value of options
granted in the years ended December 31, 1999, 1998, and 1997 were $2.53, $3.29,
and $9.98, respectively.
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options which have no vesting restrictions and are fully
transferable. In addition, option valuation models require the input of highly
subjective assumptions including the expected stock price volatility. Because
the Company's employee stock options have characteristics different from those
of traded options, and because changes in the subjective input assumptions can
materially affect the fair value estimate, in management's opinion, the existing
models do not necessarily provide a reliable single measure of the fair value of
its employee stock options.
10. Stockholders' Equity (continued)
Stock Option Plans (continued)
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized over the options' vesting period. Because the effect of SFAS No.
123 is prospective, the initial impact on pro forma net income may not be
representative of compensation expense in future years.
For the years ended December 31, 1999, 1998, and 1997, pro forma net income and
pro forma net income per common share were as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
1999 1998 1997
---------------- ----------------- ---------------
Pro forma net income $ 1,072,713 $(96,762) $553,214
Pro forma basic net income per common share .31 (.03) .26
Pro forma diluted net income per common share .31 (.03) .23
</TABLE>
Additionally, SFAS No. 123 requires that companies with wide ranges between the
high and low exercise prices of its stock options segregate the exercise prices
into ranges that are meaningful for assessing the timing and number of
additional shares that may be issued and the cash that may be received as a
result of the option exercises. Below are the segregated ranges of exercise
prices as of December 31, 1999:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
Options Outstanding Options Exercisable
- ---------------------------------------------------------------------- -------------------------------
Weighted
Average Weighted Weighted
Range of Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life Price Exercisable Price
- ----------------- ----------------- ---------------- ----------------- --------------- ---------------
$2.50-3.50 29,840 2.07 years $3.19 29,840 $3.19
3.85-5.00 674,200 4.31 years 4.94 201,600 4.85
- ----------------- ----------------- ---------------- ----------------- --------------- ---------------
$2.50-5.00 704,040 4.21 years $4.86 231,440 $4.64
================= ================= ================ ================= =============== ===============
</TABLE>
11. Lease Commitments
In 1996 the Company and its subsidiary occupied an administrative and
manufacturing facility under the terms of an operating lease agreement. In June
1997 the Company moved into a new facility owned by and constructed for the
Company.
Lease expense of $55,695 has been charged to operations for the year ended
December 31, 1997. The lease expired in April 1997.
12. Fair Value of Financial Instruments
The following methods and assumptions were used by the Company in estimating its
fair value disclosures for financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance
sheet for cash and cash equivalents approximates its fair value.
Marketable securities: The Company determines fair values based on quoted
market prices.
Convertible debt and industrial development bond: The fair values of the
Company's long-term debt are estimated using discounted cash flow analyses,
based on the Company's current incremental borrowing rates for similar
types of borrowing arrangements.
The carrying amounts and fair values of the Company's financial instruments are
as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
1999 1998
----------------------------------------------------------------------
Carrying Amount Fair Carrying Amount Fair
Value Value
----------------- ---------------------------------- -----------------
Cash and cash equivalents $ 3,383,544 $ 3,383,544 $ 7,960,511 $ 7,960,511
Marketable securities:
Trading securities 302,500 302,500 134,739 134,739
Available-for-sale securities 2,922,317 2,922,317 1,463,293 1,463,293
Convertible debt 5,470,000 5,378,376 4,350,000 4,350,000
Industrial development bond 1,800,000 1,800,000 1,900,000 1,900,000
</TABLE>
13. Major Customers
Sales to major customers for the years ended December 31, 1999, 1998 and 1997,
are summarized as follows (percent of product sales):
Year ended December 31,
-----------------------------------------------
1999 1998 1997
----------------- ---------------- ------------
Customer A *% 16% 17%
Customer B 13% 15% 15%
Customer C *% 13% 18%
Customer D *% *% 15%
----------------- ---------------- ------------
13% 44% 65%
================= ================ ============
- -----------------
* Less than 10% of sales.
14. Related Party Transactions
On April 15, 1997, the Company entered into a consulting agreement with another
company owned by certain stockholders to provide services related to strategic
planning, public relations, financing and potential acquisition of new products
or companies. Under the consulting agreement, the Company paid an initial fee of
$50,000 and paid $10,000 per month for two years. The agreement expired in April
1999. In
14. Related Party Transactions (continued)
addition, these certain stockholders have the right to appoint one director to
the Company's Board of Directors. The certain stockholders exercised this right
with its nomination of Kirk Blosch in June 1998. Mr. Blosch is serving a 3-year
term as a director, which term expires at the annual meeting of shareholders in
June 2002.
Of the 470,000 warrants purchased by the Company in 1999 (See Note 10), 350,000
were purchased from a related party for $875,000.
On December 31, 1998, the Company acquired JTech pursuant to a Stock Purchase
Agreement among the Company and the four shareholders of JTech (the "JTech Stock
Purchase"). Leonard C. Smith, one of the selling JTech shareholders, received
$1,257,900 in cash and a convertible debenture in connection with the JTech
Stock Purchase. The convertible debenture, in the principal amount of $1,365,250
(inclusive of the 1999 earn-out provision) is due January 6, 2002 and is
convertible to common stock at Mr. Smith's option during the period from January
6, 2000 to January 6, 2002 at $11 per share.
JTech also entered into an Employment Agreement with Leonard C. Smith, dated
December 31, 1998, which provides that Mr. Smith serve as President of JTech for
three years at a salary of $100,000 per year. Pursuant to the employment
agreement, Mr. Smith also received an option to purchase 40,000 shares of the
Company's common stock, vesting over four years, at $5.00 per share, the closing
price of such stock on Nasdaq on the date of the JTech Stock Purchase. Mr. Smith
was appointed to fill a vacancy on the Company's Board of Directors, effective
April 26, 1999. Mr. Smith's term on the Board will expire at the 2001 annual
meeting of shareholders, but is subject to extension based upon election.
15. Subsequent Event
On March 29, 2000, the Company entered into an agreement to acquire certain
assets from Nestle USA, Inc. ("Nestle") relating to Nestle's enteral nutrition
delivery devices. The purchase price will range from $1.5 million to
approximately to $2.7 million, depending upon sales generated by the
acquired assets during the 12 months following the closing of the purchase,
plus the actual cost of certain inventory acquired by the Company which is
estimated to be approximately $700,000. Upon closing of the acquisition, cash
of $500,000 will be paid, and a note payable of $1 million will be issued
in connection with this purchase. The remainder of the purchase price will be
settled upon resolution of contingencies within the purchase agreement.
<PAGE>
EXHIBIT 10.20
Grant No.
ZEVEX INTERNATIONAL, INC.
STOCK OPTION GRANT
Optionee:
Address:
Grant Date: January 8, 1999
-----------------
Exercise Price: $5.00 per share
Number of Option Shares: 30,000 shares
Expiration Date: January 7, 2008
-----------------
Type of Option: X Incentive Option X Non-Statutory Option
----- -----
Exercise Schedule: All of the Option Shares shall become purchasable by
the Optionee the date which is nine years and nine months following the
Grant Date if the Optionee is continuously in the Service of the
Corporation during that time. Additionally, one-third of the Option
Shares (10,000 shares or a portion thereof, as described below) shall
become purchasable following each of the first three anniversary dates
of the Grant Date upon the Corporation's achieving annual revenue and
earnings in the three fiscal years ending December 31, 1999, 2000, and
2001 as follows:
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
YEAR 1999 2000 2001
---- ---- ----
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
REVENUE $24,640,000 $30,900,000 $38,600,000
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
EARNINGS $ 1,987,000 $ 2,886,000 $ 3,774,000
- ------------------------------- ---------------------------- ---------------------------- ----------------------------
</TABLE>
For the purpose of calculating the number of Option Shares that may
become purchasable at the end of each of these first three years, the
relevant revenue and earnings targets shall each account for the
vesting of 50% of the Option Shares. Furthermore, within each target,
25% of the Option Shares shall become purchasable if 80% of the target
is achieved, 50% of the Option Shares shall become purchasable if 90%
of the target is achieved, and 100% of the Option Shares shall become
purchasable if 100% of the target is achieved. By way of example, for
the year 1999, one-third (10,000) of the Option Shares potentially may
become purchasable, with 5,000 shares potentially becoming purchasable
if 100% of the revenue target is achieved, and with 5,000 shares
potentially becoming purchasable if 100% of the earnings target is
achieved. However, if the Corporation's revenue for 1999 are only
$23,000,000 or 93% of the targeted revenues, then only 50% of the 5,000
Option Shares will become purchasable with respect to that target. If,
in contrast, the earnings for 1999 are $2,002,000 or 102% of the target
earnings, then 100% of the 5,000 Option Shares will become purchasable
with respect to that target. The result of this scenario is that a
total of 7,500 Option Shares shall become purchasable with respect to
1999 and 2,500 Option Shares shall become exercisable on January 7,
2005 if the Optionee is continuously in the Service of the Corporation
during that time. If the Optionee is not continuously in the Service of
the Corporation during that time, then 2,500 Option Shares shall
expire.
The extent to which the Corporation has achieved the revenue and
earning targets for each of these three years and the number of Option
Shares that become purchasable following each such year shall be
determined by the Plan Administrator within ninety (90) day s of the
end of the Corporations fiscal year based on the Corporation's audited
financial statements for such fiscal year. For purposes of determining
whether the revenue and earning targets have been achieved in any year,
the Plan Administrator may, in its discretion, exclude or otherwise
adjust annual revenue and earnings due to the occurrence of one or more
extraordinary events during the fiscal year. Extraordinary events shall
include the merger of the Corporation with another corporation, the
Corporation's acquisition of all or substantially all assets or stock
of another company, the sale of all or substantially all assets or
stock of the Corporation to a third party, a change in the Company's
fiscal year, and other extraordinary transactions that are outside the
ordinary course of business. In no event shall the Option Shares become
purchasable that are not purchasable at the time of Optionee's
cessation of Service.
1. Grant of Option. ZEVEX International, Inc, a Delaware
corporation (the "Corporation"), hereby grants to the Optionee named above, as
of the Grant Date, an option to purchase up to the total number of Option Shares
specified above. This grant includes the terms of the Stock Option Exercise
Notice and Purchase Agreement attached hereto as Exhibit A, and is subject to
all of the terms and conditions of this Grant and the Corporation's 1999 Stock
Option Plan, a copy of which is attached hereto as Exhibit B. All capitalized
terms not defined herein have the meaning set for the in the Appendix to the
Plan.
2. Option Term. The option term shall be measured
from the Grant Date and shall accordingly expire at the close of business
on the Expiration Date specified above, unless sooner terminated in
accordance with paragraph 5 below.
3. Limited Transferability. This option shall be neither
transferable nor assignable, in whole or in part, by Optionee other than by will
or by the laws of descent and distribution following Optionee's death and may be
exercised, during Optionee's lifetime, only by Optionee. However, if this option
is designated a Non-Statutory Option above, then this option may also, in
connection with Optionee's estate plan, be assigned in whole or in part during
all other items in this form relating to the grant document are the same as
previously filed Exhibits 10.19#
all grants are the same for Messrs. Constantine, McNally and McStotts
<PAGE>
ASSET PURCHASE AGREEMENT
BETWEEN
ZEVEX, INC.
AND
NESTLE USA, INC.
March 29, 2000
<PAGE>
ASSET PURCHASE AGREEMENT
This Asset Purchase Agreement ("Agreement") is entered into as of March
29, 2000, by and between ZEVEX, Inc., a Delaware corporation ("Buyer"), and
Nestle USA, Inc., a Delaware corporation ("Seller"). Buyer and Seller are at
times also referred to herein individually as a "Party" and collectively as the
"Parties."
This Agreement contemplates a transaction in which Buyer will purchase
selected assets of the clinical delivery business of Seller in return for cash.
Now, therefore, in consideration of the premises and the mutual
promises herein made, and in consideration of the representations, warranties,
and covenants herein contained, the Parties agree as follows.
1. Basic Transaction.
(a) Purchase and Sale of Assets. On and subject to the terms and
conditions of this Agreement, Buyer agrees to purchase from Seller, and Seller
agrees to sell, transfer and convey to Buyer, for the consideration specified
below, all of Seller 's right, title and interest in and to the assets
identified in subparagraphs (i) through (viii) below, as such group of assets
may change during the period from the date hereof until the Closing as a result
of Seller's conducting of the Business (as defined below) in the ordinary course
of business and consistent with the terms of this Agreement (collectively, the
"Acquired Assets"):
(i) all enteral feeding pumps owned by Seller, including those
identified on the list designated as "Pump Inventory" (electronic file
number: NCN_pumpinventory.mdb), previously provided to Buyer by Seller,
which lists the model and serial number of each enteral feeding pump
and its location as of December 31, 1999 (the "Pumps");
(ii) Seller's inventory (if any) of "Disposables" (defined
herein as enteral feeding pump administration sets, enteral feeding
tubes, enteral irrigation kits and ancillary device products) as of the
date of the Closing (defined in Section 1(f) below), excluding,
however, Seller's inventory of handi-crush syringes and handi-crush
syringe kits (the "Disposables Inventory");
(iii) any custom tooling or molds owned by Seller and used in
connection with the manufacture of Disposables (the "Tooling");
(iv) printed copies or, where available, electronic copies of
the following books and records: Seller's customer list as of December
31, 1999, including customer name and address, of those customers (the
"Pump Customers") with whom Seller has placed or provided a Pump(s) and
to whom Seller sold Disposables during calendar year 1999, as well as,
with respect to such Pump Customers, (1) the following documents
previously provided to Buyer for the periods of 1997-99 and January
through February, 2000: "Summary of Delivery Adjustments (1999 only)",
"Baxter Exports," "Delivery Total Sales Top 20 Distributors," "National
Accounts with Delivery Products," "Delivery Top 20 Customers Direct
Business," and "Delivery Net Sales as of October 1999" "Customer
Complaints", (2) Seller's pricing lists for Disposables (electronic
file number: NCN_Deliverypricing.mdb), (3) Seller information regarding
Pump tracking information (referenced by Pump serial number)
(electronic file number: NCN_Pumpinventory.mdb), (4) Pump forecasts,
(5) Seller's "sell sheets" for the Disposables, including digital and
film artwork therefor, (6) Ultra Pak Support Studies, (7) training and
operating manuals for Pumps, and (8) Seller information regarding Pump
service histories (referenced by Pump serial number);
(v) all medical device reporting ("MDR") records associated
with the Pumps or Disposables;
(vi) all rights of Seller under all outstanding "Pump
Bilateral Agreements", defined herein as those contracts between Seller
and its Pump Customers covering Seller's agreement to provide the Pump
Customer with a Pump(s) and the Pump Customer's commitment to purchase
Disposables from Seller;
(vii) any drawings and specifications used to manufacture
the Disposables in Seller's possession or readily available to
Seller;
(viii) to the extent assignable by Seller without the consent
of any third party, any manufacturer's warranties or guarantees
applicable to the Disposables Inventory and any and all rights to bring
claims against such parties for defective Disposables Inventory.
Additionally, Seller shall (i) arrange for its affiliate,
Nestle, S.A. ("Nestle S.A.") to issue to Buyer at the Closing hereof an
irrevocable, royalty free license, in the form of the document attached hereto
as Exhibit A, granting to Buyer the right and license to make, use and sell in
the United States enteral adapter and tip protectors embodying the invention of
U.S. Patent No. 5,267,983 granted December 7, 1993 (the "Patent License") and
(ii) provide to Buyer a copy of Seller's August 18, 1998 Notice Of Medical
Device Correction to the Food and Drug Administration ("FDA") relating to the
Pumps, and correspondence to and from the FDA relating to said Notice.
(b) Retained Assets. Notwithstanding the foregoing, Seller is
not selling, transferring, assigning or conveying to Buyer any assets other
than those specifically identified and described in Section 1(a) above.
(c) Retention of Liabilities. Except as otherwise expressly provided in
this Agreement, any and all liabilities which accrue or arise prior to the
Closing relating to the Acquired Assets (including without limitation any
liabilities or obligations under the Pump Bilateral Agreements which accrue or
arise prior to the Closing) and any liabilities of any kind associated with any
"Products" (defined herein as Pumps and Disposables) placed, sold or leased by
Seller or any other Seller products or services, or any agreements made by
Seller related to the foregoing, shall be retained by Seller and Buyer shall be
released from same. Any and all liabilities which accrue or arise after the
Closing relating to the Acquired Assets (including without limitation any
liabilities or obligations under the Pump Bilateral Agreements which accrue or
arise after the Closing) and any liabilities of any kind associated with any
Products placed, sold or leased by Buyer or any other Buyer products or
services, or any agreements made by Buyer related to the foregoing, shall be
retained by Buyer and Seller shall be released from same. Notwithstanding
anything contained herein to the contrary, Buyer hereby acknowledges and agrees
that it shall retain and shall not be released from any responsibilities,
warranties, indemnity or other obligations given, imposed upon, made or assumed
by Buyer as the original manufacturer of Pumps, including without limitation the
responsibility to repair any defective Pumps and the obligation to indemnify,
defend and hold Seller harmless from and against any injury or death to person
or damage to property resulting from the use or operation of the Pumps, all of
which responsibilities, warranties or obligations so given, imposed upon, made
or assumed by Buyer shall be retained by Buyer. As part of its obligations
hereunder, Buyer agrees that, from and after the Closing, Buyer shall be
responsible for complying with any and all regulatory obligations associated
with the Products including, without limitation, the retention of all MDR
related records; Product complaint handling; filing of MDRs with the Federal
Food and Drug Administration ("FDA"); requirements relating to Product repair;
filing of Product applications with the FDA; and FDA registration and listing.
(d) Purchase Price. Subject to the provisions of this
Agreement, the purchase price for the Acquired Assets (the "Purchase Price")
shall be as follows:
(i) Five Hundred Thousand Dollars ($500,000.00) paid
by wire transfer or other immediately available funds upon Closing; plus
(ii) One Million Dollars ($1,000,000) paid by wire
transfer or other immediately available funds on a date six months from
Closing;
(iii) an amount equal to Seller's original purchase price
(including freight paid as F.O.B. destination) of the Disposables
Inventory (as determined pursuant to Section 1(e)) paid by wire
transfer or other immediately available funds on a date six months from
Closing; and
(iv) On a date which is twelve (12) months from the Closing,
the lesser of $1,000,000 or the product of $1,000,000 multiplied by the
percentage determined by dividing the "Sales Amount" (as defined below)
by $9,000,000. For purposes of the foregoing, the "Sales Amount" shall
mean the total gross revenues under orders actually received by Buyer
during the 12-month period following Closing for sales of Disposables
to Pump Customers.
(e) Inventory Procedure. Promptly following the Closing, Seller shall
take a physical inventory of the Disposables Inventory in accordance with
procedures to be established by mutual agreement of Buyer and Seller prior to
Closing. Buyer shall have the right to have representatives present during such
inventory. Within sixty (60) days after Closing, Seller shall prepare and
deliver to Buyer a statement (the "Inventory Statement"), which has been
reviewed and reported on by Buyer's independent auditors in accordance with
procedures to be established by Buyer and Seller, without exception or
qualification (except as to scope) setting forth the results of the physical
inventory and the original purchase price of the Disposables Inventory. For a
period of ninety (90) days following Closing, Buyer shall have the right to
reject any item(s) in the Disposables Inventory which is defective or not in
merchantable condition, and Buyer shall not be required to purchase any such
rejected items. For the purposes of this Section 1 (e), the Disposables
Inventory shall include, but Buyer shall not be required to pay for, any
Disposables Inventory for which there exists more than a two (2) year supply
based on Seller's average use for the six (6) months prior to Closing.
(f) The Closing. The closing of the transactions contemplated by this
Agreement (the "Closing") shall take place at Seller's offices at Three Parkway
North, Suite 500, Deerfield, IL 60015-0760, on or before the date which is ten
(10) business days from the date the parties execute this Agreement, as the
parties shall mutually determine, or such other date as the parties may mutually
determine (the "Closing").
(g) Deliveries at the Closing. At the Closing, (i) Seller shall deliver
to Buyer, against receipt of the Purchase Price, a Bill of Sale and Assignment
in the form of the document attached as Exhibit B to this Agreement, Buyer's
list of its Pump Customers, the License and the documentation described in
Section 1 (a) (iv) (5), (6) and (7) (Buyer hereby acknowledging that it has, as
of the date hereof, received from Seller the documentation identified in Section
1 (a) (iv) (1), (2), (3), (4) and (8) ), 1 (a) (v) and 1 (a) (vii) above; (ii)
Buyer shall deliver to Seller the Purchase Price and an Assumption Agreement in
the form of the document attached as Exhibit C to this Agreement; and (iii) the
parties shall execute and deliver any other documents necessary to give effect
to the transaction contemplated herein. All deliveries at the Closing shall be
considered to have taken place simultaneously as a single transaction, and no
delivery shall be considered to have been made until all deliveries are
completed. With respect to any of the Acquired Assets sold hereunder which
cannot be physically delivered because they are in the possession of third
parties, including specifically the Pumps, Seller shall, reasonably promptly
after the Closing, notify such third parties in possession that its right, title
and interest in and to the same have been vested in Buyer.
(h) Allocation. The parties agree to allocate the Purchase Price among
the Acquired Assets for all purposes (including financial accounting and tax
purposes) in accordance with the allocation schedule attached hereto as Schedule
1(h).
2. Representations and Warranties of Seller. Seller represents and
warrants to Buyer that the statements contained in this Section 2 are correct
and complete as of the date of this Agreement and will be correct and complete
as of the Closing (as though made then and as though the Closing were
substituted for the date of this Agreement throughout this Section 2).
(a) Organization of Seller. Seller is a corporation duly
organized, validly existing, and in good standing under the laws of the
jurisdiction of its incorporation.
(b) Authorization of Transaction. Seller has full power and authority
(including full corporate power and authority) to execute and deliver this
Agreement and to perform its obligations hereunder. The execution, delivery and
performance by Seller of this Agreement and such other agreements have been duly
authorized by all necessary and appropriate corporate action on the part of the
Seller. This Agreement and any agreements to be executed at Closing constitutes
the valid and legally binding obligation of Seller, enforceable in accordance
with its terms and conditions.
(c) Noncontravention. Except to the extent the following would have no
adverse effect on the Acquired Assets or their use by Buyer following Closing,
neither the execution and delivery of this Agreement nor the consummation of the
transactions contemplated hereby will with or without the giving of notice or
the passage of time, or both (i) result in a violation or breach of, or
constitute a default under, any term or provision of Seller's charter or bylaws,
or of any indenture, lease, agreement, instrument, commitment or other
arrangement to which Seller is a party or by which it is bound; (ii) result in
the creation of any lien, pledge, charge, security interest or encumbrance upon
the Acquired Assets pursuant to the terms of any such indenture, lease,
agreement, instrument or commitment or other arrangement; (iii) violate any
judgment, order, permit, injunction, decree or award of any court,
administrative agency or governmental body against, or binding upon, Seller or
upon its property or business; or (iv) constitute a violation by Seller of any
statute, law, rule or regulation of any governmental or regulatory authority. To
the best of Seller's knowledge, Seller does not need to give any notice to, make
any filings with, or obtain any authorization, consent or approval of any third
party or governmental agency in order to transfer or assign the Acquired Assets
to Buyer or otherwise consummate the transactions contemplated by this Agreement
(d) Brokers' Fees. Seller has no liability or obligation to pay
any fees or commissions to any broker, finder, or agent with respect to the
transactions contemplated by this Agreement for which Buyer could become liable
or obligated.
(e) Title to Acquired Assets. As of the date hereof, Seller has, and on
the Closing will have and will convey to Buyer, good and marketable title to the
Acquired Assets, free and clear of any mortgage, pledge, lien, encumbrance,
charge or other security interest, other than statutory liens arising from trade
payables and taxes not yet due and payable.
(f) Legal Compliance. Seller, as the distributor of the Pumps and
Disposables, is not in violation of or in default under any applicable laws
(including rules, regulations, codes, plans, injunctions, judgments, orders,
decrees, rulings, and charges thereunder) of federal, state, local, and foreign
governments (and all agencies thereof) and no action, suit, proceeding, hearing,
investigation, charge, complaint, claim, demand, or notice has been filed or
commenced against it alleging any failure so to comply, the effect of which
individually or in the aggregate could reasonably be expected to have a material
adverse effect on Buyer's ownership or use of the Acquired Assets. To the best
of Seller's knowledge, Seller has complied, in all material respects, with all
FDA requirements and notifications with respect to the Pumps and Disposables,
including the August 18, 1998 Notice of Medical Device Correction to the FDA.
(g) Tooling. To the best of Seller's knowledge, Schedule
2(g) is a true and correct list of the Tooling and its location.
(h) Inventory. Seller has on hand or has ordered and expects timely
delivery of such quantities of Disposables (other than those Disposable "sku's"
with erratic or small demand) that are reasonably required to timely fill orders
on hand which require delivery within ninety (90) days.
(i) Litigation. Except as set forth in Schedule 2 (i) to this
Agreement, there are no claims, actions, suits, hearings, investigations, legal
or administrative arbitrations or other proceedings before any court or
governmental or regulatory authority pending against Seller or, to Seller's
knowledge, threatened against Seller, and relating primarily to the Acquired
Assets, that could have a material adverse effect on the Acquired Assets or
their contemplated use by Buyer.
(j) Customers and Suppliers. Seller's customer list referenced in
Section 1 (a) (iv) above, to be delivered to Buyer at Closing, is true and
accurate in all material respects. Since June 30, 1999, Seller has not received
written notice from any Pump Customer that it will stop or materially decrease
the rate of business done with Seller, except for changes in the ordinary course
of business. The following documents (covering the periods 1997-1999 and January
and February, 2000) previously delivered to Buyer are, except with respect to
pricing information for the fourth quarter of 1998, true and accurate in all
material respects: "Summary of Delivery Adjustments (1999 only)", "Baxter
Exports," "Delivery Total Sales Top 20 Distributors," "National Accounts with
Delivery Products," "Delivery Top 20 Customers Direct Business," and "Delivery
Net Sales as of October 1999", Seller information regarding Pump tracking
information (electronic file Number: NCN_Deliverypricing.mdb), and "Customer
Complaints". Seller additionally represents that the "Seller's pricing lists for
Disposables (electronic file number: NCN_Deliverypricing.mdb)" accurately
reflects, in all material respects, the gross sales price charged the Pump
Customer, exclusive, however, of those reductions reflected on the Summary of
Delivery Adjustments (1999 only).
(k) Intellectual Property. To the best of Seller's knowledge (which for
purposes of this subparagraph (k) shall be deemed to refer to the actual
knowledge of Mr. Rock Foster), the Acquired Assets do not infringe upon or
misappropriate any intellectual property rights of third parties. Seller has not
received any written complaint, claim, demand or notice alleging that Seller's
use of an Acquired Asset infringes a third party's intellectual property right.
(l) Contracts. To the best of Seller's knowledge, Schedule 2(l) is a
complete and correct list of the Pump Bilateral Agreements. Attached hereto as
Exhibit D is the form of Pump Bilateral Agreement used by Seller for each Pump
Customer (except for University Hospital Consortium), except to the extent such
form specifically provides for individualized terms and exhibits. With respect
to each Bilateral Pump Agreement: (A) the agreement is legal, valid, binding,
enforceable and in full force and effect; and (B) to the best of Seller's
knowledge, no party is in breach or default, and no event has occurred which
with notice or lapse of time would constitute a breach or defaults, provided
however that a Pump Customer's failure to order or purchase any minimum or
requisite volume of Products referenced in the Pump Bilateral Agreement shall
not, for purposes of this representation and warranty, be deemed a breach or
default of the Pump Bilateral Agreement by the Pump Customer. As of Closing,
Seller has delivered to Buyer a correct and complete copy of each Bilateral Pump
Agreement identified on Schedule 2(l).
(m) Disclosure. The representations and warranties contained in this
Section 2 do not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements and
information contained in this Section 2 not misleading.
(n) Limitations on Representatives and Warranties. Except as expressly
set forth in this Agreement, neither Seller nor any of its affiliates or agents
makes any representations or warranties, express or implied, in connection with
the transactions contemplated by this Agreement. Without limiting the generality
of the foregoing and except as specifically set forth in this Agreement: (i) the
Acquired Assets shall be transferred to Buyer pursuant to this Agreement in
their present condition, "AS IS" and without any warranty, express or implied;
(ii) no patent or latent physical condition or defect in any of the Acquired
Assets, whether or not now known or discovered shall affect the rights of either
party; and (iii) no representations, warranties or agreements are made as to the
compliance of any of the Acquired Assets with any applicable federal, state,
local or foreign laws, rules or regulations, or as to the merchantability,
fitness for a particular purpose, physical condition, state of repair or
operating capabilities of any of the Acquired Assets.
3. Representations and Warranties of Buyer. Buyer represents and
warrants to Seller that the statements contained in this Section 3 are correct
and complete as of the date of this Agreement and will be correct and complete
as of the Closing Date (as though made then and as though the Closing Date were
substituted for the date of this Agreement throughout this Section 3).
(a) Organization of Buyer. Buyer is a corporation duly organized,
validly existing, and in good standing under the laws of the jurisdiction of
its incorporation.
(b) Authorization of Transaction. Buyer has full power and authority
(including full corporate power and authority) to execute and deliver this
Agreement and to perform its obligations hereunder. The execution, delivery and
performance by Buyer of this Agreement and such other agreements have been duly
authorized by all necessary and appropriate corporate action on the part of the
Buyer. This Agreement and any agreements to be executed at Closing constitutes
the valid and legally binding obligation of Buyer, enforceable in accordance
with its terms and conditions
(c) Noncontravention. Neither the execution and delivery of this
Agreement nor the consummation of the transactions contemplated hereby will with
or without the giving of notice or the passage of time, or both (i) result in a
violation or breach of, or constitute a default under, any term or provision of
Buyer's charter or bylaws, or of any indenture, lease, agreement, instrument,
commitment or other arrangement to which Buyer is a party or by which it is
bound; (ii) violate any judgment, order, permit, injunction, decree or award of
any court, administrative agency or governmental body against, or binding upon,
Buyer or upon its property or business; or (iii) constitute a violation by Buyer
of any statute, law, rule or regulation of any governmental or regulatory
authority.
(d) Brokers' Fees. Buyer has no liability or obligation to pay
any fees or commissions to any broker, finder, or agent with respect to the
transactions contemplated by this Agreement for which Seller could become liable
or obligated.
4. Pre-Closing Covenants. The Parties agree as follows with
respect to the period between the execution of this Agreement and the
Closing.
(a) General. Each of the Parties will exercise its commercially
reasonable best efforts to take all action and to do all things necessary,
proper, or advisable in order to consummate and make effective the transactions
contemplated by this Agreement.
(b) Efforts and Assurances. Each party to this Agreement shall use its
commercially reasonable best efforts to cause the satisfaction of all conditions
to the consummation of this Agreement which are in the control of such party and
to cooperate as necessary in the satisfaction of all other conditions to the
consummation of this Agreement. Each party to this Agreement shall, from time to
time after the execution and consummation of this Agreement, execute and deliver
such instruments, documents and assurances and take such further actions as the
other party may reasonably request to carry out the purpose and intent of this
Agreement. To the extent that the transfer or assignment of any Acquired Asset
shall require the consent of any other party in order to permit or effect such
transfer, this Agreement shall not constitute a contract to transfer the same
unless and until such consent is obtained.
(c) Operation of Business. The Acquired Assets being sold under this
Agreement are part of Seller's clinical delivery business (the "Business").
Seller agrees that in connection with the operation of its Business from the
date hereof until the earlier of the Closing or the termination of this
Agreement, except as otherwise consented to or approved by Buyer in writing,
Seller shall , to use its commercially reasonable best efforts to continue to
operate the Business in the ordinary course of business consistent with past
custom and practice, except for taking such steps as may be necessary or proper
to carry out and consummate the transactions contemplated by this Agreement.(d)
Notice of Certain Events. Each party shall promptly notify the other of (A) any
fact or circumstance of which a party has actual knowledge which would make any
representation or warranty set forth herein untrue or inaccurate, in any
material respect, as of the Closing or as of the date of this Agreement; or (B)
any claim against the Acquired Assets. Notwithstanding anything to the contrary
contained herein, if Buyer has actual knowledge that any representation or
warranty is untrue or inaccurate as of the Closing and elects to close this
transaction notwithstanding such untruth or inaccuracy, Buyer shall not be
entitled to be indemnified by or recover damages from Seller due to such
representation and warranty failing to be true or accurate.
(e) Access and Due Diligence. From the date of execution of this
Agreement until the Closing, Seller shall permit Buyer, its counsel and other
advisors reasonable access during normal business hours to the books, contracts,
records and personnel of Seller (excluding any records relating to federal,
state or local income or franchise tax) to the extent that they relate
exclusively to the Business or the Acquired Assets, and shall furnish Buyer such
other information as Buyer may from time to time reasonably request in
connection with the Business or the Acquired Assets. Buyer acknowledges that it
remains bound by the terms of the confidentiality agreement dated December 2,
1999, with respect to all information received by it from Seller prior to the
Closing.
5. Post-Closing Covenants. The Parties agree as follows with
respect to the period following the Closing.
(a) General. In case at any time after the Closing any further action
is necessary to carry out the purposes and intent of this Agreement, each of the
parties will take such further action (including the execution and delivery of
such further instruments and documents) as the other party reasonably may
request. Specifically, if any Pump Customer asserts that its Pump Bilateral
Agreement was not properly assigned to Buyer, (i) Seller shall provide
reasonable assistance, at Seller's expense, to convince the Pump Customer to
either accept the assignment to Buyer of the Pump Bilateral Agreement or to
enter into a new Usage Agreement directly with Buyer, or (ii) if such efforts
are unsuccessful, Seller shall, in circumstances where the Pump Customer fails
or refuses to purchase the minimum quantity of Disposables required under the
Pump Bilateral Agreement, assign to Buyer Seller's right to enforce the
provisions of the Pump Bilateral Agreement in order to permit Buyer (at its
expense) to bring an action to recover the Pump(s) from such Pump Customer.
(b) Transition Services and Post-Closing Obligations. (i)
Seller shall, reasonably promptly after the Closing, notify the Pump
Customers that its Pump Bilateral Agreement with Seller has been
assigned to Buyer and that Seller has sold to Buyer all of the Pumps
placed by Seller with said Pump Customer. For a period of twelve (12)
months after the Closing, Seller shall exercise its commercially
reasonable best efforts to assist Buyer in establishing with each Pump
Customer a new contract (each, a "Usage Agreement") covering use of the
Pumps held by the Pump Customer and the purchase by the Pump Customer
and the sale by Buyer of Disposables, each of which Usage Agreements
would, by its express terms, replace and supersede the Pump Bilateral
Agreement assigned to and assumed by Buyer at the Closing. Such efforts
will include Seller's sales representatives recommending that the Pump
Customers purchase Products from Buyer rather than Seller. Buyer shall
promptly notify Seller of each Pump Customer with whom it secures a
Usage Agreement. With respect to each Pump Customer, Buyer agrees that
unless and until a Usage Agreement is entered into between Buyer and a
Pump Customer, (1) Buyer shall perform all obligations regarding the
placement, sale and/or delivery of Products to a Pump Customer under
the Pump Bilateral Agreement arising from and after the Closing and (2)
in the event Buyer fails or refuses to perform such obligations with
respect to a Pump Customer, Seller, in addition to any other rights and
remedies available to Seller, shall have the right (but not the
obligation) to place or sell, or arrange for the placement or sale of,
Products to such Pump Customer as required by the terms of the Pump
Bilateral Agreement.
(ii) In consideration of Seller's assisting Buyer in its'
efforts to secure from each Pump Customer a Usage Agreement as provided
above, and in addition to the amounts paid to Seller under the terms of
Section 1 (d) above, Buyer shall pay Seller a one-time fee of Ten
Dollars ($10) per Pump for which a properly completed Usage Agreement
is entered into with Buyer during the 12-month period set forth in
Section 5(b)(i) above. Thus, for purposes of illustration, if Buyer and
a Pump Customer with 100 Pumps sign a Usage Agreement, Seller shall
receive $1,000. Buyer shall pay this fee within thirty (30) days at the
end of each calendar quarter with respect to Pump Customers who sign
Usage Agreements during such quarter.
(iii) Seller shall, for a period of ninety (90) days following
the Closing (or such shorter period as the parties may mutually agree),
on behalf of and as an accommodation to Buyer: take orders for
Disposables from the Pump Customers; place all such orders with Buyer;
invoice, on behalf of Buyer, the Pump Customers for such orders;
exercise its commercially reasonable best efforts to collect the
invoiced amount from such Pump Customers and remit the payments so
received to Buyer. Buyer agrees that Seller shall not be responsible
for any failure on the part of a Pump Customer(s) to pay all or a
portion of the full invoiced amount. In consideration for providing
such services, Buyer shall pay Seller a fee of one percent (1%) of the
total "gross" sales amount of all orders for Disposables so processed
by Seller and placed with Buyer. Buyer shall pay Seller said fee within
thirty (30) days at the end of each calendar quarter. After such ninety
(90) day period, Buyer shall undertake all such tasks directly and
Seller shall (except as otherwise provided in Section 5 (b) (i) above)
direct to Buyer all Pump Customers seeking to order Disposables.
Additionally, Seller shall advise any party which is not a Pump
Customer but is seeking to purchase or acquire Products that Buyer is a
supplier of Products.
(iv) Seller shall, at its expense, secure a recall termination
letter or other written confirmation from the FDA that the recall which
is the subject of the August 18, 1998 Notice Of Medical Device
Correction referenced in Section 1 (a) above has been terminated by the
FDA and be responsible for such further action (if any) required by the
FDA to obtain the termination of the recall which is the subject of
said August 18, 1998 Notice.
(c) Transfer of Possession of the Assets. Except for Pumps in the
possession of the Pump Customers and any other Acquired Assets held by a third
party, all tangible forms of the Acquired Assets shall be available for physical
possession by Buyer immediately upon Closing. Such Acquired Assets shall be
packaged by Seller in a form reasonably necessary for safe and insurable
shipment by common carrier. Seller shall ship such Acquired Assets to a location
designated by Buyer, fully insured, within seven (7) days of the Closing Date.
The parties shall share equally the expense of such shipping. Transfer of the
Acquired Assets (other than Pumps in the possession of the Pump Customers) held
by third parties shall be determined by Buyer and such third parties. Seller
shall, on or before the Closing, send a letter (in a form reasonably acceptable
to Buyer) to Venusa, Ltd. ("Venusa"), the entity which is in possession of the
Tooling, advising Venusa that Seller has sold and transferred the Tooling to
Buyer.
6. Conditions to Obligation to Close.
(a) Conditions to Obligation of Buyer. The obligation of Buyer to
consummate the transactions contemplated by this Agreement is expressly subject
to the satisfaction, on or prior to the Closing, of all the following conditions
(compliance with which or the occurrence of which may be waived in whole or in
part by the Buyer in writing):
(i) the representations and warranties set forth in
Section 2 above shall be true and correct in all material respects at
and as of the Closing;
(ii) Seller shall have performed and complied in all material
respects with all of its covenants hereunder which are required to be
performed or complied with by it prior to or on the Closing;
(iii) no action, suit, or proceeding shall be pending or
threatened before any court or quasi-judicial or administrative agency
of any federal, state, local, or foreign jurisdiction or before any
arbitrator wherein an unfavorable injunction, judgment, order, decree,
ruling, or charge would (A) prevent consummation of any of the
transactions contemplated by this Agreement, (B) cause any of the
transactions contemplated by this Agreement to be rescinded following
consummation, or (C) have a material adverse affect on the right of
Buyer to own and use the Acquired Assets;
(iv) all material actions required to be taken by Seller in
connection with consummation of the transactions contemplated hereby
and all certificates, instruments, and other documents required to
effect the transactions contemplated hereby will be reasonably
satisfactory in form and substance to Buyer;
(v) Seller shall have received all material consents and
approvals of third parties to the transactions contemplated by this
Agreement as may be required to be received by or on the part of
Seller.
(b) Conditions to Obligation of Seller. The obligation of Seller to
consummate the transactions contemplated by this Agreement is expressly subject
to the satisfaction, on or prior to the Closing, of all the following conditions
(compliance with which or the occurrence of which may be waived in whole or in
part by the Seller in writing):
(i) the representations and warranties set forth in
Section 3 above shall be true and correct in all material respects at
and as of the Closing;
(ii) Buyer shall have performed and complied in all material
respects with all of its covenants hereunder which are required to be
performed or complied with by it prior to or on the Closing, including
without limitation Buyer's obligation to pay Seller amounts due on the
Closing under the terms of Section 1 (d) above;
(iii) no action, suit, or proceeding shall be pending or
threatened before any court or quasi-judicial or administrative agency
of any federal, state, local, or foreign jurisdiction or before any
arbitrator wherein an unfavorable injunction, judgment, order, decree,
ruling, or charge would (A) prevent consummation of any of the
transactions contemplated by this Agreement or (B) cause any of the
transactions contemplated by this Agreement to be rescinded following
consummation (and no such injunction, judgment, order, decree, ruling,
or charge shall be in effect);
(iv) all material actions required to be taken by Buyer in
connection with consummation of the transactions contemplated hereby
and all certificates, instruments, and other documents required to
effect the transactions contemplated hereby will be reasonably
satisfactory in form and substance to Seller;
(v) Buyer shall have received all material consents and
approvals of third parties to the transactions contemplated by this
Agreement as may be required to be received by or on the part of Buyer.
7. Remedies for Breaches of This Agreement.
(a) Survival of Representations and Warranties. All of the
representations and warranties of Buyer and Seller contained in this Agreement
shall survive the Closing (even if the party to whom such representation and
warranty was given had reason to know of any misrepresentation or breach of
warranty at the time of Closing) and continue in full force and effect for a
period of nine (9) months thereafter.
(b) Seller's Indemnification. Seller agrees to indemnify Buyer and its
affiliates and hold them harmless from and against any and all damages, losses,
obligations, liabilities, actions, claims or expenses (including court costs and
reasonable attorneys' fees associated therewith) (the "Buyer's Losses") which
arise or result from or are incident or related to (i) the inaccuracy of any
representation or breach of any warranty of Seller that survives the Closing
contained in this Agreement (including any certificate, agreement or other
instrument delivered by or on behalf of Seller in connection with the
transactions contemplated by this Agreement); (ii) any default by Seller in the
observance or performance of any of its covenants or obligations under this
Agreement (including any certificate, agreement or other instrument delivered by
or on behalf of Seller in connection with the transactions contemplated by this
Agreement); (iii) any act or omission of Seller which constitutes a breach or
default under this Agreement, or (iv) any liability retained by Seller under
this Agreement. Subject to compliance with this Section 7, Seller shall
reimburse Buyer on demand for any Buyer's Losses at any time after the execution
of this Agreement. Consummation of the transactions contemplated under this
Agreement shall not be deemed or construed to be a waiver of any right or remedy
of Buyer.
(c) Buyer's Indemnification. Buyer agrees to indemnify Seller and its
affiliates and hold them harmless from and against any and all damages, losses,
obligations, liabilities, claims or expenses (including court costs and
reasonable attorneys' fees associated therewith) (the "Seller's Losses") which
arise or result from or are incident to (i) the inaccuracy of any representation
or breach of any warranty of Buyer contained in this Agreement (including any
certificate, agreement or other instrument delivered by or on behalf of Buyer in
connection with the transactions contemplated by this Agreement); (ii) any
default by Buyer in the observance or performance of any of its covenants or
obligations under this Agreement (including any certificate, agreement or other
instrument delivered by or on behalf of Buyer in connection with the
transactions contemplated by this Agreement); (iii) any act or omission of Buyer
which constitutes a breach or default under this Agreement; or (iv) any
liability retained by Buyer under this Agreement. Subject to compliance with
this Section 7, Buyer shall reimburse Seller on demand for any Seller's Losses
at any time after the execution of this Agreement. Consummation of the
transactions contemplated under this Agreement shall not be deemed or construed
to be a waiver of any right or remedy of Seller.
(d) Tender of Defense. The party indemnified hereunder (the
"Indemnitee") shall promptly notify the indemnifying party (the "Indemnitor") of
the existence of any claim, demand, or other matter involving liabilities to
third parties to which the Indemnitor's indemnification obligations would apply
and shall give the Indemnitor 20 calendar days (or such shorter period as
required by the contingencies of such claim, demand or other matter involving
liabilities to third parties) in which to elect to defend the same at its own
expense and with counsel of its own selection (who shall be approved by the
Indemnitee, which approval shall not be unreasonably withheld or delayed);
provided that the Indemnitee shall at all times also have the right to fully
participate in the defense at its own expense. If the Indemnitor assumes the
defense of an action, (a) the Indemnitee shall be entitled to meaningfully
participate therein, (b) no settlement or compromise thereof may be effected (i)
by the Indemnitor without the consent of the Indemnitee (which consent shall not
be unreasonably withheld or unreasonably delayed) unless (A) there is no finding
or admission of any violation of law or any violation of the rights of any
person by any Indemnitee and no adverse effect on any other claims that may be
made against any Indemnitee and (B) all relief provided is paid or satisfied in
full by the Indemnitor or (ii) by the Indemnitee without the consent of the
Indemnitor and (c) the Indemnitee may subsequently assume the defense of such
action, at the Indemnitor's expense, if a court of competent jurisdiction
determines that the indemnifying party is not vigorously defending such action.
If the Indemnitor shall, within such 20 calendar day (or shorter) period, fail
to defend, the Indemnitee shall have the right, but not the obligation, to
undertake the defense of, and to compromise or settle (exercising reasonable
business judgement) the claim or other matter on behalf, for the account, and at
the risk and expense of the Indemnitor; provided, however, the Indemnitee shall
not compromise or settle the claim or other matter without the written consent
of the Indemnitor, such consent not to be unreasonably withheld or delayed. If
the claim is one that cannot by its nature be defended solely by the Indemnitor,
the Indemnitee shall make available all information and assistance that the
Indemnitor may reasonably request; provided that any associated expenses shall
be paid by the Indemnitor.
(e) Indemnity Threshold. No party shall be entitled to indemnification
under this Section 7 unless and until the aggregate amount of valid claims
against the other party pursuant to the provisions of Section 7(b) or 7(c)
exceed Fifty Thousand Dollars ($50,000.00) (the "Indemnity Threshold"). If the
Indemnity Threshold is exceeded, the Indemnified Party shall be entitled to the
entire amount of such claims from the other party, including the amount up to
the Indemnity Threshold as well as the amount exceeding the Indemnity Threshold.
(f) Exclusive Remedy. After the Closing, the rights set forth in this
Section 7 shall be each party's sole and exclusive remedies against the other
party for misrepresentations or breaches of covenants contained in this
Agreement; provided, however, that nothing herein shall prevent any party from
demanding arbitration or bringing an action in accordance with the terms of this
Agreement based upon allegations of fraud or intentional breach of an obligation
of or with respect to either party in connection with this Agreement.
8. Termination.
(a) Termination of Agreement. Certain of the parties may
terminate this Agreement as provided below:
(i) Buyer and Seller may terminate this Agreement by mutual
written consent at any time prior to the Closing; (ii) Buyer
may terminate this Agreement by giving written notice to
Seller at any time prior to the Closing (A)
in the event Seller has breached any material representation, warranty,
or covenant contained in this Agreement in any material respect, Buyer
has notified Seller in writing of the breach, and the breach has
continued without cure for a period of 10 days after the notice of
breach or (B) if the Closing shall not have occurred on or before June
30, 2000, by reason of the failure of any condition precedent under
Section 6(a) hereof (unless the failure results primarily from Buyer
itself breaching any representation, warranty, or covenant contained in
this Agreement); and
(iii) Seller may terminate this Agreement by giving written
notice to Buyer at any time prior to the Closing (A) in the event Buyer
has breached any material representation, warranty, or covenant
contained in this Agreement in any material respect, Seller has
notified Buyer in writing of the breach, and the breach has continued
without cure for a period of 10 days after the notice of breach or (B)
if the Closing shall not have occurred on or before June 30, 2000, by
reason of the failure of any condition precedent under Section 6(b)
hereof (unless the failure results primarily from Seller itself
breaching any representation, warranty, or covenant contained in this
Agreement).
(b) Effect of Termination. If any party terminates this Agreement
pursuant to Section 8(a) above, all rights and obligations of the parties
hereunder shall terminate without any liability of any party to the other party
(except for any liability of any party then in breach).
9. Miscellaneous.
(a) Press Releases and Public Announcements. No party shall issue any
press release or make any public announcement relating to the subject matter of
this Agreement without the prior written approval of the other party; provided,
however, that any party may make any public disclosure it believes in good faith
is required by applicable law or any listing or trading agreement concerning its
publicly-traded securities (in which case the disclosing party will use its best
efforts to advise the other party prior to making the disclosure).
(b) Risk of Loss. The risk of loss or damage by fire or other casualty
to the Acquired Assets (to the extent they exist in tangible form) shall be upon
Seller until Closing for those Acquired Assets in the possession of third
parties, and until delivery to a common carrier for shipping for those Acquired
Assets in the possession of Seller. In the event losses or damages to any of the
tangible Acquired Assets occur prior to the Closing which, in total, exceed
$10,000 (based on the market value of such Acquired Assets), Buyer shall have
the option of: (i) taking such damaged assets and receiving at Closing all
insurance proceeds to which Sellers would be entitled as a result of such loss
or damage; or (ii) rejecting such damaged assets entirely and the Purchase Price
shall be equitably reduced to reflect the non-transference of same. In the event
such damages exceed $100,000, Buyer may at its election terminate this Agreement
pursuant to 8(a)(ii).
(c) No Third-Party Beneficiaries. This Agreement shall not confer any
rights or remedies upon any Person other than the Parties and their respective
successors and permitted assigns.
(d) Entire Agreement. This Agreement (including the documents referred
to herein (but excluding the Confidentiality Agreement, dated December 2, 1999,
between the Parties) constitutes the entire agreement between the parties and
supersedes any prior understandings, agreements, or representations by or
between the parties, written or oral, to the extent they have related in any way
to the subject matter hereof, including the Letter of Interest, dated February
17, 2000, between the parties.
(e) Succession. This Agreement shall be binding upon and inure
to the benefit of the parties named herein and their respective successors
and permitted assigns.
(f) Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument.
(g) Headings. The section headings contained in this Agreement
are inserted for convenience only and shall not affect in any way the meaning
or interpretation of this Agreement.
(h) Notices. All notices, requests, demands, claims, and other
communications hereunder will be in writing. Any notice, request, demand, claim,
or other communication hereunder shall be deemed duly given five (5) days after
it is sent by registered or certified mail, return receipt requested, postage
prepaid, and addressed to the intended recipient as set forth below:
If to Seller: Copy to:
Nestle Clinical Nutrition Nestle USA, Inc.
Three Parkway North, #500 800 No. Brand Blvd.
Deerfield, IL 60015 Glendale, CA 91203
Attn: General Manager Attn: Legal Department
Fax: 847 317 3186 Fax: 818 549-5840
If to Buyer: Copy to:
ZEVEX, Inc. Jones, Waldo, Holbrook & McDonough
4314 ZEVEX Park Lane 1500 Wells Fargo Plaza
Salt Lake City, UT 84123 170 South Main
Attention:President Salt Lake City, UT 84101-1644
Fax: 801 264-1051 Attention: Ronald S. Poelman, Esq.
Fax: 801 328-0537
A party may send any notice, request, demand, claim, or other communication
hereunder to the intended recipient at the address set forth above using any
other means (including personal delivery, expedited courier, messenger service,
telecopy or telefax, telex, ordinary mail, or electronic mail), but no such
notice, request, demand, claim, or other communication shall be deemed to have
been duly given unless and until it actually is received by the intended
recipient. Any party may change the address to which notices, requests, demands,
claims, and other communications hereunder are to be delivered by giving the
other party notice in the manner herein set forth.
(i) Governing Law. This Agreement shall be governed by and
construed in accordance with the domestic laws of the State of New York without
giving effect to any choice or conflict of law provision or rule.
(j) Amendments and Waivers. No amendment of any provision of this
Agreement shall be valid unless the same shall be in writing and signed by Buyer
and Seller. No waiver by any party of any default, misrepresentation, or breach
of warranty or covenant hereunder, whether intentional or not, shall be deemed
to extend to any prior or subsequent default, misrepresentation, or breach of
warranty or covenant hereunder or affect in any way any rights arising by virtue
of any prior or subsequent such occurrence.
(k) Severability. Any term or provision of this Agreement that is
invalid or unenforceable in any situation in any jurisdiction shall not affect
the validity or enforceability of the remaining terms and provisions hereof or
the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction.
(l) Expenses. Buyer and Seller will bear its own costs and expenses
(including legal fees and expenses) incurred in connection with this Agreement
and the transactions contemplated hereby.
(m) Construction. The parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any of
the provisions of this Agreement. Any reference to any federal, state, local, or
foreign statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise. The
word "including" shall mean including without limitation. Nothing in any
disclosure schedule shall be deemed adequate to disclose an exception to a
representation or warranty made herein unless the disclosure schedule identifies
the exception with reasonable particularity and describes the relevant facts in
reasonable detail. Without limiting the generality of the foregoing, the mere
listing (or inclusion of a copy) of a document or other item shall not be deemed
adequate to disclose an exception to a representation or warranty made herein
(unless the representation or warranty has to do with the existence of the
document or other item itself).
(n) Incorporation of Schedules. The Schedules identified in
this Agreement are incorporated herein by reference and made a part hereof.
(o) Specific Performance. Each of the parties acknowledges and agrees
that the other party would be damaged irreparably in the event any of the
provisions of this Agreement are not performed in accordance with their specific
terms or otherwise are breached. Accordingly, each of the parties agrees that
the other party shall be entitled to an injunction or injunctions to prevent
breaches of the provisions of this Agreement and to enforce specifically this
Agreement and the terms and provisions hereof in any action instituted in any
court of the United States or any state thereof having jurisdiction over the
parties and the matter.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.
"Buyer"
ZEVEX, INC.
By: DEAN G. CONSTANTINE
-------------------
Its:CEO
-------
"Seller"
NESTLE USA, INC.
By: ROCK D. FOSTER
--------------
Its:VP GM NCN
---------
<PAGE>
EXHIBIT A
EXCLUSIVE LICENSE AGREEMENT
This is an agreement between Nestle, S.A., a corporation having an
address at Avenue Nestle 55, 1800 Vevey, Switzerland (hereinafter "LICENSOR"),
and ZEVEX, Inc., a corporation of the State of Delaware, having a business
address at 4314 Zevex Park Lane, Salt Lake City, Utah 84123 (hereinafter
"LICENSEE").
Whereas, LICENSOR is the owner by assignment of U.S. Patent No.
5,267,983 entitled ENTERAL ADAPTER AND TIP PROTECTOR (hereinafter "the `983
patent"); and
Whereas, LICENSEE is desirous of acquiring an exclusive license to the
`983 patent;
For good and valuable consideration, receipt of which is hereby
acknowledged, except as is hereinafter provided in this paragraph, the LICENSOR,
by these presents, does hereby grant unto the LICENSEE an exclusive license to
make, have made, use, sell, and offer to sell, in the United States any
apparatus or method which falls within the scope of the claims of the `983
patent. Notwithstanding the exclusive character of the license granted in this
Agreement, the LICENSEE, its successors and assigns shall take the aforesaid
license subject only to an outstanding non-exclusive, royalty-free license under
the `983 patent to Baxter International, Inc. of Deerfield, IL under an
agreement executed by the LICENSOR prior to the effective date of this
Agreement.
<PAGE>
The LICENSEE, as exclusive licensee, shall have the right to institute
and prosecute at its own expense, suits for infringement of the `983 patent, and
if required by law, to join the LICENSOR as party plaintiff in any such suit.
All expenses in such suits, including all costs and reasonable attorney's fees
which may be incurred by the LICENSOR in connection with any such suit , will be
borne entirely by the LICENSEE. The LICENSEE shall be empowered in any such suit
to enjoin infringement and/or to collect for its use, damages, profits, and
awards of whatever nature recoverable for such infringement. The LICENSEE shall,
subject to the prior written approval of the LICENSOR, have the right to settle
any claim or suit for infringement of the `983 patent by granting the infringing
party a sublicense under the `983 patent.
The LICENSOR further acknowledges and agrees that the LICENSEE shall
not have any obligation to make, use, sell, import, offer for sale, or promote
any apparatus or method which falls within the scope of the `983 patent. Nothing
in this Agreement or in the relationship between the parties shall be construed
to impose such an obligation on the LICENSEE.
The LICENSOR hereby agrees and acknowledges that the exclusive license
of rights and property set forth herein is and shall be irrevocable and binding
upon the assigns, representatives and successors of the undersigned LICENSOR and
extend to the successors, assigns and nominees of the LICENSEE for the life of
the `983 patent, including any and all extensions.
IN WITNESS WHEREOF, each of the parties hereto has caused this License
Agreement to be signed by its duly authorized representative.
Zevex, Inc Nestle, S.A.
By_______________________ By____________________
Its ___________________________ Its_____________________
Date______________________ Date___________________
<PAGE>
Exhibit 21
List of Subsidiaries
1. ZEVEX, Inc., a Delaware corporation
2. JTech Medical Industries, Inc., a Utah corporation
3. Aborn Electronics, Inc., a California corporation
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000827056
<NAME> ZEVEX International
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> DEC-31-1999
<EXCHANGE-RATE> 1
<CASH> 3383544
<SECURITIES> 3224817
<RECEIVABLES> 6018229
<ALLOWANCES> 175000
<INVENTORY> 5119291
<CURRENT-ASSETS> 17717843
<PP&E> 7579540
<DEPRECIATION> 2245963
<TOTAL-ASSETS> 34049689
<CURRENT-LIABILITIES> 5782319
<BONDS> 1700000
0
0
<COMMON> 3421
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 34049689
<SALES> 23026208
<TOTAL-REVENUES> 23026208
<CGS> 12474210
<TOTAL-COSTS> 12474210
<OTHER-EXPENSES> 7658930
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 481615
<INCOME-PRETAX> 2893068
<INCOME-TAX> 1187989
<INCOME-CONTINUING> 1626373
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1626373
<EPS-BASIC> .48
<EPS-DILUTED> .47
</TABLE>
